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Tour along the nephron
The kidney controls body fluid volume and osmolality
Sodium (Na+), calcium (Ca2+) and magnesium (Mg2+) play crucial roles in the normal 
functioning of cells and organs [1-3]. Careful maintenance and regular monitoring of these 
electrolyte levels is essential for proper function of cells. Na+, Ca2+ and Mg2+ balances are 
tightly maintained by regulating their absorption in the intestine, exchange from bone, 
and reabsorption and secretion by the kidneys [4-6]. 
The functional unit of the kidney is the nephron, which consists of the corpuscle and 
tubule [7]. A renal corpuscle functions as the blood-filtering component and is build up 
by the glomerulus and Bowman’s capsule [8]. Small molecules, water, and metabolic 
waste can be filtered through the glomerulus, but large molecules like proteins (>45 kDa) 
will remain in the blood. The filtrate flows through the renal tubule where electrolytes 
will be reabsorbed or secreted. Nearly 97% of the filtered Na+, Ca2+ and Mg2+ will be reab-
sorbed along the nephrons. They consist of several distinct functional and anatomical 
parts where all of the Na+, Ca2+ and Mg2+ reabsorption take place: the proximal tubule 
(PT); the thick ascending limb of loop of Henle (TAL); the distal convoluted tubule (DCT); 
the connecting tubule (CNT), and collecting duct (CD) (Figure 1).
Segments along the nephron
The proximal tubule
The PT is the first segment of the nephron and is also the major site for Na+ and Ca2+ 
reabsorption [9, 10]. It is divided into three parts, S1, S2 and S3. In the early PT (S1 and 
S2), large amounts of filtered amino acids, phosphate, glucose, lactate, and citrate will 
be reabsorbed [11, 12]. Approximately 65% of the Na+ will be reabsorbed in the PT, 
mainly through passive paracellular or active transcellular pathways [13]. The sodium-
glucose transporter (SGLT), sodium-dependent phosphate cotransport protein (NaPi-
2a) and sodium–hydrogen exchanger 3 (NHE3) are the predominant apical transporters 
that are responsible for the transport of Na+ in the PT [14-18]. The intracellular Na+ 
concentration must be kept low to facilitate Na+-coupled co-transport. The basolateral 
sodium/potassium  ATPase (Na+/K+-ATPase) pumps three Na+ ions out of the cell and 
transports two K+ ions back into the cell [19]. Nearly 60-70% of the filtered Ca2+ will also 
be reabsorbed in the PT [20]. Na+ reabsorption coincides with passive water reabsorption. 
The Na+-driven water movement can increase the concentration of Ca2+ in the lumen, 
which will drive passive Ca2+ diffusion through the tight junctions of epithelial cells into 
the renal interstitium. Only 10-25% of filtered Mg2+ is reclaimed in the PT [21] (Figure 1).
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Figure 1.  Na+, Ca2+ and Mg2+ reabsorption along the nephron. 
Around 95-99% of Na+, Ca2+ and Mg2+ in the filtered pro-urine is reabsorbed along the nephron in the proximal 
tubule (PT), thick ascending limb of loop of Henle (TAL), distal convoluted tubule (DCT), connecting tubule 
(CNT), and the collecting duct (CD). The remaining Na+, Ca2+, and Mg2+ will be excreted with urine. TDL, the 
descending loop of Henle.
The loop of Henle
The loop of Henle consists of a descending limb and an ascending limb (Figure 1). The 
descending loop of Henle (TDL) is permeable to water because of the water channel 
aquaporin 1 (AQP1), but impermeable to electrolytes [22-24]. Vice versa, the TAL is 
impermeable to water, but it is permeable to electrolytes [25]. The TAL is responsible for 
roughly 25% of the filtered Na+ reabsorption. In addition, it is also a crucial segment for 
Mg2+ and Ca2+ reabsorption [4, 26, 27], taking in about 20-25% of filtered Ca2+, and 50%-
70% of filtered Mg2+ by paracellular processes [28, 29]. 
The PT reabsorbs bulk of filtrated Ca2+ via the paracellular pathway. Subsequently, Ca2+ 
is passively reabsorbed in the TAL. Here, the driving force for paracellular cation transport 
is a lumen-positive transepithelial voltage, which is mainly generated by the sodium-po-
tassium-chloride cotransporter (NKCC2) and the renal outer medullary potassium chan-
nel (ROMK) [27]. The calcium sensing receptor (CaSR) can regulate this transport without 
changing the transepithelial voltage [30]. Studies have shown that CaSR can regulate Ca2+ 
reabsorption by inhibiting the activity of ROMK or by affecting tight junction permeabil-
ity [31, 32]. Impaired regulation of Ca2+ transport in the TAL can result in several diseases, 
such as hypocalcemia, hypercalcemia, or kidney stone disease. 
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The reabsorption of the divalent cations such as Mg2+ and Ca2+ mainly depends on tight 
junction permeability in this segment. Claudin proteins are the crucial constituents of 
the tight junction complexes [33]. The claudin family has 24 members. Some claudin 
family members play fundamental roles in forming impermeable barriers, while others 
modulate the permeability to small molecules and electrolytes [34-36]. Claudins 3, 10b, 
11, 14, 16, and 19 are specifically localized in the TAL [36-38]. The tight junctions formed 
by claudins 16 and 19 are highly permeable to Mg2+ and Ca2+ [39], while the tight junctions 
made by claudin 10b are highly permeable to Na+ [40, 41]. Mutations in CLDN16 (claudin 
16) and CLDN19 (claudin 19) can result in familial hypomagnesemia with hypercalciuria 
and nephrocalcinosis (FHHNC) [42-45]. Recently, several studies showed that increased 
plasma Ca2+ and Mg2+ levels can alter the tight junctions by causing them to incorporate 
claudin 14 in the structure which will shift the preference from divalent cations such as 
Ca2+ and Mg2+ towards monovalent ions like Na+ [31, 46].
The distal convoluted tubule connecting tubule
The DCT is responsible for 3–8% of Na+ reabsorption [47]. It has two parts, namely an early 
segment and a late segment, also known as DCT1 and DCT2, respectively [48]. The key 
player in Na+ reabsorption is the thiazide-sensitive sodium-chloride co-transporter (NCC) 
on the apical side of DCT1 cells [49]. Additionally, the epithelial sodium channel (ENaC) 
also participates in Na+ reabsorption in DCT2 and CNT [50]. 
Approximately 1-10 % of filtered Mg2+ is reabsorbed in the DCT1 [50]. The transient 
receptor potential cation channel subfamily M, member 6 (TRPM6) plays a crucial role in 
epithelial Mg2+ transport in the kidney [51]. Recessive TRPM6 mutations cause disturbances 
in intestinal Mg2+ absorption and urinary Mg2+ wasting which lead to severe hypomagne-
semia [52, 53]. Several other proteins may play roles in transporting Mg2+ across the baso-
lateral membrane, such as solute carrier family 41 member 1 (SLC41A1) and solute carrier 
family 41 member 3 (SLC41A3). Knocking down slc41a1 caused renal Mg2+ wasting in zebraf-
ish larvae [54]. In another study, Slc41a3 knockout mice exhibit low serum Mg2+ levels [55]. 
The DCT2 and CNT reabsorb nearly 10% of the filtered Ca2+ [50]. Unlike other seg-
ments of the nephron, Ca2+ reabsorption in the DCT and CNT occurs by active transcellu-
lar mechanisms. The apical transient receptor potential channel subfamily V member 5 
(TRPV5) plays a key role in transepithelial Ca2+ transport [56]. Trpv5 knockout mice exhib-
ited urinary Ca2+ wasting [56]. In addition, Ca2+-binding protein calbindin-D
28K
, which is 
used to buffer intracellular Ca2+ levels [57], carries Ca2+ to the basolateral surface. Then, 
the plasma membrane calcium-ATPase (PMCA) and type 1 sodium/calcium exchanger 
(NCX1) work together to extrude Ca2+ to the extracellular space [58].
The collecting duct
The CD is the final part of the kidney to regulate the fluid balance and electrolytes [59, 60]. 
The CD extends all the way from the cortex to the medulla section of the kidney and the 
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DCT and the ureter are connected by the CD. Nearly 1% of filtered Na+ is reabsorbed in 
the collecting duct. The CD plays a very minimal role in the reabsorption of Ca2+ and Mg2+ 
[61]. Under normal conditions, CD is slightly permeable to Na+. Filtered Na+ is diffused 
through the apical side of CD by ENaC. Then, the Na+-K+-ATPase on the basolateral side 
will extrude the Na+ to the interstitial space [62-64]. Any remaining Na+, Ca2+ and Mg2+ will 
be excreted in the urine by the kidney.
 
Na+ handling in diabetes and hypertension
Na+ transport in the proximal tubule
Disturbed Na+ and glucose reabsorption in the PT typically leads to Na+ and glucose 
disorders and subsequent hypertension and diabetes, since the PT is the main segment 
for Na+ and glucose reabsorption in the kidney. SGLT2 is a key transporter for Na+ and 
glucose reabsorption in the PT [65].
Figure 2. Glucose and Na+ reabsorption in the proximal tubule. 
Na+ and glucose reabsorption through SGLT2 in the proximal tubule epithelial cell. G, glucose; SGLT1, sodium-
glucose co-transporter 1; GLUT1, glucose transporter 1; SGLT2, sodium-glucose co-transporter 2; GLUT2, 
glucose transporter 2; S1/2, segment 1/2; S3, segment 3.
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Na+ and glucose transport in the proximal tubule in diabetes and 
hypertension
Type 2 diabetes is characterized by increasing blood glucose levels [66] due to insulin 
resistance. It is a worldwide epidemic and the number of people affected is projected 
to rise beyond 600 million in the next 25 years, which equals over 10% of the adult 
population, with equal rates in both men and women [67]. Type 2 diabetes is also the 
leading cause of nephropathy [68, 69]. In humans, the kidneys filter approximately 180 
grams of D-glucose from plasma each day, and this is normally reabsorbed in the kidney 
[70]. SGLT1 (SLC5A1) and SGLT2 (SLC5A2), which are encoded by genes from the solute 
carrier 5A family, are crucial regulators in intestinal and renal glucose handling [71]. Other 
transporters that are involved in the glucose maintenance are the facilitative glucose 
transporters: glucose transporter 1 (GLUT1) and glucose transporter 2 (GLUT2) [72]. SGLT2 
reabsorbs approximately 90% of the glucose from the lumen of the S1/S2 segment of 
the PT [73], while GLUT2 transports glucose across the basolateral membrane (Figure 2) 
[74]. The remaining glucose is reabsorbed in the S3 segment, through the coordinated 
actions of SGLT1 and GLUT1 [71]. Mutations in the Sglt1 gene result in glucose-galactose 
malabsorption and impaired glucose transport [75]. Mutations in Sglt2 gene can cause 
familial renal glycosuria, characterized by decreased renal tubular glucose reabsorption 
[76, 77]. The Sglt2 knockout mice exhibited attenuated hyperglycemia and glomerular 
hyperfiltration [78]. Increased expression and activity of SGLT2 resulted in increased 
glucose reabsorption, which causes hyperglycemia in diabetes patients [79, 80]. 
More than two-thirds of patients with type 2 diabetes have concomitant hypertension 
and salt and water retention [81, 82]. Hypertension in these patients increases their already 
elevated cardiovascular risks [83, 84]. Recent interest in the kidneys as a target for glucose 
control in diabetes has important implications for blood pressure management. Na+ reten-
tion has been implicated in the pathophysiology of hypertension in type 2 diabetes and 
in impaired vasodilatory responsiveness to angiotensin-I-converting enzyme (ACE) inhibi-
tion [85, 86]. Pharmacological inhibition of SGLT2 transporters improves glucose control by 
inducing glucosuria, but these inhibitors also lower blood pressure to a degree comparable 
with the use of thiazide diuretics [87, 88]. Studies showed that SGLT2 inhibitors increase Na+ 
delivery to macula densa, then, juxtaglomerular apparatus sense this increased Na+ deliv-
ery as an elevation in the filtrate volume which leads to afferent vasoconstriction, a reduc-
tion in intraglomerular pressure and a suppressed glomerular filtration rate (GFR) [89-91]. 
Recently, Woods and his colleagues reported that SGLT2 inhibitor canagliflozin decreases 
mRNA and protein level of renal angiotensinogen and reduced blood pressure in animal 
models with type 2 diabetes [92]. This suggests that SGLT2 inhibitors may reduce blood 
pressure through suppressing renin-angiotensin-aldosterone system (RAAS). Co-inhibition 
of glucose-coupled Na+ transport may be the driving force behind this blood pressure low-
ering effect, the effect of which may be mediated by the action of Na+ transporters located 
in the local or more distal part of the nephron.
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Hypercalciuria in kidney stone disease
Ca2+ handling in the Henle’s loop
The urinary Ca2+ concentration in the loop of Henle is an important factor in the formation 
of kidney stone. The loop of Henle serves to concentrate pro-urine [93]. Since no water 
is reabsorbed at this segment, there is a 10-fold or even higher increase in osmolality 
which results in urinary ‘supersaturation’ with poorly soluble waste salts such as Ca2+-
phosphate (CaP) and Ca2+-oxalate (CaOx). CaP and CaOx are the major components for 
crystal formation [94]. In this segment, the pathophysiology of kidney stones will be 
discussed.
Hypercalciuria 
Urinary Ca2+ excretion greater than 300 milligrams (mg) per day for men and greater than 
250 mg per day in women is considered as hypercalciuria [95, 96]. Conditions known 
to cause hypercalciuria include: i) diet, such as excessive dietary intake of Ca2+, Na+, 
carbohydrates, animal protein, alcohol, and reduced intake of phosphate and potassium, 
ii) increased intestinal Ca2+ absorption, iii) reduced renal tubular reabsorption of Ca2+, and 
iv) increased osteoclastic bone reabsorption [97-99]. Remarkably, a large percentage of 
patients have idiopathic hypercalciuria, with no explanation for the increased urinary 
Ca2+ levels [99, 100]. Hypercalciuria is considered a risk factor for Ca2+ crystal deposition 
in the kidneys, which can ultimately result in kidney stone formation (nephrolithiasis). 
This occurs by at least two mechanisms: first, by increasing the concentration of urinary 
Ca2+ salts (CaP and CaOx), and second, urinary Ca2+ binds stone inhibitors such as citrates, 
leading to a reduction in the activity of this inhibitor [101].
Nephrolithiasis
Nephrolithiasis is a highly widespread urologic disease with prevalence rates ranging from 
7-13% in North America, 5-9% in Europe and 1-5% in Asia [102]. The prevalence of kidney 
stones has increased worldwide over the last four decades, with the prevalence in women 
rising disproportionately compared to men [103]. This growing trend is considered to be 
associated with lifestyle changes such as lack of physical activity and altered dietary habits 
[104]. Medical management of urinary stones includes pharmacological interventions, 
minor endourological intervention for stone removal, and extracorporeal shock wave 
lithotripsy [105]. They are highly effective but are associated with some serious side 
effects and without complete preventing of the recurrence of kidney stones [105]. There 
is currently no effective drug on the market to cure or prevent kidney stone recurrences. 
Without proper treatment, the rate of the secondary stone formation ranges from 10% 
in the first year up to 75% in 20 years [106, 107]. The high prevalence and recurrent 
nature of kidney stones make it a substantial economic burden. In addition, kidney stone 
disease is associated with an increased rate of chronic kidney disease, end-stage renal 
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failure, hypertension, and myocardial infarction [104, 108]. These results suggest that 
the emphasis should not only be placed on finding new treatments for kidney stones, 
but also on finding a new method to prevent stone formation in high risk groups and 
recurrent in kidney stone patients.
Pathophysiology of kidney stones
Biochemically, there are different types of stones depending on the type of abnormalities 
in urine composition. Ca2+ stones are the most common type of renal stones, compromising 
about 80% of all kidney stones [109]. The formation of kidney stones is a multifactorial 
process that involves intrinsic factors such as age, sex, genetic predisposition, and 
extrinsic factors such as geography, diet, and water intake [110]. The pathogenesis of 
kidney stones is still not completely understood. They often begin from a foundation 
called Randall’s plaque present at the renal papillary surface, but there are several steps 
involved in the formation of stones [108]. Step 1: Urine supersaturation. In this phase, the 
supersaturation is the result of the excretion of poorly soluble minerals such as CaP or 
CaOx in a relatively small volume of urine [108]. Step 2: Nucleation. The free atoms, ions, 
or molecules in the supersaturated urine begin to form microscopic clusters [104]. Step 3: 
Crystal growth and crystal aggregation. The preformed crystals stick together and form 
a hard rock mass. These small hard mass of stones stay together and form a larger stone 
in a process called crystal aggregation. Crystal aggregation results in more nucleation 
sites, leading to a snowball effect [104]. Step 4: Crystal-cell interaction. At this stage, the 
formed crystals adhere to the lining of the epithelial cells in the renal tubules [104]. This 
process results in oxidative stress leading to cell damage and cell membrane rupture. 
The damaged cells can then invert their cell membrane, allowing close contact between 
the anionic side of the cell and the urine. This interaction results in crystal bonding at 
that location. Step 5: Crystal retention and stone formation. At this stage, the formation 
of kidney stones depends on the presence of promoting and inhibiting molecules in the 
urine (Figure 3) [104]. All of the steps are crucial for the formation of stones. Researchers 
have shown that urine contains small molecules such as citrate and pyrophosphate, 
and macromolecules such as glycoproteins, glycosaminoglycans, and proteoglycans 
can alter and inhibit the formation of stones [110-116]. Abnormalities in the structure 
or function of these molecules have been identified in recurrent kidney stone patients 
[104, 108]. Theoretically, Ca2+-containing kidney stones can be prevented by increasing 
physiological inhibitory molecules such as nephrocalcin (NC), Tamm-Horsfall protein 
(THP), and osteopontin (OPN) or by reducing the urinary Ca2+ concentration [117-121]. NC 
is a Ca2+-binding glycoprotein and one molecule of NC can bind to four molecules of Ca2+ 
[122]. NC is able to inhibit the nucleation phase, Ca2+ oxalate monohydrate (COM) crystal 
growth, crystal aggregation and crystal adherence to renal tubules [120, 122]. THP is a 
strong crystal aggregation inhibitor that is reported to significantly reduce COM crystal 
endocytosis [123]. This indicates that THP may prevent the COM crystals uptake by the 
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distal tubular epithelial cells of the kidney and thereby inhibit renal crystal retention 
and urolithiasis [124]. OPN plays a crucial role in inhibiting the nucleation step and CaOx 
crystal growth and aggregation phase [125]. What is more, OPN is able to direct CaOx 
crystallization to the CaOx dihydrate phase instead of CaOx monohydrate phase [126]. 
Hypercalciuria is present in about 40 to 60% of all patients with kidney stones [127]. 
Therefore, targeting urinary Ca2+ is an appealing intervention that should be further 
investigated in the future.
Figure 3.  Mechanisms of kidney stone formation. 
The process of kidney stone formation includes several steps such as urine supersaturation, nucleation, 
crystal growth and crystal aggregation, crystal-cell interaction and crystal retention and stone formation.
Fine tuning of Mg2+ reabsorption
Mg2+ transport in the distal convoluted tubule
The DCT reabsorbs nearly 10% of the filtered Mg2+ in the kidney [128]. There is no Mg2+ 
reabsorption beyond the DCT. Mg2+ reabsorption is tightly controlled by the Mg2+ 
transporters, channels, and sensors in the DCT [4, 5, 129]. However, it is still not totally 
understood how these transporters, channels, and sensors mediate the Mg2+ influx and 
efflux. In 2011, patients carrying mutations in CNNM2, which encodes cyclin and CBS 
domain divalent metal cation transport mediators (CNNM2), were found to suffer from 
hypomagnesemia [130]. Later studies demonstrated that CNNM2 is involved in Mg2+ 
transport in the kidney [131, 132]. In this segment, the structure and molecular function 
of CNNMs and a novel urinary Mg2+ excretion related gene, Arl15, will be described.
Domain distribution of CNNMs
CNNM (1-4) proteins are also known as ancient conserved domain proteins (1-4) and 
share homology with cyclins. However, the function of CNNMs in the cell cycle has not 
been identified. Structurally, CNNMs possess four different domains that are combined 
by linkers [132] (Figure 4). The extracellular amino (N)-terminal domain which contains 
a conserved N residue (N112 in CNNM2, N73 in CNNM3 and N85 in CNNM4) is crucial for 
glycosylation. This glycosylation site is also important for cell surface expression [132]. 
After the N-terminal domain is a domain of unknown function-21 (DUF21) that crosses 
the plasma membrane three times [132]. The cytosolic cystathionine β-synthase (CBS) 
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domains, known as the ‘Bateman module’, consist of two consecutive CBS motifs [132]. 
As with most CBS domain proteins, the Bateman modules of CNNMs interact with each 
other. The CBS2 domain of CNNMs contains an extended loop that makes this Bateman 
motif in CNNMs different from the Bateman motifs discovered in other proteins [133-135]. 
Figure 4. Structural overview of CNNM. 
A, Linear model of CNNMs, showing the four color-coded independent domains. Extracellular domain is 
indicated in dark blue, DUF21 transmembrane domain is indicated in orange, Bateman domain is indicated 
in light blue and CNBH domain is indicated in light green, the remaining part is the intracellular carboxyl (C)-
terminal tail (C-tail). B, Structure of CNNMs, with color-coded domains matching with A. DUF21, domain with 
unknown function 21. CNBH, cyclic nucleotide monophosphate-binding homology domain (Figure adapted 
from [135]). 
This extended loop plays a crucial role in interacting with other proteins. Studies showed 
that phosphatase of the regenerating liver (PRLs) bind to the extended loop of the CBS2 
domain of CNNM3 to mediate intracellular Mg2+ levels [136, 137]. The CBS domains are 
followed by a cyclic nucleotide monophosphate-binding homology domain (CNBH) and 
an unstructured carboxyl (C)-tail [132]. 
20
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Organ distribution and localization of the CNNM protein family
The tissue distribution and expression pattern of the CNNMs are quite diverse [130, 132, 
138, 139]. CNNM1 functions as a copper chaperone or storage protein that is mainly 
expressed in the brain. Northern blots revealed that CNNM1 is moderately expressed 
in the testis and very low expression levels of CNNM1 have also been detected in the 
stomach, small intestine, colon, spleen, heart, lungs, liver, kidney, and skeletal muscles 
[138]. CNNM2 is ubiquitously expressed in the body and is highly expressed in the kidney, 
brain, liver, and heart. CNNM2 is localized in the TAL and DCT of the kidney [130]. CNNM3 
is also ubiquitously present but has the highest expression in the brain, lung, spleen, and 
heart. It is moderately expressed in the liver, colon, lung, testis, and placenta. However, 
little expression is detected in skeletal muscles or small intestine [132, 140]. CNNM4 is 
abundant in the heart, kidney, lung, placenta, testis, and intestinal tract [132, 140]. CNNM4 
expression can also be detected in the epididymis and sperm [141].
Importance of CNNM2 in regulating Mg2+ homeostasis
In 2011, Stuiver et al. reported that renal Mg2+ reabsorption is disturbed in patients carrying 
CNNM2 mutations [130]. Later, Arjona et al. identified five new mutations in CNNM2 in 
five families suffering from intellectual disability, seizures, and hypomagnesemia [142]. 
Interestingly, CNNM2 mutations (except for p.L330F) identified in the hypomagnesemic 
patients resulted in significantly decreased 25Mg2+ uptake in HEK293 cells [142]. Cnnm2-
knockdown zebrafish exhibited neurodevelopmental impairments, weak touch-evoked 
escape behavior, and decreased total body Mg2+ content [142]. These phenotypes were 
rescued by injecting mammalian wildtype cnnm2 cRNA [142]. Similar studies investigating 
the function of CNNM2 in Mg2+ homeostasis have also been performed by using Cnnm2 
heterozygous (Cnnm2+/-) mice and kidney-specific knockout mice [131]. Homozygous 
Cnnm2 knockout mice died during embryonic development [131]. Compared with Cnnm2 
wildtype (Cnnm2+/+) mice, Cnnm2+/- mice exhibited lower serum Mg2+ levels. However, 
urinary and fecal Mg2+ excretion in Cnnm2+/+ mice and Cnnm2+/- mice did not differ 
significantly [131]. Cnnm2 kidney-specific knockout mice demonstrated a decrease in 
serum Mg2+ level [131]. Collectively, all of these results suggest that CNNM2 plays a crucial 
role in maintaining the Mg2+ balance. 
Regulation of CNNMs localization and activity by CNNM ligands and 
interacting partners
Studies have indicated that ligands and CNNM binding partners can modify the cellular 
localization and activity of CNNM proteins [136, 137, 143]. For example, clathrin adaptor 
protein (AP) complex-1 mediates the localization of CNNM4 at the basolateral membrane 
[144]. Mutations of three dileucine motifs (L575/576, L758/759, and L765/766) in the CNBH 
domain of CNNM4 abrogated CNNM4 basolateral localization and CNNM4’s interaction 
with AP-1A and AP-1B [144].
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The activity of CNNMs can also be regulated by either small ligands such as Mg2+ and ATP 
or proteins. Hirata et al. first found the direct binding of ATP to the Bateman module of 
CNNM2 by surface plasmon resonance (SPR) [137]. ATP binding assays demonstrated that 
this binding is Mg2+ dependent since the binding affinity of the CBS domain for ATP is 
stronger in the presence of Mg2+ than the conditions when Mg2+ is absent [137]. 
In 2014, two different groups separately reported that CNNMs interact with the PRLs 
to regulate intracellular Mg2+ concentration [136, 137]. PRL has three members: PRL1, 
2, and 3, which are highly expressed in a large number of cancers [145, 146]. Binding 
between CNNM3 and PRL-2 is important for breast cancer cell proliferation and tumor 
growth, and inhibition of this binding can hinder human breast cancer cell proliferation 
[147]. Later studies revealed that all PRL family members bind to CNNMs (CNNM1-4), and 
truncated CNNM3 mutagenesis studies showed that the CBS domain plays a fundamen-
tal role in forming the complex [136, 143]. Moreover, the highly conserved D558 residue, 
which is localized at the extended loop of the CBS2 motif of CNNM2, was found to play a 
determinant role in forming the CNNM/PRL complex [134]. This conserved residue act as 
a pseudosubstrate of PRL and their binding inhibits Mg2+ efflux [134, 136]. 
ARL15 as a novel gene in renal Mg2+ handling
ADP ribosylation factor like GTPase 15 (ARL15), which is a member of the GTP-binding 
proteins, plays a crucial role in renal Mg2+ handling [148]. Recently, Corre et al. reported 
that ARL15 influences renal Mg2+ reabsorption through regulating the activity of the 
epithelial Mg2+ channel TRMP6 [148]. The T46N ARL15 mutant, which was predicted to 
possess a dominant negative nature, failed to increase TRPM6 channel activity [148]. 
Immunohistochemistry results indicated that ARL15 is highly expressed in the TAL and 
DCT [148]. In their zebrafish model, arl15 knockdown resulted in increased urinary Mg2+ 
excretion. ARL15 is shown to be mainly localized in the Golgi, but it is also expressed in 
the plasma membrane and intracellular vesicles in 3T3-L1 cells [149]. This indicates that 
ARL15 might be involved in vesicular trafficking and posttranslational modification [149]. 
A genome-wide association study (GWAS) showed that ARL15 is associated with low 
serum adiponectin levels, lipid levels, fasting insulin levels, and type 2 diabetes [150]. 
Rocha et al. reported that the Arl15 mRNA expression level was significantly increased 
with the process of adipogenesis in 3T3-L1 adipocytes. Knocking down Arl15 expression 
significantly impaired 3T3-L1 preadipocyte differentiation and droplet formation [149]. 
Moreover, decreased mRNA expression levels of adiponectin and reduced secretion of 
adiponectin in 3T3-L1 adipocytes were demonstrated in Arl15 knockdown cells [149]. 
However, Arl15 knockdown does not affect insulin-signaling and glucose uptake, sug-
gesting that the function of ARL15 may be restricted to adiponectin secretion and adi-
ponectin vesicle trafficking [149].
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Chapter 1
Outline of this thesis
The aim of this thesis is to get insight into the role of Na+, Ca2+, and Mg2+ transporters in 
diseases such as diabetes, hypertension, kidney stone disease, hypomagnesemia, and 
renal carcinoma. Although much is known about the (patho) physiology of these diseases, 
little is known about the molecular mechanisms underlying these transport disorders in 
the kidney. Chapter 2 provides new insights into renal Na+-glucose handling. Diabetic 
mice were treated with dapagliflozin, an SGLT2 inhibitor, and the expression of Na+ 
transporters in the kidney was investigated. This study will help us to better understand 
the effect of dapagliflozin treatment on the local and downstream Na+ transporters in 
the kidney. In Chapter 3, we studied an out-of-the-box idea to prevent kidney stone 
formation. Based on the literature on the Ca2+-binding loop of EF-hand proteins, several 
small peptides (20-30 residues) were developed and analyzed for their Ca2+-binding 
affinity. To assess the efficacy of such peptides in vivo, we aimed to generate a kidney 
stone mouse model. This study provides the first step towards testing a novel approach 
to the treatment and prevention of kidney stones. In Chapter 4, we investigated the role 
of ARL15 in Mg2+ homeostasis. ARL15 expression and tissue distribution were investigated. 
Arl15+/- mice were generated to investigate its role in renal Mg2+ handling by analyzing 
urine and serum Mg2+ levels, as well as the expression of renal Mg2+-related genes. In 
Chapter 5, the functional relevance of binding between ARL15 and CNNMs was outlined. 
Proximity-dependent biotin identification, affinity-purification/mass spectrometry, 
and co-immunoprecipitation were used to investigate the binding of ARL15 to CNNMs 
proteins. Furthermore, ARL15-mediated CNNMs’ cell surface expression and Mg2+ 
transport activities were studied in various types of renal cell carcinoma cell lines. These 
findings revealed a novel regulatory mechanism of Mg2+ transport within the DCT, which 
will help to understand the regulation of Mg2+ handling in this segment. Finally, the 
findings from the studies of this thesis are discussed and summarized in Chapter 6 and 7.
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Inhibition of the sodium/glucose co-transporter 2 (SGLT2) is a new therapeutic strategy 
for diabetes. It is unclear how proximal loss of sodium (Na+) (and glucose) affects the 
subsequent Na+ transporters in the proximal tubule (PT), thick ascending limb of loop 
of Henle (TAL), distal convoluted tubule (DCT), and collecting duct (CD). Mice on a high 
fat diet were administered 3 doses streptozotocin (STZ) 6 days prior to oral dapagliflozin 
administration or vehicle for 18 days. A control group of lean mice were also included. 
Body weight and glucose were recorded at regular intervals during treatment. The 
expression of renal Na+ transporters in nephron segments were analyzed by RT-qPCR 
and Western blot. Dapagliflozin treatment resulted in a significant reduction in body 
weight and blood glucose compared to vehicle treated controls. mRNA results showed 
that sodium-hydrogen antiporter 3 (Nhe3), solute carrier family 34 member 1 (Slc34a1) 
and sodium channel epithelial 1 subunit alpha (Scnn1a) expression was increased, Solute 
carrier family 8 member 1 (Slc18a1), sodium channel epithelial 1 subunit beta (Scnn1b) and 
sodium channel epithelial 1 subunit gamma (Scnn1g) expression declined, respectively, 
in dapagliflozin-treated mice when compared with saline vehicle mice. Solute carrier 
family 12 member 1 (Slc12a1) and solute carrier family 12 member 3 (Slc12a3) mRNA 
expression were not affected by dapagliflozin treatment. ATPase, sodium-potassium 
transporting, beta 1 polypeptide (Atp1b1) expression was also increased significantly by 
dapagliflozin treatment, but it did not affect ATPase, sodium-potassium transporting, 
alpha 1 polypeptide (Atp1a1) and solute carrier family 2 member 2 (Slc2a2) expression. 
Western blot analysis showed that sodium-phosphate cotransporter (NaPi-2a), NHE3 
and sodium-potassium-ATPase subunit beta 1 (Na+-K+-ATPase β1) expression was up-
regulated in dapagliflozin-treated diabetic mice when compared with saline vehicle mice. 
Our findings suggest that dapagliflozin treatment augments compensatory changes in 
the renal PT in diabetic mice. 
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Introduction
Type 2 diabetes mellitus (T2DM) is a major health problem affecting 415 million people 
worldwide [1, 2]. This represents 8.3% of the adult population, with equal rates in 
women and men [3]. From 2012 to 2015, approximately 1.5 to 5.0 million deaths each 
year resulted from diabetes [4]. Diabetes and hypertension frequently occur together [5]. 
Hypertension in these patients further increases their already elevated cardiovascular 
risks, yet is difficult to manage. Indeed, in about half of the diabetic population, blood 
pressure targets are not met despite the use of multiple blood pressure lowering drugs, 
including diuretics [6-8].
Recently, dapagliflozin, a SGLT2 (SLC5A2) inhibitor, was introduced as a novel class of 
glucose-lowering agents for the treatment of type 2 diabetes. As SGLT2 is responsible 
for approximately 90% of the filtered glucose reabsorption in the PT segment 1 and 2 
(S1/2) [9-11], its inhibition reduces renal glucose and Na+ reabsorption, leading to urinary 
glucose excretion and a reduction in blood glucose levels [12]. Therefore, dapagliflozin is 
considered to be an efficient and novel drug to treat patients with T2DM [13-16].
Some studies have also demonstrated that SGLT2 inhibitors exhibit an impressive diu-
retic effect and consequent blood pressure reduction, whereas others described modest 
effects on volume status [17-20]. SGLT2 inhibition reduces Na+ reabsorption in the PT and 
thereby increases the distal tubular Na+ load, which inhibits the renin-angiotensin-aldos-
terone system (RAAS) activation [21]. The kidneys efficiently reabsorb 99% of filtered Na+ 
by the combined action of: i) the PT where 60-70% is reabsorbed via NHE3, SGLT1 and 
SGLT2 [22]; ii) the TAL that is responsible for 15-25% reabsorption via paracellular routes 
and NKCC2; iii) the DCT that reabsorbs 15-25% via the thiazide-sensitive NCC [23]; iv) the 
CD where the Epithelial sodium channel (ENaC) facilitates the reabsorption of the remain-
ing 1-2% [10, 24].
A recent study has found that treatment with an SGLT2 inhibitor increases the expres-
sion of medullary transport proteins [1]. However, a systematic analysis of the compensa-
tory mechanisms that regulate renal Na+ reabsorption after SGLT2 treatment is lacking. 
Knowledge of which nephron segment compensates for proximal Na+ loss is of great fun-
damental and clinical interest, as this would provide the major pharmacological target 
for antihypertensive treatment.
Therefore, the purpose of this study was to identify the compensatory impact of prox-






Adult male Swiss mice (Harlan, Oxon, UK) at 16 weeks of age were housed in an air-
conditioned room at 22±2°C with 12:12 h light/dark cycle. Mice had free access to 
high fat diet (45% AFE Fat; Special Diet Services, Witham, UK; total energy 26.15 kJ/g). 
An additional lean group had free access to standard rodent chow (Teklad Global 18% 
Protein Rodent Diet; Harlan, UK; total energy 13.0 kJ/g). All animals were free to access 
drinking water and respective diet, and no adverse effects were observed during the 
entire experimental study. All experiments were performed according to the principles 
of Laboratory Animal Care (NIH publication no. 86-23, revised 1985) and UK Home Office 
Regulations (UK Animals Scientific Procedures Act 1986). 
Experimental treatments 
Mice commenced high fat diet on day -20 and remained on this diet for the duration of 
the study. On day -6, streptozotocin (50 mg/kg; i.p; Sigma-Aldrich, Dorset, UK) freshly 
prepared in ice-cold 0.1 M Na+ citrate buffer (HCl/pH 4.5) was administered 3 doses in 
total over a period of 6 days to induce diabetes. On day 0, one group of high fat mice 
(n=8) commenced daily treatment with dapagliflozin (1 mg/kg; p.o.; Stratech Scientific 
Ltd.,Suffolk, UK) for 18 days whereas high fat control group (n=8) received saline vehicle 
(0.9% w/v NaCl; p.o.) once-daily for the same time period. The volume for the oral gavage 
was 100 μL. A diagrammatic representation of the experimental design is shown in 
Figure 1.
Quantitative analyses of gene expression
At study termination, total RNA was extracted from mouse kidney tissues with Trizol 
(Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer’s protocol. 
Subsequently, mouse RNA samples were subjected to DNase treatment (Invitrogen, 
Breda, The Netherlands) to prevent genomic DNA contamination and the reverse tran-
scriptase reaction was subsequently performed to synthesize cDNA [25]. mRNA levels 
of the target genes were determined by relative RT-qPCR following the MIQE guidelines 
20 with a CFX96TM real-time PCR detection system (Bio-Rad Laboratories, Hercules, CA, 
USA) using iQTM SYBR Green Supermix (Bio Rad) detection of single PCR product accu-
mulation. Each group had 8 kidneys and RT-qPCR experiments were commenced in trip-
licate. All primers for Slc5a2, Slc5a1, Nhe3, Slc34a1, Slc12a1, Slc12a3, Slc18a1, Scnn1a, Scnn1b, 
Scnn1g, Atp1a1, Atp1b1, Slc2a2, and Gapdh were purchased from Biolegio BV (Nijmegen, 
Netherlands). In this study, gene expression levels were normalized to the expression 
levels of the standard species-specific reference genes glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh). Relative mRNA expression was analyzed using the Livak method 
(2-ΔΔCt). Primer sequences are shown in Table 1. 
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Figure 1. Timeline for the experimental study. 
Group 1 (lean control), lean mice on normal diet for 38 days. Group 2 (high fat controls), mice commenced 
a high fat diet on day -20 and subsequently received STZ treatment on day -6. At day 0, saline vehicle was 
administered for 18 days. Group 3 (high fat dapagliflozin), mice commenced high fat diet on day -20 and 
subsequently received STZ on day -6. At day 0, dapagliflozin was administered for 18 days. STZ, streptozotocin; 
Lean, lean control mice; HFD, high fat diet treatment mice; DAPA, dapagliflozin treated mice.
Table 1. Primer sequences used for real-time quantitative RT-PCR.















Slc5a1, Solute carrier family 5 member 1; Slc5a2, Solute carrier family 5 member 2; Slc34a1, Solute carrier family 
34 member 1; Slc12a1, Solute carrier family 12 member 1; Slc12a3, Solute carrier family 12 member 3; Slc18a1, 
Solute carrier family 8 member 1; Scnn1 (a, b, g), Sodium channel epithelial 1 subunit (alpha, beta, gamma); 
Nhe3, Sodium-hydrogen antiporter 3; Atp1a1, ATPase, sodium-potassium transporting, alpha 1 polypeptide; 





Lysis buffer: 150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM EGTA, 1 mM 
sodium-orthovanadate, 1% (v/v) Triton X-100, 10 mM sodium-glycerophosphate, 50 
mM sodium fluoride, 0.27 M sucrose, 10 mM sodium pyrophosphate, containing freshly 
added tablet of complete protease inhibitor cocktail (Roche, Basel, Switzerland) and 
0.1% (v/v) β-mercaptoethanol. SDS-PAGE sample buffer: 5x 10% (w/v) SDS, 10 mM 
β-mercaptoethanol, 50% (v/v) glycerol, 0.3 M Tris-HCl (pH 7.5), 0.05% (w/v) bromophenol 
blue. TBS-T (Tris-buffered saline, 0.1% (v/v) Tween 20): Tris-HCl (200 mM, pH 7.5), 0.15 M 
NaCl, and 0.2% (v/v) Tween-20. 
Immunoblotting 
Kidney tissues were isolated from mice and homogenized in ice cold lysis buffer. The kidney 
lysates were clarified by centrifugation at 4°C for 15 minutes at 16, 110 g and supernatants 
were stored at -80°C. Protein concentrations were measured by performing a Bicinchoninic 
acid protein assay (BCA) (Fisher Scientific, Hampton, NH, USA) and 20 µg of protein was 
used for western blot. Blots were then incubated in primary antibody overnight rolling 
at 4 °C. The following primary antibodies were used: sodium-chloride cotransporter 
(NCC) (Millipore, Billerica, MA, USA), sodium-potassium-chloride cotransporter (NKCC2) 
(Millipore, Billerica, MA, USA) [26], NaPi-2a (kind gift of Dr. Jürg Biber [27]), NHE3 (Millipore, 
Billerica, MA, USA) [28], Na+-K+-ATPase β1 (Merck KGaA, Darmstadt, Germany) [29], 
β-actin (Sigma-Aldrich, St. Louis, MO, USA). Next day, the blots were washed with TBS-T 
to remove unbound primary antibody and incubated with secondary antibodies for 1 
hour at room temperature. Secondary antibodies were as follows: peroxidase conjugated 
goat anti-rabbit (Sigma Aldrich, Zwijndrecht, The Netherlands); peroxidase conjugated 
sheep anti-mouse (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA). 
After subsequent washes, the protein was visualized with chemiluminescent reagent 
(SuperSignal West femto/pico; Thermo Scientific, Waltham, MA, USA). Photos were made 
with Chemidoc (Bio-Rad Laboratories Inc, Hercules, CA, USA).
Statistical analysis
Parametric data were analyzed using a one-way analysis of variance with Tukey’s post hoc 
test to correct for multiple comparisons using GraphPad Prism software 5.0 (GraphPad, 
CA, USA). One-way ANOVA followed by Scheffe’s test was used to examine the differences 
among groups. All data were shown as mean ± SEM. Differences were considered to be 
significant if P<0.05.
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Results
Effects of high fat feeding and dapagliflozin on body weight and blood 
glucose
Mice receiving the high fat diet increased in body weight from day -20 to day 0 more than 
those receiving normal chow. From day 0 to 18, high fat control mice displayed a further 
modest increase in body weight, whereas mice treated with dapagliflozin exhibited a 
significant reduction in body weight. Body weight of lean mice did not differ during the 
study. High fat control mice displayed increased blood glucose concentrations from day 
0 to 18. In contrast, high fat mice treated with dapagliflozin exhibited a marked reduction 
in blood glucose. Glucose concentrations were unchanged in lean mice. Results are 
shown in Table 2.
Table 2. Effects of high fat feeding and dapagliflozin on body weight and blood glucose.
Parameter
lean (n=8) HF+saline (n=8) HF+DAPA (n=8)
d0 d18 d0 d18 d0 d18
Body weight (g) 37.6±5.2 36.0±2.3 45.7±4.2 50.2±4.3a 43.5±5.7 37.6±5.2b
Blood glucose (mM) 5.2±0.9 5.8±0.4 18.5±3.7 22.3±4.1a 17.6±1.7 7.6±2.1b
Lean, lean control mice; HF + saline, high fat diet fed mice receiving saline vehicle; HF + DAPA, high fat diet fed 
mice receiving dapagliflozin (1mg/kg). d0, day 0, saline vehicle or DAPA were administered; d18, day 18, saline 
vehicle or DAPA were administered for 18 days; aP<0.05 vs. lean, bP<0.05 vs. HF + saline.
The effect of dapagliflozin on Na+ transporter expression in the proximal 
tubule
RT-qPCR was performed to analyze the renal expression of Slc5a1, Slc5a2, Nhe3, and 
Slc34a1 in the dapagliflozin-treated and control group mice. Gene expression of Nhe3 and 
Slc34a1 was increased significantly by 33% and 34%, respectively, in the dapagliflozin-
treated mice compared to high fat control group (Figure 2C and Figure 2D).In contrast, 
there were no significant differences in the expression of Slc5a1 and Slc5a2 between 
dapagliflozin-treated group and vehicle control group (Figure 2A and Figure 2B). Protein 
expression level of NaPi-2a and NHE3 was further investigated by Western blot analysis 
(Figure 2E). The expression of NHE3 and NaPi-2a (Slc34a1) was increased by 55% and 
139% in dapagliflozin treatment group when compared with saline vehicle diabetic mice 
(P<0.05) (Figure 2F and Figure 2G).
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Figure 2. Effect of dapagliflozin on the expression of the Na+ transporters in the proximal 
tubule. 
A, B, C, and D, Quantitative RT-PCR analyses for the expression of Slc5a1, Slc5a2, Nhe3, and Slc34a1 in the 
proximal tubule. E, Immunoblot analysis of NaPi-2a (∼70 kDa), NHE3 (∼93 kDa) in mice fed the indicated diet. 
F and G, Histograms for NaPi-2a, NHE3 Western blots results and normalized for β-actin expression. *P<0.05. 
Lean, lean control mice; HF + saline, high fat diet fed mice receiving saline vehicle; HF + DAPA, high fat diet 
fed mice receiving dapagliflozin (1mg/kg). 
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The effect of dapagliflozin on Na+ transporter expression in thick ascending 
limb of loop of Henle and distal convoluted tubule 
In order to study the effect of dapagliflozin on the expression of the Na+ transporters in 
the TAL and DCT, the expression of Slc12a1, Slc12a3, and Slc18a1 was analyzed by RT-qPCR. 
The expression of Slc12a1 and Slc12a3 tended to increase by 23% and 17%, respectively, 
in the dapagliflozin treatment group (P<0.05) (Figure 3A and Figure 3B). However, these 
changes did not reach statistical significance. The expression of Slc18a1 was shown to 
decrease by 27% in the dapagliflozin treatment group when compared with saline vehicle 
control group (P<0.05) (Figure 3C). Dapagliflozin treatment did not alter the protein 
abundance of NCC and NKCC2 when compared with saline vehicle treated diabetic mice 
(Figure 3D-F)
Figure 3. Effect of dapagliflozin on the expression of the Na+ transporters in the loop of 
Henle and distal convoluted tubule. 
A, B, and C, Quantitative RT-PCR analyses for the expression of Slc12a1, Slc12a3, and Slc18a1 in the loop of 
Henle and distal convoluted tubule. D, Immunoblot analysis of NKCC2 (∼150 kDa), NCC (∼120 kDa) in mice 
fed the indicated diet. E, Histograms for NCC Western blot results and normalized for β-actin expression. F, 
Histograms for NKCC2 Western blot results and normalized for β-actin expression. *P<0.05. Lean, lean control 




The effect of dapagliflozin on the expression of Na+ channels in the 
collecting duct
To further investigate the effect of proximal Na+ loss on the Na+ transporters in the CD, 
we tested the expression of the Scnn1 (a, b and g) by RT-qPCR. Dapagliflozin treatment 
increased the expression of Scnn1a by 29% when compared with vehicle control mice 
(Figure 4A). In addition, the expression of Scnn1b and Scnn1g declined significantly by 
13% and 26%, respectively, in dapagliflozin-treated group compared to vehicle controls 
(Figure 4B and Figure 4C).  
Figure 4. Effect of dapagliflozin on the expression of the Na+ transporters in the collecting 
duct.
A, B, and C, Quantitative RT-PCR analyses for the expression of Scnn1a, Scnn1b, and Scnn1g, in the collecting 
duct. *P<0.05. Lean, lean control mice; HF + saline, high fat diet fed mice receiving saline vehicle; HF + DAPA, 
high fat diet fed mice receiving dapagliflozin (1mg/kg).
The effect of dapagliflozin on the expression of Na+-K+-ATPase and glucose 
transporter 2
We also evaluated the effect of dapagliflozin on Slc2a2 and Na+-K+-ATPase transporters by 
RT-qPCR. The expression of Atp1b1 was significantly increased by 32% in the dapagliflozin-
treated mice compared to the vehicle control group (Figure 5B). The expression of Atp1a1 
was not changed in the dapagliflozin-treated group (Figure 5A). Dapagliflozin treatment 
caused a slight reduction in the expression of Slc2a2 compared to vehicle control group, 
but this effect failed to reach statistical significance (Figure 5C). Western blot analysis 
was further used to investigate the protein expression level of Na+-K+-ATPase β1. Na+-
K+-ATPase β1 expression was increased by 123% in dapagliflozin treatment group when 
compared with saline vehicle diabetic mice (Figure 5D-E).
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Figure 5. Effect of dapagliflozin on Na+-K+-ATPase and Slc2a2. 
A, B, and C, Quantitative RT-PCR analyses for the expression of Atp1a1, Atp1b1, and Slc2a2. D, Immunoblot 
analysis of Na+-K+-ATPase β1 (∼50 kDa) in mice fed the indicated diet. E, Histogram for Na+-K+-ATPase β1 Western 
blots results and normalized for β-actin expression. *P<0.05. Lean, lean control mice; HF + saline, high fat diet 
fed mice receiving saline vehicle; HF + DAPA, high fat diet fed mice receiving dapagliflozin (1mg/kg).
Discussion
In this study, we demonstrated that inhibition of SGLT2 increased the mRNA expression 
level of Nhe3, Slc34a1, and Scnn1a. Western blotting results showed that the protein 
expression level of NHE3 and NaPi-2a was increased in dapagliflozin-treated mice. 
Moreover, Na+-K+-ATPase β1 protein expression level was also increased. Our findings 
demonstrated that proximal inhibition of Na+ reabsorption via SGLT2 is compensated by 
increased expression of local Na+ transporters in the PT but not in the TAL, DCT and CD. 
The kidneys reabsorb large amounts of filtered glucose to clear urinary glucose, pri-
marily through the SGLT2 in the S1 segment of the PT. Inhibitors of SGLT2 are newly 
developed anti-diabetic agents and interfere with the pathway of physiological glu-
cose reabsorption in the kidney. In this study, high fat and STZ induction significantly 
increased blood glucose when compared with lean group mice. In the dapagliflozin 
treatment group, we found that the blood glucose levels decreased significantly when 
compared with the vehicle control group. In our study, STZ-induced diabetes decreased 
SGLT2 expression. María F et al. have also demonstrated that STZ decreased SGLT2 
expression and activity [30]. In contrast, SGLT2 expression was increased in Akita mice 
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[31], humans [32] with type 2 diabetes, and alloxan-induced diabetic rats [33]. Indeed, 
the use of different diabetic models may, therefore, result in different SGLT2 expression. 
However, despite lower SGLT2 expression in STZ-induced mice, dapagliflozin treatment 
reduced blood glucose levels. We, therefore, expect that in other studies with higher 
SGLT2 expression, the observed effects may even be larger. Moreover, dapagliflozin 
treatment did not change SGLT2 expression in our experiment. The expression of SGLT2 
does not necessarily alter upon dapagliflozin treatment. Other studies also found that 
pharmacological SGLT2 inhibition does not affect the expression of SGLT2 [31, 34]. Given 
the reduction of blood glucose concentrations in the dapagliflozin-treated group at day 
18 when compared with saline vehicle mice, the unchanged SGLT2 expression did not 
impair the effects of dapagliflozin treatment. Therefore, we do not expect that this has a 
major impact on our results. 
The management of hypertension in diabetes is not without controversy [17]. Hence, 
the precise level at which anti-hypertensive therapy should be initiated and what the tar-
get blood pressure should be, remain difficult issues. Many patients with type 2 diabetes 
receive multiple drugs to treat both hyperglycemia and hypertension. The new class of 
SGLT2 inhibitors also induces renal Na+ wasting and, therefore, will have blood pressure 
reducing properties. However, some studies report an impressive diuretic effect and con-
sequent reduction in blood pressure, others described modest effects on volume status 
[17, 35]. It is known that the compensatory capacity of the kidney is immense [36]. Inhi-
bition of Na+ reabsorption in the PT will turn on compensatory systems in local or more 
distally located segments to counteract the proximal Na+ loss. 
In this study, dapagliflozin treatment significantly increased the mRNA expression 
level of Nhe3, Slc34a1 and Scnn1a. In line with the mRNA expression level, Western blot 
results showed that NHE3, NaPi-2a also increased in the dapagliflozin treatment group 
when compared with saline vehicle mice. Therefore, our results suggest that the inhibi-
tion of SGLT2 in the PT can turn on the local Na+ compensatory systems. Increased reab-
sorption of Na+ may result in Na+ retention and elevate blood pressure in type 2 diabetes 
[37-39]. Wang et al. showed that changed expression of Na+ transport in renal PT can be 
compensated by changes in more distal tubule in nephron, by tubuloglomerular feed-
back and also by glomerular filtration rate adjustments. Nevertheless, extracellular fluid 
volume and consequently blood pressure can also be affected by the changed expression 
of Na+ transport in the PT. Na+  reabsorption initially happens at the PT apical membrane, 
therefore resulting in making apical Na+  transport critical in adjusting the extracellular 
fluid volume and ultimately blood pressure control [38]. Indeed, in polygenic human 
essential hypertension, the increase in Na+ transport occurs at the PT and TAL [40-42] 
rather than in more distal nephron segments [43]. Unfortunately, there were no plasma 
and urine electrolytes results in this study. Therefore, further studies are needed to better 
understand of the compensatory mechanisms of the Na+ transporters on adjusting blood 
pressure control. 
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SGLT2 is located in the S1 segment and accounts for 90% of the glucose reabsorption 
[44-47]. Na+ reabsorption across the cell membrane creates an energy gradient 
that in turn allows the reabsorption of glucose. On the other side of the cell, Na+ is 
extruded through Na+-K+-ATPase into the bloodstream [48-50]. Slc2a2 is responsible 
for transporting glucose into bloodstream [51-53]. In order to evaluate if the increased 
expression of Na+ transporters in the PT influenced the expression of Na+-K+-ATPase and 
Slc2a2, we furthermore tested the expression of Atp1a1, Atp1b1, and Slc2a2 transporters 
by RT-qPCR. The results revealed that the expression of Atp1b1 increased significantly 
in the dapagliflozin-treated group, however, the expression of Atp1a1 and Slc2a2 did 
not change. Furthermore, Na+-K+-ATPase β1 protein expression level was also increased 
in the dapagliflozin-treated group. The increased expression of Na+-K+-ATPase β1 may 
facilitate Na+ to be transported into the bloodstream, which could lead to salt retention 
and hypertension. These effects may blunt the potential blood pressure-lowering effects 
of the SGLT2 inhibitor. 
In conclusion, we demonstrated that the SGLT2 inhibitor, dapagliflozin, increased 
NHE3, NaPi-2a expression in the PT. Furthermore, Na+-K+-ATPase β1 was also up-regu-
lated which may facilitate the transport of the Na+ into the bloodstream. Our findings 
provide insights that dapagliflozin treatment augments compensatory changes in the 
renal PT in diabetic mice.
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The incidence of nephrolithiasis has been increasing worldwide in recent decades. 
Although medical therapies have significantly improved nephrolithiasis treatment, the 
recurrence rate is still very high after 5 years. Thus, an improved, possibly preventive 
treatment is needed. Our study aims to develop a novel drug to prevent kidney stone 
formation, based on our body’s calcium (Ca2+) regulation. We developed several Ca2+-
binding peptides, analyzed their Ca2+-binding affinity by circular dichroism and tested 
their safety on renal proximal tubule cells. Results showed a Ca2+-induced change in 
ellipticity at 220 nm for peptide 4 (Ac-DKNGDGYIDAAE-NH
2
). This peptide did not induce 
cell toxicity and exhibited cellular uptake in Human Kidney-2 (HK-2) cells. To ultimately 
investigate the biological function of these peptides in vivo, we aimed to establish a 
mouse model of nephrolithiasis. 20 male C57BL/6J mice were given 1% (v/v) ethylene 
glycol (EG) via drinking water and were administrated either a normal Ca2+ diet (0.92% 
w/w) or a high Ca2+ diet (2% w/w) for 28 days. Blood and 24 hours urine were collected on 
day 1, 7, 14, 21, and 28 for electrolyte analysis. Serum Ca2+ concentrations and urinary Ca2+ 
excretions were similar between the two groups, except for day 21 on which serum Ca2+ 
concentration was significantly higher in the high Ca2+ diet group. Ca2+ crystal deposits 
were not detected in the kidneys by Von Kossa staining. Together, our study indicated 
that peptide 4 (Ac-DKNGDGYIDAAE-NH
2
) may have the potential to serve as a peptide 
with low Ca2+-binding affinity in future studies in the kidney stone mouse model. So far, 
we did not establish such a model as we demonstrated that 1% (v/v) EG administration 
in drinking water supplied with a high Ca2+ diet cannot cause kidney stones in C57BL/6J 
mice.
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Introduction 
Nephrolithiasis (kidney stone disease) is a major medical problem with a prevalence 
ranging from 7-13% in North America, 1-5% in Asia and 5-9% in Europe, and the incidence 
is predicted to rise in the next decades [1, 2]. This growing trend is generally considered to 
be due to changes in our lifestyle such as lack of physical activity and poor dietary habits 
[3]. Kidney stone disease is linked to an increased rate of chronic kidney disease, end-stage 
renal failure, hypertension, and myocardial infarction [4]. Medical treatment of kidney 
stones includes dietary management, pharmacological interventions, extracorporeal 
shock wave lithotripsy, and minor endourological intervention for stone removal [5, 6]. 
These treatments can result in severe side effects, such as shock wave lithotripsy that 
may cause acute renal damage [7]. Although medication and minimally invasive surgery 
have significantly improved acute stone management, the recurrence rate can be up to 
14% after 1 year and 35% after 5 years [8]. These data suggest the need for finding a more 
effective approach to prevent stone recurrence.
Two main predisposing factors for kidney stone formation are hyperoxaluria and 
hypercalciuria, with the majority of kidney stones being Ca2+ oxalate (CaOx) stones [9]. 
An estimated 40-60% of kidney stone patients have an increased urinary Ca2+ excretion 
[10-12]. Most of these patients have idiopathic hypercalciuria, meaning that the exact 
underlying mechanism responsible for their hypercalciuria remains unknown [13, 14]. 
The pathogenesis of nephrolithiasis is a complicated process that is still not 
entirely elucidated. In general, stone formation includes a cascade of events: urinary 
supersaturation, nucleation, crystal growth, crystal aggregation, and crystal retention 
[3, 8]. The pro-urine becomes increasingly concentrated towards the loop of Henle. The 
osmolality in this segment can increase 10-fold or even higher as a result of the 180-degree 
turn of the limb of Henle’s loop and the minimal reabsorption of water at this segment. 
This hyperosmolar microenvironment, although crucial for the function of kidney, leads 
to urinary ‘supersaturation’ with poorly soluble waste salts such as Ca2+ phosphate (CaP) 
and CaOx, which are the main components for crystal formation [15]. The inability to 
excrete crystalline material results in the onset of nucleation and is highly appropriate 
for accumulating Ca2+-binding proteins that promote crystal growth and aggregation [3].
In this study, we aimed to develop a Ca2+-binding peptide with supersaturation-specific 
Ca2+-buffering capacity that may ultimately be used to investigate the peptide’s safety 
and efficacy by repeated administration in a kidney stone mouse model. Therefore, we 
used the peptide sequence of the so-called EF-hand protein domain [16]. The structure 
of an EF-hand is a helix-loop-helix motif linked by a loop of 12 amino acids that are key 
for Ca2+ binding (Figure 2A) [17]. Yap et al. compared 90 EF-hand motif structures in 31 EF-
hand containing proteins, and found that variations in the amino acids of the Ca2+-binding 
loop can lead to a wide range of Ca2+-binding affinities [18]. Based on this knowledge, we 
synthesized several small EF-hand peptides (around 20-30 residues) and tested their Ca2+-
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binding affinity. In addition, the present study aimed to establish a kidney stone mouse 
model. Wildtype (C57BL/6J) mice were treated with 1% (v/v) ethylene glycol (EG) for 28 days 
via their drinking water while simultaneously placed on either a high-Ca2+ (2% w/w) diet or 
normal Ca2+ diet (0.92% w/w) in order to induce Ca2+ crystal deposition in the kidney. 
Methods and materials 
Ethical approval of the study protocol
This study has been approved by the Dutch Central Commission for Animal Experiments 
(CCD; AVD1030020186805) and the Animal Ethics Board of Radboud University Nijmegen 
(RU-DEC2018-0030; Nijmegen, The Netherlands).
Chemicals
The EG was provided by Merck Schuchardt OHG and was diluted to 1% (v/v) EG in demi 
water. Peptides were purchased from EMC Microcollections (Tübingen, Germany), with 
peptide sequences depicted in Figure 2. All of the peptides in the figure were amino (N)-




HK-2 cells were cultured in Dulbeccos Modified Eagles Medium (DMEM; Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA ) supplemented with Hams-F12 (GE Healthcare, 
Chicago, USA), HEPES (20 mM) (Gibco, Thermo Fisher Scientific), 1% (v/v) penicillin-
streptomycin (Gibco, Thermo Fisher Scientific), 10% (v/v) fetal bovine serum  and non-
essential amino acids (Lonza Westburg, Arnhem, The Netherlands). The cells were 




The resazurin assay (Sigma Aldrich, Zwijndrecht, The Netherlands), staining mitochondrial 
viability, is used as a measure of cell viability upon exposure of increasing concentrations 
of peptide to HK-2 cells. At the start of the experiment, 10,000 cells per well were seeded 
into 96-well plates. After 24 hours, the medium was replaced by a series of peptide 
concentrations (0-1 mM, dissolved in 50 mM HEPES, pH 8.0 adjusted with NaOH), with 
peptide diluted in the cell culture medium. Cells were incubated with the peptide for 2, 
4, and 24 hours at 37 °C. At the indicated time points, the peptide solution was removed 
from the cells and 50 μl resazurin (0.1 mg/ml, diluted in medium) was added to the cells 
and incubated for 4 hours at 37 °C. Subsequently, the quantity of resorufin production 
(colorimetric change) was measured on a microplate fluorometer (Gibco, Thermo Fisher 
Scientific) using 540 nm excitation and 620 nm emission wavelength. As controls, three 
wells were added to each plate with only resazurin (no cells), cells without resazurin, and 
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100% cell death (1% (v/v) Triton-X-100 (Sigma Aldrich)). All measurements were performed 
in duplo (1 mM peptide) and triplo (0, 0.01, and 0.1 mM peptide).
Circular dichroism spectroscopy
Circular dichroism (CD) experiments were conducted by using a Jasco J-810 
spectropolarimeter (Jasco, Dunmow, United Kingdom) at 20 °C in the wavelength 
range from 250 to 200 nm. The experiments were done according to Jasco J-810 
Spectropolarimeter manual. The measurement was acquired at a scanning speed of 
50 nm/min, a bandwidth of 1 nm, a 0.1 nm data pitch and a 2 seconds data integration 
time were used. Peptide concentration was 250 µM (dissolved in 500 mM HEPES, pH 8.0 
adjusted with NaOH) and Ca2+ concentrations were 0, 0.5, 1, 5 and 10 mM (dissolved in 
Milli-Q). Samples were placed in High Precision Cell (Hellma Analytics, College Park, USA) 
for absorbance measurements.
Proximal tubule cellular peptide uptake
To investigate the potential cellular uptake of the peptide, fluorescence activated cell 
sorting (FACS) was performed. Cy5-labeled peptides were dissolved in 50 mM HEPES, 
pH 8.0 NaOH. One day prior to the FACS measurements, 20,000 HK-2 cells per well were 
seeded in a 96-well plate. After 24 hours, cells were incubated for 15 minutes at 37 °C 
with different concentration of cy5-labeled peptide (0, 0.01, 0.05, and 0.1 mM, diluted in 
DMEM) and penetratin-cy5 (0.01 mM) was used as a positive control. Subsequently, cells 
were washed 3 times with ice cold PBS followed by trypsinization. The cell pellet was 
resuspended in DMEM and cellular uptake was measured by BD FACSMelody™ cell sorter 
(Becton Dickinson, Heidelberg, Germany). Cy5-positive cells were excited at a wavelength 
of 633 nm and emitted at a wavelength of 643–714 nm. The results were analyzed by 
using FlowJo™ v10.6.1 software (ACEA Biosciences, San Diego, USA).
Animal study
20 healthy 8 weeks-old male C57BL/6J mice were obtained from Charles River Laboratories 
(Wilmington, MA, USA). All mice had 2 weeks to adjust to the new environment (Animal 
Research Facility of the Radboud University in Nijmegen, The Netherlands) and their 
pelleted food (Ssniff Spezialdiäten, Soest, Germany). Next, the animals were placed 
on a synthetic chow (Ssniff Spezialdiäten) for another 2 weeks. Throughout the whole 
experiment, the mice were kept in a temperature-controlled room, had free access to 
water and food, and were exposed to 12 hours dark-light cycles. The mice were randomly 
grouped in 4 cages (Eurostandard Type II, Amersfoort, The Netherlands) with 5 animals 
in each cage. During the follow-up period, the animals were kept in their initial cage till 
the day of their sacrifice. 
The cages were randomly divided into two groups: 10 mice were placed on a high 
Ca2+ (HC) diet (2% (w/w) Ca2+) while receiving 1% (v/v) EG via their drinking water, and 
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the other 10 mice continued on the normal Ca2+ (NC) (0.92% (w/w) Ca2+) and received 
1% (v/v) EG in their water. Both the animal conductor and the researchers were blinded 
for the experimental diets. The EG-containing water was changed each week to prevent 
potential breakdown over time. 
The mice were placed in individual metabolic cages (Techniplast, Amersfoort, The 
Netherlands) to collect 24 hour urine on day 1, 7, 14, 21, and 28 (D1, D7, D14, D21, and D28) 
(Figure 1). To prevent evaporation, 100 μl of mineral oil (Sigma-Aldrich) was added to the 
urine collecting tubes in the metabolic cage. After each metabolic cage period, two mice 
from each group were anesthetized with 4% (v/v) isoflurane and sacrificed. Both kidneys 
were harvested for subsequent analysis. Blood was collected from the retro-orbital sinus 
bleeding in the sacrificed mice and from the submandibular vein in the mice that were 
still part of the experiment (Figure 1). 
Figure 1. Timeline for the experimental study (days). 
At day 0 of the experiment and every following week, the mice were placed in individual metabolic cages. 
After each metabolic cage period, blood and 24 hours urine were collected from all the mice and two mice 
from each experimental group were sacrificed and kidneys were harvested, the remaining mice were kept for 
longer time points. MC, metabolic cage.
Von Kossa staining
The kidney tissues were fixed in 4% (v/v) (neutral) buffered formalin for 24 hours. The 
kidneys were subsequently put in a descending series of ethanol concentrations (from 
100 to 50% (v/v)), cleared in xylene, and embedded in paraffin wax. The paraffin blocks 
were cut in 5 µm thick sections. Subsequently, 1% (w/v) aqueous silver nitrate solution 
(Sigma-Aldrich) was added to these samples and they were exposed to 365 nm ultraviolet 
(UV) light for 30 minutes. The unreacted silver nitrate was removed with 5% (w/v) sodium 
thiosulfate (Sigma-Aldrich), rinsed in distilled water, and counterstained with 0.1% 
(w/v) nuclear fast red (Sigma-Aldrich). Subsequently, the slides were dehydrated in an 
ascending series of ethanol concentrations (from 50-100% (v/v)) and cleared in xylene 
and mounted with pertex (Histolab, Gothenburg, Sweden). The presence of Ca2+ crystal 
deposits in the kidney tissue was analyzed by using the light microscope Axio Imager M.2 
(Carl Zeiss, Oberkochen, Germany) with 10x magnification. Images of the samples were 
taken using the ZEISS ZEN microscope software (Carl Zeiss). 
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Serum and urine analysis
Blood was collected on D1, D7, D14, D21, and D28 in microvette tubes (Sarstedt Inc, North 
Carolina, USA) and was allowed to solidify at room temperature for 30 minutes. Serum 
was separated from plasma by centrifugation at 1,792 g for 5 minutes and an additional 
5 minutes at 11,200 g. Urinary pH was measured with the SCHOTT pH meter CG 840 
(Thermo Fisher Scientific). The serum and urinary magnesium (Mg2+) concentrations 
were measured by using a xylidyl blue colorimetric assay kit in accordance with the 
manufacturer’s protocol (Roche Diagnostics, Woerden, The Netherlands). In short, 5 μl 
of standard, precinorm, and diluted samples were added to a 96-well plate. Next, 100 μl 
Tris-buffered EGTA pH 11.25 (Roche Diagnostics GmbH, Mannheim, Germany) was added 
to each well followed by 100 μl xylidyl blue (Roche Diagnostics GmbH). The results were 
determined by a VictorX multilabel plate reader (PerkinElmer, Waltham, MA, USA) set 
to 600 nm. For the serum and urinary Ca2+ measurements, a colorimetric assay kit was 
used in accordance with the manufacture’s protocol (Roche Diagnostics, Woerden, The 
Netherlands). Serum and urinary Ca2+ values were measured by using a VictorX multilabel 
plate reader (PerkinElmer, Waltham, MA, USA) set to 570 nm. Sodium (Na+), potassium 
(K+), chloride (Cl-), oxalate, and citrate measurements were performed at the laboratory 
for diagnostics on an automated system in accordance with the manufacturer’s protocol 
(Abbott Diagnostics, Belgium) at Radboudumc, Nijmegen, The Netherlands. 
Statistical analysis
All data were analyzed using Graphpad Prism 7.0 (Graphpad Software, La Jolla, CA, USA), 
and results were presented as means ± SEM. Unpaired T-test was used to analyze the 
difference between the two experimental groups. One-way ANOVA was used to analyze 
the data within the same group but at the various time points. P<0.05 was considered as 
statistically significant.
Results
Peptides and Ca2+-binding stoichiometry
In order to design our low-affinity Ca2+-binding peptides, we used the EF-hand domain 
as a template. The structure of an EF-hand is comprised of two alpha helices connected 
by a 12-residue Ca2+-binding loop (Figure 2A). This conserved structural motif is present 
in many protein families and is reported to be important for Ca2+-binding [19]. Therefore, 
several variations in these residues of the Ca2+-binding loop were designed and showed in 
Figure 2B. The Ca2+-binding affinity of designed peptides was measured using CD which is 
able to detect the secondary conformation change of the peptides upon binding of Ca2+. 
A Ca2+-induced change in ellipticity at 220 nm was detected upon the addition of Ca2+ 




In the CD study, peptide 4 was selected based on its Ca2+-binding affinity. To further 
investigate the potential toxicity of this peptide on living cells, increasing concentrations 
of peptide 4 (0-1 mM) were added to HK-2 cells for 2, 4 and 24 hours. A resazurin assay 
was performed to assess cell viability at these time points. As shown in Figure 3, none of 
the peptide concentrations resulted in a decreased number of viable HK-2 cells over time, 
compared to 0 mM peptide, suggesting that peptide 4 is not toxic to the cells. Of note, 1% 
(v/v) Triton-X100 resulted in significant cell death (Figure 3).
Figure 2. Circular dichroism monitored Ca2+ and peptide binding.  
A, Schematic figure of a consensus EF hand and Ca2+-binding motif in orange color (figure adapted from 
[20]). The blue and red colors depict the flanking regions of the binding motif. B, The sequence for designed 
peptides and consensus EF-hand motif. Negative charged amino acids that bind with Ca2+ were marked in dark 
green color. C-G, Circular dichroism detection for indicated peptides to assess conformational changes upon 
Ca2+-binding under different concentrations of Ca2+. H, zoom in image from figure G. The data is an average of 
three measurements in one experiment, with the experiment performed once. CD, Circular dichroism.
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Cellular peptide uptake in HK2 cells
In order to detect whether peptide 4 can be taken up by the proximal tubule cells, HK2 
proximal tubular cells were incubated with increasing concentrations of Cy5-labelled 
peptide 4 and Cy5-labelled penetratin as positive control for 15 minutes at 37 °C. FACS 
results showed that the Cy5 signal increased with a higher concentration of peptide 4. 
Yet, the Cy5-labelled signal of 0.01 mM penetratin was 9.5 and 1.5 times higher than the 
Cy5-labelled signal of 0.01 mM and 0.1 mM peptide, respectively (Figure 4). 
Figure 3. Resazurin assay for testing the cell viability by adding peptide 4 in HK-2 cells. 
Increasing concentrations (0-1 mM) of peptide 4 were added to HK-2 cells and incubated for 2, 4, and 24 hours. 
Resorufin production was measured after 4 hours of incubation with resazurin. The red line represents the 
condition in which all the HK-2 cells are dead. This experiment was performed twice in triplicate.
Metabolic parameters in mice
In order to investigate crystal deposition in mouse kidney, C57BL/6J mice were placed 
on a high Ca2+ (HC) or normal Ca2+ (NC) diet while receiving 1% (v/v) EG via their drinking 
water for 28 days. Body weight, food intake, water intake were measured and were not 
statistically different between the groups throughout the whole experiment (Table 1). 
Of note, the water intake in the group of mice treated with the NC diet was significantly 
higher on D14 and D21 compared to D1. Blood and 24 hours urine were collected after 
each metabolic cage period. In line with an increased water intake, urine volume in the 
NC group was higher on D21 compared to D1, D7, and D14. The 24 hours urine volume in 
the HC diet group was also significantly increased on D21 compared to D1 (Table 1).
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Figure 4. Peptide 4 exhibited cellular uptake in HK-2 cells.
Increasing concentrations of peptide 4 (0-0.1 mM) and penetratin as positive control were added to HK-2 
cells for 15 minutes. After cell lysis, cellular uptake of the cy5-labeled peptides was counted by FACS with Cy5 
fluorescence. This experiment was performed twice in triplicate.
Serum and urinary electrolyte handling in mice
To investigate the effect of EG and the diets on electrolyte handling, serum, and 24 
hours urine electrolyte levels were analyzed. Serum Ca2+ concentrations and urinary Ca2+ 
excretion were similar between NC and HC groups, except on D21 where the serum Ca2+ 
concentration was significantly higher in the HC group (2.6±0.1 mmol/L) compared to 
the NC group (2.3±0.1 mmol/L) (Table 2-3). Other serum values (Na+, K+, Cl-, and Mg2+) 
did not differ significantly between HC and NC groups (Table 3). The urinary values were 
also similar between groups, except for two conditions. The urinary Na+ excretion on D7 
increased by 14% in the HC group compared to the NC group. The urinary Mg2+ excretion 
on D14 decreased by 19% in the NC group compared to the HC group (Table 2). 
However, we observed changes in urinary electrolyte excretion within either group 
over the time course of the experiment. Within the NC groups, the urinary Na+, Cl- and 
K+ concentrations were significantly higher on D21 compared to D1, D7, and D14 (Table 
2). While urinary Ca2+ levels on day 21 in the NC group were higher compared to all 
other days (D1, D7, D14), urinary Ca2+ excretion in the HC group was only higher on D21 
compared to D1. Moreover, there was no significant difference in urinary Mg2+ levels over 
time in the NC group and higher urinary Mg2+ levels were detected on D21 in the HC 
group compared to D1 and D14 (Table 2).
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Measurement of urinary citrate and urinary oxalate excretion and the 
urinary pH in mice
Urinary citrate and oxalate levels were measured at the beginning and end of the 
experimental time frame. On day 28, urinary citrate excretion was increased by 37% 
in the HC group compared to the NC group (Figure 5A). In the HC group, the oxalate 
excretion was nearly 6.3 folds and 5.9 folds higher than mice fed the NC diet at D1 and 
D28, respectively (Figure 5B). The urinary pH was similar between the NC and HC groups 
(Figure 5C). 
Figure 5. Urinary citrate and oxalate excretion and pH of mice under normal Ca2+ (NC) and 
high Ca2+ (HC) diet. 
(A-C) Urinary citrate (A) and oxalate (B) excretion and pH (C) were investigated after placing the mice in 
metabolic cages for 24 hours. n=2 for each group for urinary citrate and oxalate measurement. For urinary pH 
measurement, n=10 for each group on D1, n=8 for each group on D7, n=6 for each group on D14, n=4 for each 
group on D21 and n=2 for each group on D28. D represents day.
Von kossa staining for Ca2+ deposit in mice kidney
In order to assess whether 1% (v/v) EG was able to induce crystal deposition in the kidneys 
of the mice, Von kossa staining was conducted on kidney tissue. The trachea from Klotho 
knockout mice were used as positive control since they develop CaP precipitates [21, 22]. 
Von Kossa staining results showed that Ca2+ deposits were not observed by using 1% (v/v) 
EG administration in drinking water combined with a HC diet for 28 days (Figure 6).
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Figure 6. Von Kossa staining for Ca2+ deposits in mice kidney. 
Representative staining of kidney tissue from each experimental group (normal Ca2+ (NC) and high Ca2+ (HC) 
diets) on day 1 (D1), day 7 (D7), day 14 (D14), day 21 (D21) and day 28 (D28). Trachea from Klotho knockout mice 
was used as a positive control. n=2 for each group. Size bar represents 25 µm.
Discussion
In this study, several shortened EF-hand peptides with altered sequences were analyzed for 
their Ca2+-binding capacity. The aim was to identify a peptide with low binding affinity for 
Ca2+ (2-5 mM range). Our preliminary results suggest that peptide 4 (Ac-DKNGDGYIDAAE-
NH
2
) has the potential to serve as such a peptide. Moreover, this peptide did not induce 
cellular toxicity but did show mild cellular uptake in HK-2 cells. To ultimately evaluate the 
efficacy of this peptide in vivo, we aimed to generate a nephrolithiasis mouse model by 
administrating 1% (v/v) EG via drinking water in combination with either a normal or a 
high Ca2+ diet. However, no Ca2+ crystal deposits were observed in the kidney tissues of 
mice on either diet. 
Previously, Reid et al. developed a Ca2+-binding peptide (α-helix-DKNGDGYISAAE-α-
helix) with a Ca2+-binding affinity in the micromolar range (Kd=59 μM) [23]. We used the 
Ca2+-binding loop (DKNGDGYISAAE) as template and changed the amino acid residue 
at position 9 from S to D. The CD spectra of the peptide showed  a Ca2+-induced change 
in ellipticity at 220 nm upon the incremental addition of Ca2+ in the millimolar range, 
which suggested that the Ca2+-binding affinity of this peptide is decreased compared 
to the study by Reid et al. With the alteration from S to D, our peptide had 3 acidic side 
chains. In contrast to what we found, the acid pair hypothesis suggests that more acidic 
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side chains (within four) in the loop lead to a higher Ca2+-binding affinity [24]. In addition, 
D is negatively charged and exhibits increased binding affinity to Ca2+ compared to S in 
the study of Reid et al [23]. We suspect that the decreased binding affinity to Ca2+ in our 
peptide is due to the removal of the flanking α-helices, compared to the Ca2+-binding 
peptide developed by Reid et al. This is in line with the idea proposed by Lakowski et al. 
that the absence of the flanking helix of the EF-hand loop reduces Ca2+-binding affinity 
[25]. 
Preliminary results from our study demonstrated that this peptide is not toxic. 
The presence of residues like C, H, N, and P was shown to be higher in toxic peptides 
compared to non-toxic peptides [26]. In agreement with their findings, the peptide we 
designed had only one N residue. Moreover, FACS results showed that the amount of 
peptide cellular uptake increased at higher concentrations, but remained lower than 
the uptake of the cell-penetrating peptide penetratin. This indicated that the peptide 
(Ac-DKNGDGYIDAAE-NH
2
) exhibited cellular uptake, which might be caused by the high 
concentrations of peptide added to the cells. In general, receptor-mediated endocytosis 
plays a crucial role in the reabsorption of low molecular weight proteins in the proximal 
tubule [27].  Megalin, which is expressed in the apical side of the PT, interacts with its 
associated protein such as cubilin, and contributes significantly in the receptor-mediated 
endocytosis process [28-30]. Therefore, megalin and cubilin may also play a role in the 
reabsorption of the peptide we designed. Although these peptide in vitro experiments 
are very encouraging, more repeats still need to be performed due to some of them were 
conducted less than three times. 
In contrast to our in vivo study, other studies have successfully induced nephrolithiasis 
in mice and rats by administrating EG. A study in rats showed that intraperitoneal 
injection with EG led to the development of CaOx crystal deposits after 2-4 weeks [31]. 
This suggests that the absence of crystal deposition in the renal tissue of the mice in 
our study may be due to species differences. Other studies have successfully used Swiss 
albino mice to induce crystal formation by administering 0.75% (v/v) EG via the drinking 
water for 28 days [32]. The difference in susceptibility to stone formation between 
C57BL/6J mice and Swiss albino mice may lie in the genetic background of these animals 
[32]. Though, C57BL/6J mice have been used previously to study nephrolithiasis, with 
variation in genetically modified models, the agents that were used, and the method of 
administering. In 2007, Okada et al. successfully detected kidney stones in male C57BL/6J 
(wildtype) mice by intraabdominal glyoxylate injection [33]. Here, they found that the 
expression of osteopontin (OPN), which is an important kidney stone-related protein, was 
significantly increased [33]. OPN expression was not measured in our study. In addition, 
Jiang et al. demonstrated that mice lacking solute carrier family 26 member 6 (Slc26a6), 
which is a Cl--oxalate exchanger [34], are more prone to develop CaOx nephrolithiasis 
compared to wildtype mice [35]. In their later study, they demonstrated that only the 
Slc26a6 knockout mice with hypercalciuria develop crystal deposits in the kidney, which 
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suggests that hypercalciuria plays a very important role in forming kidney stones [34]. 
This is substantiated by a study by Khan et al. concluding that hyperoxaluria alone is 
not enough to induce CaOx crystal deposits, both hypercalciuria and hyperoxaluria are 
required in mice [36]. Importantly, hypercalciuria was not detected in the mice of our 
study, which could explain the fact that we did not observe crystal deposits. 
The fact that a HC diet did not induce changes in serum and/or urinary Ca2+ levels 
might be due to the compensatory loss in the gastrointestinal tract. Under high Ca2+ 
intake conditions, Ca2+ is passively absorbed by the paracellular process in the jejunum 
and ileum leading to lower fractional absorption of Ca2+ and loss of Ca2+ in the feces [37]. 
Thus, it is necessary to measure the Ca2+ levels in the feces in order to elucidate whether 
the normal serum Ca2+ levels are caused by fecal Ca2+ loss in the mice treated with HC 
diets. 
And finally, it is important to note a few limitations of this pilot study. While EG is not 
expected to affect serum and urinary parameters, a control group (without EG) would be 
optimal. Moreover, we sacrificed 2 animals per time point, leaving only 2 mice per group 
at day 28. Therefore, it is not possible to draw any significant conclusions on urinary 
markers after day 21. Also, this resulted in more variability of the measured electrolyte 
levels, limiting statistical testing. On this note, the significantly higher water intake in the 
NC diet treated mice on D14 and D21 was due to one extreme value (mice) that we could 
not omit because of the small sample size. 
Taken together, our in vitro study revealed that peptide 4 (Ac-DKNGDGYIDAAE-NH
2
) 
can be potentially used for single or repeated injection in a kidney stone mouse model. 
Our in vivo study showed that the EG administration in drinking water supplied with a 
HC diet is not sufficient for nephrolithiasis induction in C57BL/6J mice. For future studies, 
it might be interesting to use Swiss albino mice or rats to induce kidney stone disease. 
When the kidney stone model is set up, we can investigate if the peptide can be served 
as the first step towards the development of a new therapeutic intervention for kidney 
stone recurrence.
Acknowledgements
This work was financially supported by grants from the Netherlands Organization for 
Scientific Research (NWO VICI 016.130.668), from the Radboud Institute for Molecular Life 
Sciences, and the Netherlands Organization for Health Research and Development (Off 
Road Grant 451001 004). The authors thank Dr. Roland Brock and Sander van Asbeck for 




1. Romero, V., H. Akpinar, and D.G. Assimos, Kidney stones: a global picture of prevalence, incidence, 
and associated risk factors. Rev Urol, 2010. 12(2-3): p. e86-96.
2. Edvardsson, V.O., et al., Incidence of kidney stone disease in Icelandic children and adolescents from 
1985 to 2013: results of a nationwide study. Pediatr Nephrol, 2018. 33(8): p. 1375-1384.
3. Khan, S.R., et al., Kidney stones. Nat Rev Dis Primers, 2016. 2: p. 16008.
4. Rule, A.D., et al., Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol, 2009. 
4(4): p. 804-11.
5. Sorokin, I. and M.S. Pearle, Medical therapy for nephrolithiasis: State of the art. Asian J Urol, 2018. 
5(4): p. 243-255.
6. Barnela, S.R., et al., Medical management of renal stone. Indian J Endocrinol Metab, 2012. 16(2): p. 
236-9.
7. Lingeman, J.E., et al., Shock wave lithotripsy: advances in technology and technique. Nat Rev Urol, 
2009. 6(12): p. 660-70.
8. Alelign, T. and B. Petros, Kidney Stone Disease: An Update on Current Concepts. Adv Urol, 2018. 
2018: p. 3068365.
9. Heilberg, I.P. and N. Schor, Renal stone disease: Causes, evaluation and medical treatment. Arq Bras 
Endocrinol Metabol, 2006. 50(4): p. 823-31.
10. Hussein, N.S., et al., Twenty-four-hour urine constituents in stone formers: a study from the northeast 
part of Peninsular Malaysia. Saudi J Kidney Dis Transpl, 2013. 24(3): p. 630-7.
11. Mittal, R.D., et al., Stone composition, metabolic profile and the presence of the gut-inhabiting 
bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract, 2003. 
12(4): p. 208-13.
12. Kumar, R., et al., Evaluation of urinary abnormalities in urolithiasis patients: A study from North 
India. Indian J Clin Biochem, 2003. 18(2): p. 209-15.
13. Albright, F., et al., Idiopathic hypercalciuria: a preliminary report. Proc R Soc Med, 1953. 46(12): p. 
1077-81.
14. Henneman, P.H., et al., Idiopathic hypercaicuria. N Engl J Med, 1958. 259(17): p. 802-7.
15. Miller, N.L. and J.E. Lingeman, Management of kidney stones. BMJ, 2007. 334(7591): p. 468-72.
16. Nakayama, S., [Evolution of EF-hand proteins]. Seikagaku, 1995. 67(2): p. 131-7.
17. Kretsinger, R.H. and C.E. Nockolds, Carp muscle calcium-binding protein. II. Structure determination 
and general description. J Biol Chem, 1973. 248(9): p. 3313-26.
18. Yap, K.L., et al., Diversity of conformational states and changes within the EF-hand protein 
superfamily. Proteins, 1999. 37(3): p. 499-507.
19. Nakayama, S. and R.H. Kretsinger, Evolution of the EF-hand family of proteins. Annu Rev Biophys 
Biomol Struct, 1994. 23: p. 473-507.
20. Zhou, Y., T.K. Frey, and J.J. Yang, Viral calciomics: interplays between Ca2+ and virus. Cell Calcium, 
2009. 46(1): p. 1-17.
21. Alexander, R.T., et al., Klotho prevents renal calcium loss. J Am Soc Nephrol, 2009. 20(11): p. 2371-9.
22. Ter Braake, A.D., et al., Magnesium prevents vascular calcification in Klotho deficiency. Kidney Int, 
2019.
23. Reid, R.E., Synthetic fragments of calmodulin calcium-binding site III. A test of the acid pair hypothesis. 
J Biol Chem, 1990. 265(11): p. 5971-6.
24. Reid, R.E., A synthetic 33-residue analogue of bovine brain calmodulin calcium binding site III: 
synthesis, purification, and calcium binding. Biochemistry, 1987. 26(19): p. 6070-3.
25. Lakowski, T.M., et al., Calcium-induced folding of a fragment of calmodulin composed of EF-hands 2 
and 3. Protein Sci, 2007. 16(6): p. 1119-32.
26. Gupta, S., et al., In silico approach for predicting toxicity of peptides and proteins. PLoS One, 2013. 
8(9): p. e73957.
27. De, S., S. Kuwahara, and A. Saito, The endocytic receptor megalin and its associated proteins in 
proximal tubule epithelial cells. Membranes (Basel), 2014. 4(3): p. 333-55.
67
Development of Ca2+-Binding Peptides to Control Urinary Ca2+ Concentration to Prevent Kidney Stone Formation
3
28. Leheste, J.R., et al., Megalin knockout mice as an animal model of low molecular weight proteinuria. 
Am J Pathol, 1999. 155(4): p. 1361-70.
29. Amsellem, S., et al., Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am 
Soc Nephrol, 2010. 21(11): p. 1859-67.
30. Ahuja, R., et al., Interactions of cubilin with megalin and the product of the amnionless gene (AMN): 
effect on its stability. Biochem J, 2008. 410(2): p. 301-8.
31. Oh, S.Y., et al., A comparative study of experimental rat models of renal calcium oxalate stone 
formation. J Endourol, 2011. 25(6): p. 1057-61.
32. Alenzi, M., S. Rahiman, and B.A. Tantry, Antiurolithic effect of olive oil in a mouse model of ethylene 
glycol-induced urolithiasis. Investig Clin Urol, 2017. 58(3): p. 210-216.
33. Okada, A., et al., Successful formation of calcium oxalate crystal deposition in mouse kidney by 
intraabdominal glyoxylate injection. Urol Res, 2007. 35(2): p. 89-99.
34. Aronson, P.S., Role of SLC26A6-mediated Cl(-)-oxalate exchange in renal physiology and 
pathophysiology. J Nephrol, 2010. 23 Suppl 16: p. S158-64.
35. Jiang, Z., et al., Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet, 
2006. 38(4): p. 474-8.
36. Khan, S.R. and P.A. Glenton, Experimental induction of calcium oxalate nephrolithiasis in mice. J 
Urol, 2010. 184(3): p. 1189-96.
37. Sorensen, M.D., Calcium intake and urinary stone disease. Transl Androl Urol, 2014. 3(3): p. 235-40.
Chapter 4
Arl15 Heterozygous Mice Exhibit Normal Electrolyte Homeostasis
4
4
Arl15 heterozygous mice exhibit normal 
electrolyte homeostasis 
Chao Ma1, Ying Bai2, Liz Bentley2, René JM Bindels1, Roger D Cox2, 
Joost GJ Hoenderop1, Jeroen HF de Baaij1
1Department of Physiology, Radboud Institute for Molecular Life Sciences, Radboud 
university medical center, Nijmegen, The Netherlands. 2MRC Harwell Institute, Mammalian 





Magnesium (Mg2+) homeostasis is maintained by intestinal absorption and renal 
excretion. Genome wide association studies (GWAS) investigated genetic loci associated 
with urinary Mg2+ excretion in 9099 individuals and identified ADP-ribosylation factor-
like GTPase 15 (ARL15). Moreover, it was shown that ARL15 can regulate Mg2+ reabsorption 
by regulating the channel activity of TRPM6 in the kidney, but the function of ARL15 in 
the kidney is still unknown. The objective of this study was to further characterize ARL15 
and its role in Mg2+ homeostasis in the kidney by using Arl15 heterozygous (Arl15+/−) mice. 
The ARL15 gene has 795 bp encoding a protein of 265 amino acids. Iterative Threading 
ASSEmbly Refinement (I-TASSER) prediction showed that the secondary structure of ARL15 
consists of 8 alpha-helixes, 7 beta-strands and belongs to the small GTPase superfamily. 
Furthermore, Mg2+ is predicted to bind to ARL15. Tissue distribution indicated that ARL15 is 
ubiquitously expressed in mouse tissue, with the highest abundance in the lung, inguinal 
fat, epididymal fat, spleen, testes, and kidney. Differences in serum Mg2+ concentration 
and 24 hours urinary Mg2+ excretion were not detected between Arl15 wildtype (Arl15+/+) 
and Arl15+/- mice on the high fat and low fat diets. Furthermore, on the low fat diet, water 
intake of male Arl15+/- mice was significantly increased by 60% compared to male Arl15+/+ 
mice. On the high fat diet, body weight of female Arl15+/- mice significantly decreased 
by 12% compared to female Arl15+/+ mice. However, food intake and 24 hours urine 
volume did not significantly differ between the groups on the high fat and low fat diets. 
Quantitative real-time PCR analysis showed that the mRNA expression levels of Mg2+-
related genes, metabolism-related genes, and membrane trafficking-related genes are 
not affected in the kidney of Arl15+/− mice. Thus, our results suggest that ARL15 does not 
play a role in the regulation of renal electrolyte transport.
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Introduction
Magnesium (Mg2+) plays an important role in the synthesis, folding, and stability of 
biomolecules and it works as a cofactor for various enzymatic reactions [1]. Mg2+ also 
plays an essential role in stabilization of the cell membrane, cardiac excitability, regulation 
of blood pressure, glucose-insulin metabolism, and muscle contraction [2, 3]. An adult 
human body contains approximately 22-26 grams (g) of Mg2+ [4]. Only 1% of the total 
Mg2+ in the body is found in the extracellular space, which is primarily in blood [1]. 
The kidney plays a key role in the regulation of blood Mg2+ concentration. Around 
95-99% of the filtered Mg2+ is reabsorbed in the proximal tubule (PT), the thick ascending 
limb (TAL), and the distal convoluted tubule (DCT) of the kidney [5]. Although the DCT 
reabsorbs only 5-10% of the filtered Mg2+ [6], it is the last segment to determine the final 
Mg2+ concentration in urine since no Mg2+ reabsorption takes place beyond this segment 
[5, 6]. Transient receptor potential cation channel subfamily M member 6 (TRPM6) is 
the gatekeeper of transcellular Mg2+ reabsorption in the DCT [6, 7]. Its importance in 
Mg2+ homeostasis is highlighted by the fact that mutations in the TRPM6 gene lead to 
hypomagnesemia with secondary hypocalcemia (HSH) [8].
Recently, a GWAS identified ADP-ribosylation factor-like protein 15 (ARL15) to be 
associated with urinary Mg2+ wasting [9]. ARL15 belongs to the ADP-ribosylation factor 
(ARF) family [9]. Immunohistochemical studies demonstrated its localization in the TAL 
and DCT of the kidney [9], but the function of this protein has not yet been clarified. 
A recent study proposed that ARL15 may be involved in the regulation of intracellular 
vesicle trafficking [9]. In line with this, Corre et al. found that TRPM6 channel activity is 
significantly increased in the presence of ARL15, and knockdown of Arl15 in zebrafish 
resulted in urinary Mg2+ wasting [9]. Thus, this set of experiments suggests that ARL15 is 
a key protein in maintaining Mg2+ homeostasis.
Additional GWAS showed a strong association between ARL15 locus variants and sev-
eral metabolic and cardiovascular traits including risk of diabetes mellitus type 2, ele-
vated fasting insulin concentration, hemoglobin A1C (HbA1c) levels and pancreatic beta 
cell proliferation [8, 10-14]. Indeed, Rocha et al. demonstrated that knockdown of Arl15 
significantly impaired the adipogenesis and adiponectin secretion of 3T3-L1 cells [11].
The aim of this study was, therefore, to characterize the role of ARL15 in renal Mg2+ 
handling and metabolic traits. For this purpose, Arl15 heterozygous knockout (Arl15+/−) 
mice were analyzed for electrolyte homeostasis and renal abnormalities. Furthermore, 
by challenging the mice with high fat diets, the mRNA expression of Mg2+-related, 




Methods and materials 
Ethical approval of the study protocol
All mice models used in this experiment were approved by animal ethics board of Radboud 
University (Nijmegen, The Netherlands) and the MRC Harwell Institute of Animal Welfare 
and Ethical Review Committee. All procedures were performed in accordance with the 
Home Office license 30/3146 and 30/3070 under the Animal (Scientific Procedures) Act 
1986 which is issued by the Medical Research Council. 
Mice were kept under a 12:12 hour light/dark cycle (lights on 7 am and off 7 pm), 
at a temperature of 21±2°C and a humidity of 55±10% conditions. Mice had free access 
to water (9–13 ppm chlorine) and were maintained ad libitum on either a high fat diet 
(D12492, Research Diets, New Brunswick, NJ, U.S.A.) or low fat diet (D12450J, Research 
Diets, New Brunswick, NJ, U.S.A.) for 24 weeks from weaning.
Expression profiling and quantitative real time PCR
Three 12-weeks old wildtype C57BL/6 mice were sacrificed. Brain, retina, aorta, lung, heart, 
stomach, caecum, duodenum, jejunum, ileum, colon-ascend, colon-descend, rectum, 
brown fat, inguinal fat, epididymal fat, thigh muscle, spleen, adrenal gland, kidney, and 
testes were collected. 10 Arl15+/- mice and Arl15+/+ littermate controls with C57BL/6NTac 
background were sacrificed in the end of experiment. Total RNA was extracted from 
above described tissues with Trizol (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. Subsequently, RNA samples were subjected to DNase 
(Invitrogen, Breda, The Netherlands) treatment to prevent genomic DNA contamination 
and the reverse transcriptase reaction was performed for 1 hour at 37°C to  synthesize 
cDNA. mRNA levels of the target genes were determined with a CFX96TM Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA) using iQTM SYBR Green Supermix 
(Bio-Rad) detection of single PCR product accumulation. All RT-qPCR experiments were 
executed in triplicate. Gene expression levels were normalized to the expression levels 
of the standard reference gene glyceraldehyde 3-phosphate dehydrogenase (Gapdh). 
Relative mRNA expression was analyzed using the Livak method (2-ΔΔCt). All primers were 
purchased from Biolegio BV (Nijmegen, Netherlands). Primer sequences are shown in 
Table 1. 
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Table 1. Primer sequences used for real-time quantitative RT-PCR





















Slc5a1, Solute carrier family 5 member 1; Slc5a2, Solute carrier family 5 member 2; Cldn16, Claudin-16; Cnnm2, 
Cyclin and CBS domain divalent metal cation transport mediator 2; Fxyd2, FXYD domain containing ion transport 
regulator 2; Slc41a1, Solute carrier family 41 member 1; Slc41a3, Solute carrier family 41 member 3;Trpm6, 
Transient receptor potential cation channel subfamily M member 6; Cpt 1, Carnitine palmitoyltransferase I; 
Cpt 2, Carnitine palmitoyltransferase 2; Afr6, ADP ribosylation factor 6; Afr1, ADP ribosylation factor 1; Adipor1, 
Adiponectin receptor 1; Adipor2, Adiponectin receptor 2; Pepck 1, Phosphoenolpyruvate carboxykinase; 
Arfgef-1, ADP ribosylation factor guanine nucleotide exchange factor 1; Arfgef-2, ADP ribosylation factor 
guanine nucleotide exchange factor 2; Arl15, ADP-ribosylation factor-like GTPase 15; Gapdh, Glyceraldehyde 




To further understand ARL15 protein function, bioinformatics analysis was performed. 
Gene structure analysis, homologous alignment, signal peptide and protein conserved 
domain prediction was performed using the following sources: https://blast.ncbi.nlm.
nih.gov/Blast.cgi, and https://zhanglab.ccmb.med.umich.edu/I-TASSER/. 
Serum and urinary Mg2+ measurements 
Serum and urinary total Mg2+ concentrations were measured by a colorimetric xylidyl-II 
blue assay kit (Roche Diagnostics, Woerden, The Netherlands), according to the protocol 
provided by the manufacturer. Urine volume was measured in order to calculate 24 hours 
Mg2+ excretion.
Immunohistochemistry 
Adrenal gland, kidney, testes, and fat tissue were fixed in 4% (w/v) paraformaldehyde for 
24 hours, and embedded in paraffin. Subsequently, 5 µm sections were cut and serial 5 
µm paraffin-embedded tissue sections were deparaffinned and rehydrated. Endogenous 





) (Avantor, Arnhem, The Netherlands). After blocking the sections with 
20% (v/v) goat serum in phosphate-buffered saline (PBS), the sections were incubated 
overnight at 4°C with ARL15 antibody (Abcam, Cambridge, The UK). Then, the sections 
were incubated with the swine anti-rabbit secondary antibody (Abcam, Cambridge, 
UK). Sections were imaged by using the light microscope Axio Imager M.2 (Carl Zeiss, 
Oberkochen, Germany). Blinded analysis of positive immunostained sections were 
performed using Image Pro Plus (Media Cybernetics, Warrendale, Pennsylvania).
Statistical analysis
All data were analyzed using Graphpad Prism 7.0 (Graphpad Software, La Jolla, CA, 
USA), and results were presented as means ± SEM. Results are statistically analyzed by 
performing a two-way ANOVA followed by Tukey as post-test. P<0.05 was considered as 
statistically significant. 
Results
Identification of ARL15 gene and protein comparison 
ARL15 has an open reading frame of 795 bp encoding a protein of 265 amino acids. The 
protein sequence is highly conserved and comparison analysis showed that human 
and mouse ARL15 share 74% similarity in amino acid sequence. In order to elucidate 
the function of ARL15, secondary protein analysis was performed. Structure prediction 
indicated that ARL15 consists of 8 alpha-helices and 7 beta-strands. I-TASSER prediction 
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for the tertiary structure of ARL15 showed that it belongs to the small GTPase superfamily 
(Figure 1A). Interestingly, Mg2+ is shown to interact with the surrounding T107 and T124 
residues of ARL15 (Figure 1B and C).
Analysis of Arl15 expression in different mouse tissues
To investigate the tissue distribution of Arl15, RNA was isolated from various tissues 
of adult mice and gene expression was analyzed by RT-qPCR. Arl15 mRNA was highly 
expressed in lung, inguinal fat, epididymal fat, spleen, testes, and kidney, followed by the 
retina, stomach, duodenum, ileum (Figure 2A). It was weakly detectable in brain, aorta, 
liver, heart, caecum, jejunum, colon, rectum, adrenal gland, brown fat, and thigh-muscle 
(Figure 2A). Protein expression of ARL15 in adrenal gland, brown fat, kidney, and testes 
in adult mice was further investigated by immunohistochemistry. ARL15 was highly 
expressed in the cortex and medulla of the adrenal gland (Figure 2B, panel a). In the 
kidney, ARL15 was present in the TAL and DCT (Figure 2B, panel b). There was a robust 
expression in the adipocytes in inguinal fat (Figure 2B, panel c). Moreover, ARL15 was 
highly expressed in the spermatoblast and interstitial cells in testes (Figure 2A, panel d).
Normal metabolic parameters in Arl15+/- mice
The function of ARL15 in vivo was further investigated in Arl15+/+, Arl15+/- and Arl15-/- mice 
(kindly provided by Dr. Roger Cox). The importance of ARL15 for metabolism was indicated 
by the fact that Arl15-/- mice, generated via CRISPR/Cas9 germline knockout, died after 
birth (unpublished data from Roger Cox’s group). The Arl15+/+ and Arl15+/- mice are viable 
(unpublished data from Roger Cox’s group) and were subjected to low and high fat diets 
for 24 weeks after weaning. At the end of the experiments, mice were placed in metabolic 
cages for 24 hours to collect blood and 24 hours urine for further analysis. 
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Figure 1. I-TASSER prediction for the tertiary structure of Arl15 and potentially binding 
of Mg2+. 
A, Predicted tertiary structure of ARL15 by using a model for compact volume of truncated monomeric 
cytohesin-3 (Grp1; amino acids 63-399) E161A 6GS Arf6 Q67L fusion protein. Different domains of the protein 
were color coded. B, Detail of the Mg2+ binding region. Mg2+ is shown in green in this model. Mg2+ interacts 
with the surrounding T107 and T124 residues with side chains highlighted in dark blue. C, Top 5 binding 
ligands of ARL15 and annotations on ligand binding site. C-score: The confidence score for evaluating the 
quality of the model. Lig Name: the name of the ligands that bind to ARL15.
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Figure 2. Gene and protein expression of Arl15 in a panel of mouse tissues. 
A, Arl15 mRNA expression of the indicated mouse tissues, normalized for Gapdh. Data represent the mean of 
three individual mice ± SEM and were expressed as the fold change relative to total kidney gene expression. 
B, Immunohistochemical staining of ARL15 in different regions in the adrenal gland (a), kidney (b), inguinal 
fat (c) and testes (d). Blue arrow in panel a represents cortex of the adrenal gland, black arrow in panel a 
represents medulla of the adrenal gland, black arrow in panel b represents distal convoluted tubule of 
the kidney, blue arrow in panel b represents thick ascending loop of Henle of the kidney, black arrow in 
panel c represents adipocytes, black arrow in panel d represents testis spermatoblast, blue arrow in panel d 
represents interstitial cells. Size bar represents 25 µm. 
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On the low fat diet, water intake of male Arl15+/- mice was significantly increased by 60% 
compared to male Arl15+/+ mice (Table 2). On the high fat diet, body weight of female 
Arl15+/- mice was significantly decreased by 12% compared to female Arl15+/+ mice (Table 
2). However, food intake and urine volume did not significantly differ between the groups 
on the respective diets (Table 2). 
Table 2. Metabolic parameters of Arl15+/- Mice
Male
Low fat diet High fat diet
Arl15+/+ Arl15+/- Arl15+/+ Arl15+/-
Weight (g) 35.2 ± 1.5 33.3 ± 1.1 45.4 ± 0.6 43.6 ± 1.7
Food intake (g) 4.7 ± 0.5 4.4 ± 0.5 1.5 ± 0.2 1.2 ± 0.2
Water intake (mL) 2.2 ± 0.3 3.6 ± 0.5a 1.9 ± 0.2 1.7 ± 0.2
Urine volume (mL) 1.2 ± 0.2 1.2 ± 0.1 0.9 ± 0.1 1.0 ± 0.1
Female
Low fat diet High fat diet
Arl15+/+ Arl15+/- Arl15+/+ Arl15+/-
Weight (g) 26.6 ± 0.8 27.8 ± 0.8 46.6 ± 1.5 41.8 ± 1.4b
Food intake (g) 5.0 ± 0.5 4.4 ± 0.3 0.7 ± 0.2 0.9 ± 0.2
Water intake (mL) 4.1 ± 1.2 3.1 ± 0.3 1.2 ± 0.1 1.3 ± 0.2
Urine volume (mL) 0.7 ± 0.1 0.6 ± 0.2 0.6 ± 0.1 0.5 ± 0.1
Arl15+/+ and Arl15+/- mice were kept on low fat and high fat diets for 24-weeks. During the last 24 hours, the 
mice were placed in metabolic cages to collect blood and 24 hours urine. Numbers represent mean ± SEM. 
a represents a significant difference compared to ARL15+/+ mice on low fat diet; b indicates a significant 
difference compared to ARL15+/+ mice on high fat diet. +/+, Arl15 wildtype mice, +/-, Arl15 heterozygous mice.
Effects of low and high fat diets on Mg2+ handling in Arl15+/+ and Arl15+/- 
mice 
To investigate the role of ARL15 in Mg2+ handing, serum Mg2+ concentration and 24 hours 
urinary Mg2+ excretion were measured in male and female Arl15+/+ and Arl15+/- mice. Mg2+ 
excretion was nearly 3 folds lower in female Arl15+/+ mice on high fat diets compared 
to female Arl15+/+ mice fed low fat diets (Figure 3D). However, serum Mg2+ concentration 
and 24 hours urinary Mg2+ excretion did not alter significantly between the other groups 
(Figure 3A-D). 
The expression of Mg2+-related genes in the kidney of Arl15+/+ and Arl15+/- 
mice 
To further study the role of ARL15 in renal Mg2+ handling, the expression of Mg2+-related 
genes in the kidney of Arl15+/+ and Arl15+/- mice fed low fat or high fat diets were evaluated 
by RT-qPCR. While the expression of Cldn16 did not change between male Arl15+/- mice 
on high fat and low fat diets (Figure 4A), Cldn16 expression in female Arl15+/+ mice treated 
with high fat diets was significantly decreased compared to female Arl15+/+ mice fed 
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with low fat diets (Figure 4G). Fxyd2 expression in both male and female Arl15+/- mice 
on high fat diets was significantly higher compared to the mice fed low fat diets (Figure 
4B, H). Expression of Cnnm2, Slc41a1, Slc41a3, and Trpm6 was not affected between the 
conditions (Figure 4C- F, I-L). 
Figure 3. Arl15+/- mice exhibit normal serum Mg2+ concentrations and urinary Mg2+ 
excretions. 
A, B, Serum Mg2+ concentrations of male (A) and female (B) Arl15+/+ and Arl15+/- mice fed with either low fat or 
high fat diets. C, D, 24 hours urinary Mg2+ excretion of male (C) and female (D) Arl15+/+ and Arl15+/- mice treated 
with either low fat or high fat diets. Values were presented as single data points with means ± SEM. +/+, Arl15 
wildtype mice, +/-, Arl15 heterozygous mice, LF, low fat diets, HF, high fat diets.
The expression of metabolism-related genes in the kidney of Arl15+/+ and 
Arl15+/- mice
GWAS showed that variants of ARL15 were associated with serum adiponectin levels, 
fasting insulin levels, and triglyceride concentrations [12, 15]. Therefore, RT-qPCR was 
commenced to analyze the expression of metabolism-related genes in the kidney of 
Arl15+/+ and Arl15+/- mice fed with low fat and high fat diets.
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Figure 4. Mg2+-related gene expression did not alter between Arl15+/+ and Arl15+/- mice. 
The mRNA expression levels of Cldn16, Cnnm2, Fxyd2, Slc41a1, Slc41a3, and Trpm6 in the kidney of male (A-F) 
and female (G-L) Arl15+/+ and Arl15+/- mice fed with either low fat diets (LF) or high fat (HF) diets were measured 
by RT-qPCR. Results were normalized to Gapdh expression (reference gene). * P < 0.05 indicates statistical 
significance. Cldn16, Claudin-16; Cnnm2, Cyclin and CBS domain divalent metal cation transport mediator 2; 
Fxyd2, FXYD domain containing ion transport regulator 2; Slc41a1, Solute carrier family 41 member 1; Slc41a3, 
Solute carrier family 41 member 3; Trpm6, Transient receptor potential cation channel subfamily M member 6; 
Gapdh, Glyceraldehyde 3-phosphate dehydrogenase. +/+, Arl15 wildtype mice, +/-, Arl15 heterozygous mice. 
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Figure 5. Metabolism-related gene expression did not change between Arl15+/+ and Arl15+/- 
mice. 
The mRNA expression levels of Adipor1, Adipor2, Adrb3, Cpt1, Cpt2, Slc5a1, Slc5a2, Pepck1, and Plin1 in the 
kidney of male (A-I) and female (J-R) Arl15+/+ and Arl15+/- mice fed with low fat or high fat diets were measured 
by RT-qPCR. Results were normalized to Gapdh expression (reference gene). Data represent means ± SEM and 
are expressed as fold difference compared to Arl15+/+ mice on low fat diets. * P < 0.05 indicates a statistically 
significance. +/+, Arl15 wildtype mice, +/-, Arl15 heterozygous mice, LF, low fat diet, HF, high fat diet. Adipor1, 
Adiponectin receptor 1; Adipor2, Adiponectin receptor 2; Adrb3, Beta-3 adrenergic receptor; Cpt1, Carnitine 
palmitoyltransferase 1; Cpt2, Carnitine palmitoyltransferase 2; Fabp1, Fatty acid-binding protein 1; Slc5a1, 
Solute carrier family 5 member 1; Slc5a2, Solute carrier family 5 member 2; Pepck, Phosphoenolpyruvate 
carboxykinase; Plin1, Perilipin 1. 
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Gene expression of Adipor1, Adipor2, Adrb3, Cpt1, Cpt2, Slc5a1, Slc5a2, Pepck and Plin1 
were analyzed. Gene expression of Adipor1 was significantly lower in female Arl15+/+ 
mice on high fat diets compared to the mice treated with low fat diets (Figure 5J). Gene 
expression of Adipor1 was not affected in male Arl15+/+ mice on either diet (Figure 5A). 
The expression of Slc5a2 in female Arl15+/+ or Arl15+/- mice fed with low fat diets were 
lower than female Arl15+/+ or Arl15+/- mice fed with high fat diets respectively (Figure 
5P). However, the expression of Slc5a2 in male Arl15+/+ or Arl15+/- mice was not changed 
with either diet (Figure 5G). The expression of other genes, such as Adipor2, Ardb3, Cpt1, 
Cpt2, Slc5a1, Pepck1 and Plin1 were not affected in male or female Arl15+/+ or Arl15+/- mice 
exposed to the high fat or low fat diets (Figure 5B-F, H, I, K-N, Q, and R).
Expression of membrane trafficking-related genes in the kidney of Arl15+/+ 
and Arl15+/- mice
ARL15 was predicted to be a small GTPase and protein-protein interaction prediction 
showed that ARL15 interacts with vesicular trafficking genes [9]. In order to examine 
whether reduced ARL15 expression was compensated by other small GTPase involved 
in intracellular vesicle trafficking, the expression of Arf1, Arfgef-1, Arfgef-2, and Arf6 was 
measured by RT-qPCR in the kidney of Arl15+/+ and Arl15+/- mice fed with low fat and high 
fat diets. However, the results indicated that expression of Arf1, Arfgef-1, Arfgef-2, and Arf6 
in male or female Arl15+/+ or Arl15+/- mice treated with high fat and low fat diets did not 
change significantly (Figure 6A-H). 
Discussion
This study demonstrated that Arl15+/- mice have a normal phenotype, and exhibit no 
changes in serum Mg2+ concentration or urinary Mg2+ excretion. Furthermore, there was 
no altered expression of Mg2+-related, metabolism-related, and membrane trafficking-
related genes in Arl15+/- mice compared to Arl15+/+ mice. Taken together, these findings 
showed that partial loss of ARL15 does not impair renal Mg2+ handling and metabolism. 
Other models may be required to study the role of ARL15 in the kidney. 
ARL15 was predicted to be a small GTPase that was associated with plasma adiponec-
tin, insulin, and high-density lipoprotein (HDL) cholesterol levels, obesity, and coronary 
atherosclerosis [15, 16]. However, its function is still unknown. Our tertiary analysis indi-
cated that ARL15 belongs to the small GTPase superfamily. Subfamilies like Rab and Arf 
GTPase were reported to be involved in endomembrane trafficking, from the endoplas-
mic reticulum (ER) to the Golgi in many studies [17-19]. Immunostaining results showed 
that ARL15 was predominantly localized in the Golgi apparatus [11]. Together with our 
tertiary analysis, this supports the idea that ARL15 may be involved in endomembrane 
trafficking. In line with this, Corre et al. proposed that ARL15 can influence the channel 
activity of the Mg2+ channel TRPM6, possibly by affecting channel trafficking [9].  
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Figure 6. Membrane trafficking-related genes expression did not change in Arl15+/- mice. 
The mRNA expression levels of Arf1, Arfgef-1, Arfgef-2, and Arf6 in the kidney of male (A-D) and female (E-H) 
Arl15+/+ (+/+) and Arl15+/- (+/-) mice fed with low fat diets (LF) or high fat diets (HF) were measured by RT-
qPCR. Results were normalized to Gapdh expression (reference gene). Afr1, ADP ribosylation factor 1; Afr6, 
ADP ribosylation factor 6; Arfgef-1, ADP ribosylation factor guanine nucleotide exchange factor 1; Arfgef-2, 
ADP ribosylation factor guanine nucleotide exchange factor 2. 
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In this study, we demonstrated that Arl15 mRNA was widely expressed in mice. Arl15 was 
highly abundant in white adipose tissue. The white adipose tissue was responsible for 
adiponectin secretion, which plays an important role in modulating the level of blood 
glucose and the breakdown of fatty acid [20, 21]. It had been shown that Arl15 knockdown 
in differentiated adipocytes resulted in decreased adiponectin secretion and impaired 
adipogenesis in pre-adipocytes [11]. Together, this suggests that ARL15 was directly or 
indirectly involved in the regulation of adiponectin function [11]. However, In contrast 
to the positive correlation of Arl15 and Adiponectin in 3T3-L1 cells [11], our study did not 
observe changes in mRNA expression level of Adiponectin or other metabolism-related 
genes in Arl15+/- mice compare to Arl15+/+ mice. This may due to the fact that certain 
signal pathways and/or compensatory mechanisms can be activated to counteract the 
heterozygous knockout of ARL15.
A recent GWAS analysis demonstrated that ARL15 was associated with urinary Mg2+ 
excretion [9]. Knockdown of arl15b expression in zebrafish larvae decreased the Mg2+ con-
tent compared with controls, which was suggestive of renal Mg2+ wasting [9]. Neverthe-
less, serum and urinary Mg2+ levels were normal in Arl15+/- mice. A compensatory network 
may be activated to counteract Mg2+ wasting in Arl15+/- mice. Although this could not be 
detected by RT-qPCR, changes in protein expression or function cannot be excluded. For 
instance, Mg2+ reabsorption by TRPM6 in the DCT may be altered by heterozygous knock-
out of ARL15, given the role of ARL15 in TRPM6 channel function [9]. Therefore, further 
studies on the protein level and function level should be performed to better understand 
potential compensatory mechanisms. Alternatively, Arl15+/- mice could be faced with low 
Mg2+ diets in order to challenge potential compensation. Corre et al. reported that the 
mRNA expression of arl15b increased nearly 70% to deal with Mg2+ deficiency in zebrafish 
[9]. Additionally, ARL15 kidney-specific knockout could be generated to understand more 
about the function of ARL15 in the kidney.
Taken together, our studies demonstrated that Arl15+/- mice possess a normal phys-
iological behavior and no disturbances in Mg2+ handling. Thus, to determine whether 
ARL15 is involved in renal Mg2+ handling, additional studies are warranted. Future research 
should focus on generating ARL15 kidney-specific knockout mice and challenging the 
mice with low Mg2+ diets to further elucidate the physiological and pathological role of 
ARL15 in Mg2+ homeostasis.
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Cyclin M (CNNM1-4) proteins maintain cellular and body magnesium (Mg2+) homeostasis. 
Here, we identified using various biochemical approaches that members of the CNNM 
family are direct interacting partners of ADP-ribosylation factor-like GTPase 15 (ARL15). 
ARL15 interacts with CNNMs at their carboxyl-terminal conserved cytosolic cystathionine 
β-synthase (CBS) domains. In silico modeling of the interaction using the reported 
structures of both CNNM2 and ARL15 supports that the small GTPase specifically binds 
the CBS1 domain. Immunohistochemistry and immunocytochemistry experiments 
demonstrated that CNNM2 and ARL15 co-localize in the kidney, with both proteins 
showing subcellular localization in the Golgi-apparatus. Towards understanding the role 
of this interaction, we found that overexpression of ARL15 in human embryonic kidney 
293 (HEK293) cells resulted in complex N-glycosylation of CNNMs. Moreover, Mg2+ uptake 
experiments with stable isotopes demonstrate that there is a significant increase of 25Mg2+ 
uptake upon knockdown of ARL15 in multiple kidney cancer cell lines. Altogether, our 
results establish ARL15 as a novel negative regulator of Mg2+ homeostasis by promoting 
the N-glycosylation of CNNMs. 
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Introduction
Mg2+ is an essential cation for all living organisms. As co-factor of ATP, Mg2+ is involved in 
over 600 enzymatic reactions and as such it plays important roles in a plethora of biological 
mechanisms such as DNA transcription, protein synthesis and energy metabolism [1]. 
Approximately 1% of the body Mg2+ content is present in the blood, indicating that the 
great majority of Mg2+ is stored intracellularly in soft tissues and in the hydroxyapatite 
structure of the bone [2]. Decreased intracellular Mg2+ levels suppress cell cycle 
progression and are consequently associated with cell growth impairment [3]. Recent 
studies therefore have focused on the regulation of intracellular Mg2+ concentration as a 
central mechanism for cellular metabolism and proliferation [4].
Among the various mechanisms of Mg2+ sensing and transport, proteins of the CNNM 
family were shown to play an important role in the intracellular sensing of the Mg2+ avail-
ability [5, 6]. The CNNM family has 4 members, which are highly conserved but have dif-
ferent tissue distribution [4-7]. CNNM3 shows a ubiquitous expression pattern, whereas 
CNNM1, CNNM2, and CNNM4 have the highest expression levels in the brain, kidney, and 
intestine, respectively [8]. All CNNMs interact with phosphates of the regenerating liver 
(PRL1-3) via the CBS domain of CNNMs [9, 10]. CNNMs and PRLs have been associated with 
the progression of breast and colon cancers [10, 11]. Although the exact molecular func-
tion of CNNM proteins is under debate [12, 13], it has been shown that engineered and 
naturally occurring mutations in CNNMs result in decreased Mg2+ transport in both cell 
and animal models [10, 14]. Notably, mutations in CNNM2 result in renal Mg2+ wasting [14]. 
Recently, a large genome wide association study (GWAS) identified the ARL15 locus to 
be associated with urinary Mg2+ excretion [15]. ARL15 is structurally similar to Ras-related 
GTP-binding proteins, which regulate intracellular vesicle trafficking [16, 17]. Within the 
kidney, ARL15 is highly expressed in the thick ascending limb (TAL) and distal convoluted 
tubule (DCT), like CNNM2, where Mg2+ reabsorption is tightly regulated [15]. However, the 
exact function of ARL15 and the mechanism by which ARL15 regulates Mg2+ homeostasis 
is still unknown.
In this study, we identified CNNMs as direct interacting partners of ARL15 by binding 
to the CBS1 domain of CNNM2. We demonstrate that ARL15 is a negative regulator of 
cellular Mg2+ homeostasis through its modulation of CNNMs glycosylation and the direct 
correlation of its expression to levels of intracellular Mg2+. 
Methods and materials
DNA constructs
Human CNNM2 cDNA with an in-frame HA tag before CNNM2 stop codon and 
an XhoI restriction site after CNNM2 stop codon was amplified using Phusion 
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polymerase (New England Biolabs, Ipswich, MA, USA) and then the product was 
cloned into the pCINeo-IRES-GFP vector using NheI and XhoI (New England Biolabs). 
To obtain truncated CNNM2 plasmids, primers (Forward:5’-CGGCTAGCGCCACCATGA
TTGGCTGTGGCGCTTG-3’ and Reverse 1 (full-length CNNM2:05’-CCCTCGAGCTATGCG
TAGTCTGGCACGTCGTATGGGTAACCGGTGATGGCGCCTTCGTTG-3’), Reverse 2 (CNNM2 
transmembrane region: 5’-CCACCGGTCACGTCCTCCACCGTC-3’), Reverse 3 (CNNM2 
transmembrane+CBS1 region: 5’-CCACCGGTGTCATCGGGATCCAC-3’), Reverse 4 (CNNM2 
transmembrane+CBS1+link region: 5’-CCACCGGTGTGGTTATAAAATTTGGTGATG-3’) 
or Reverse 5 (CNNM2 transmembrane+CBS1+link+CBS2 region: 
5’-CGGCTAGCGCCACCATGATTGGCTGTGGCGCTTG-3’) were synthesized. All primers were 
purchased from Biolegio BV (Nijmegen, Netherlands). The PCR product was purified using a 
NucleoSpin® Gel and PCR Clean up kit (Macherey Nagel, Düren, Germany). Subsequently, the 
truncated CNNM2 PCR products were cloned into the pCINE-IRES-GFP vector by digestion 
with restriction enzymes NheI (New England Biolabs) and XhoI (New England Biolabs).
To obtain C-terminal FLAG-tagged ARL15 and CNNM constructs, human coding 
sequences were amplified with appropriate primers containing attB1 and attB2 recom-
bination site overhangs. Amplification was carried out with KAPA HiFi polymerase using 
GC buffer (Kapa Biosystems, Wilmington, MA, USA). Amplicons were gel purified and 
Gateway cloning was used to first recombine the amplicon into pDONR221 vector and 
then, pDEST26 (Addgene #79275) vector, using Gateway BP or LR Clonase II enzyme mix, 
respectively (Thermo Fisher Scientific, Waltham, MA, US). Chemically competent DH5α E. 
coli were transformed with pDONR221 and pDEST26 vectors. All constructs were verified 
by sequence analysis.
Cell culture, transfection and transduction
HEK293 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (Biowhittaker 
Europe, Vervier, Belgium) supplemented with 10% (v/v) fetal calf serum (PAA Laboratories, 
Linz, Austria), non-essential amino acids, and 2 mM L-glutamine at 37 °C in a humidified 
incubator with 5% (v/v) CO
2
 (New Brunswick Galaxy 170s). Cells were seeded 6 hours before 
transient transfection with Lipofectamine 2,000 (Invitrogen, Breda, The Netherlands), the 
ratio of DNA: Lipofectamine 2,000 was 1:2.
ACHN, Caki-1, HeLa, RCC4 and SK-RC-39 cells were grown in DMEM, high glucose 
(Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (FBS) (Thermo 
Fisher Scientific) and 2 mM GlutaMAX at 37 °C in a humidified incubator with 5% (v/v) CO
2
. 
For lentivirus production, HEK293T/17 cells were transfected with a 4:2:1 ratio of lenti-
viral construct of interest: PAX2: VSV-G. 24 hours later, the media was changed. 48 hours 
later, the media was collected and filtered through a 0.45 μm filter. To infect the cells, 
media was substituted with HEK293T/17 supernatant containing virus with 8 μg/ml poly-
brene. 48 hours later, the media was changed to fresh media containing a selection rea-
gent and the selection was carried out for 7 days. 
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Site-directed mutagenesis
To mutate asparagine 73 (N73) that was predicted to be the site of N-glycosylation of 
CNNM3 into alanine (A), pDONR221-CNNM3 carrying the wild-type sequence without 
a stop codon was amplified using a single primer PCR. Amplification was carried out 
with KAPA HiFi polymerase using GC buffer (Kapa Biosystems, Wilmington, MA, USA). 
The following primer was used: 5’-GGCCCGGGCTTCGCCgcCAGCTCTTGGTCCTGGGTGG-3’, 
indicating the nucleotides necessary to introduce the mutation in lower-case letters. 
After amplification, the original plasmid was digested with DpnI (New England Biolabs) 
for 2 hours at 37 °C, which was followed by transformation of chemically competent 
DH5α E. coli. The construct was verified by sequencing.
Pull down assay
A pull down assay was performed to determine which proteins of mice DCT interact 
with CNNM2. pGEX-mCNNM2 c-tail-GST was inserted in bacteria to be able to multiply 
the protein. Afterwards, bacteria were lysed with lysis buffer (150mM NaCl, 5mM EGTA, 
Triton 1% (v/v), 1mg/ml pepstatin, 1mM PMSF, 5mg/ml leupeptin, 5mg/ml aproptinin, 
50mM Tris/HCl, pH 7.5). Glutathione beads (Thermo Fisher, Rockford, IL, USA) were used 
to purify the samples to obtain only CNNM2 c-tail. The beads were washed with pull 
down buffer (20mM Tris-HCL pH 7.4, 140mM NaCl, 1 mM CaCl
2
, 0.2% (v/v) triton-x-100, 
0.2% (v/v) NP-40, 1:1000 pepstatin, 1:1000 Aprotinin, 1:400 Leupeptin, 1:100 PMSF) and 
bacterial lysate was added to the beads followed by an incubation of 3 hours at 4 °C. After 
incubation, beads were transferred into a new tube and washed with pull down buffer. 
For kidney tissue, kidneys of 8 PV-GFP mice were dissected and minced in small pieces. 
The DCT was selected and dissolved in pull down buffer followed by homogenizing 
of the mixture using ultra turrax. After 30 minutes of incubation on ice, aliquots were 
taken and centrifuged. Supernatant was added to the beads followed by an incubation 
overnight rotating at 4 °C. After incubation, beads were washed with pull down buffer, 
Laemmli and DTT were added, and Western blot was performed. Migration was stopped 
when the sample was 1 cm in the running gel. Then samples were cut out and measured 
with mass spectrometry.
Biotin identification (BioID)
BioID was performed as previously described [18]. The graph of ARL15 interacting partners 
was generated using ProHits-viz [19]. Gene ontology overrepresentation analysis was 
performed using PANTHER 15.0 [20].
ARL15 model
A model of the structure of ARL15 was generated by simulated annealing as implemented 
in Modeller [21] using as templates the X-ray diffraction coordinates of the complex 
between human ARL2 and BART (pdb code 3DOE chain A; 36.3 identity) complex 
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between murine ARL2 and PDEδ (pdb code 1KSG chain A; 36.3 identity) murine ARF6 
(pdb code  6BBQ; 35.67% identity) human ARF6 (pdb code 2A5G; 35.67% identity). Results 
were monitored in UCSF Chimera [22]. A single structure, displaying the lowest zDOPE 
[23] score (-0.58) and an RMSD value of 3.54 Å with respect to the closest template, out of 
100 results were selected. This structure was subjected to energy minimization using the 
Amber 14SB force field [24]. A final check was performed with Coot [25] before deposition 
and the ModelArchive server.
CNNM models
To generate alternative linker conformations, in addition to completing sidechains from 
a SAXS model, simulated annealing computations were carried out using Modeller 9.3 
[21]. 100 conformations were generated, arranged according to their zDOPE scores and 
tested for collisions with other subunits with UCSF Chimera. At the end, three different 
conformations were tested. A model of the cytosolic domains of CNNM3 was also 
generated using the full precursor sequence (NCBI accession code 060093.3) and the XRD 
coordinates of the CNNM2 cytosolic domains in their flat conformation [26].
Docking models 
Docking computations were carried out with benchtop HEX [27] and compared with 
Brownian dynamics (BD) computations. Hex computations included shape evaluation, 
in vacuo electrostatics and Decoys As a Reference State (DARS) potentials [28]. In every 
simulation, 20,000 structures were generated, clustered using a RMSD cut-off value of 
3 Å and arranged according to their energies. First 100 were selected for analysis. Post-
processing consisted in a short Optimized Potentials for Liquid Simulations (OPLS) energy 
minimization as implemented in the software.
Brownian dynamics
Docking modeling was complemented with BD computations using the WebSDA server 
[29] to test if results could be reproduced by other methods. The force-field grids used 
in BD included all electrostatics and desolvation [30, 31] grids. Charges were added with 
PDB2PQR tool [32].
200 trajectories of BD computations were run in docking mode. A total of 500 non-re-
dundant complexes were recorded along the computations. Table 1 displays the sum-
mary of the clustering analysis of the distinct complexes found. First cluster corresponds 
to binding to cyclic nucleotide monophosphate-binding homology (CNBH) domains at 
regions nearby missing structure, so they are considered artefactual. Cluster 2, however, 
showed the highest population and—on average— displayed lowest energies, and the 
lowest dispersion of conformations, according to RMSD values with respect to the repre-
sentative structure.
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Glycosidase and tunicamycin treatment
20 ug of protein from SK-RC-39 cells were treated with N-glycosidase F (PNGase F) and 
Endoglycosidase H (Endo H) (New England Biolabs) according to the manufacturer’s 
instructions. Briefly: protein was denatured at 100 °C for 10 minutes, 1 unit/ul of a 
glycosidase was added with appropriate buffers and digested at 37 °C for 1 hour. SK-
RC-39 cells grown in DMEM were treated with tunicamycin (Sigma-Aldrich, St. Louis, MO, 
USA) at 1 ug/ml for 8 hours to inhibit N-glycosylation.
Immunohistochemistry
5 μm kidney frozen sections were fixed with formalin and washed with TN buffer (0.1 
M Tris/HCl (pH7.6) 0.15 M NaCl). Then, the sections were permeabilized in TN-Triton (TN 
with 0.1% Triton X-100) for 30 minutes. After incubation, the sections were washed and 
blocked with TN with 0.5% (w/v) blocking reagent TSA fluorescein system (Perkin Elmer, 
Waltham, MA, USA) for 30 minutes. The sections were incubated overnight at 4 °C with the 
following primary antibodies: guinea pig anti-CNNM2 (kindly received from Dr. Muller), 
rabbit anti-ARL15 (Sigma-Aldrich, St. Louis, MO, USA). For detection, kidney sections 
were incubated with Alexa Fluor 488 conjugated goat anti-rabbit and Alexa Fluor 596 
conjugated goat anti-guinea pig IgG secondary antibodies (Thermo Fisher, Rockford, IL, 
USA). Images were visualized using AxioCam cameras (Zeiss, Oberkochen, Germany) and 
AxioVision software (Zeiss).
Immunocytochemistry
HEK293 cells were seeded at a low density on 0.01% (w/v) poly-L-lysine (Sigma, St Louis, 
MO, USA) coated coverslips and were transfected the subsequent day using Lipofectamine 
2000 (Invitrogen, Breda, The Netherlands). Then, the following constructs: pCINEO-
CNNM2-HA-IRES-GFP, pLenti6-CNNM3-V5, pDEST26-ARL15-FLAG, and mCherry-Golgi-7 
were transfected. 24 hours after transfection, cells were washed with PBS, followed 
by fixation for 10 minutes using 4% (w/v) methanol-free formaldehyde (ThermoFisher, 
Waltham, MA, USA) in PBS. Afterwards, cells were permeabilized for 10 minutes in 0.1% 
(v/v) Triton-X100 and 0.3% (w/v) bovine serum albumin (BSA) (ThermoFisher, Waltham, 
MA, USA) solution. Subsequently, cells were treated with 50 mM NH
4
Cl in PBS in order 
to reduce the background. Thereafter, cells were washed in PBS followed by blocking 
in 16% (v/v) normal goat serum (Merck Millipore, Burlington, MA, USA) supplemented 
with 0.1% (v/v) Triton-X100 for 30 minutes in room temperature. Then, cells were probed 
with primary antibody diluted in blocking buffer overnight at 4 °C, washed three times 
and incubated in secondary antibodies for 45 minutes at room temperature in the dark. 
Cells were washed three times with PBS and subsequently mounted using mounting 
medium supplemented with 4’, 6-diamidino-2-phenylindole (DAPI; Southern Biotech, 
Birmingham, AL, USA). Images were made using the Zeiss LSM880 (Oberkochen, Germany) 
and analyzed using the freely available Fiji software [33]. The following antibodies were 
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used: mouse monoclonal anti-HA (Sigma-Aldrich, St. Louis, MO, USA), mouse monoclonal 
anti-V5 (Thermo Fisher, Rockford, IL, USA) and rabbit polyclonal anti-FLAG (Sigma-
Aldrich, St. Louis, MO, USA), Alexa Fluor 488 conjugated goat anti-rabbit and Alexa Fluor 
647 conjugated goat anti-mouse (Thermo Fisher, Rockford, IL, USA).
Western blot
Cells were lysed with lysis buffer containing 1mg/ml pepstatin, 1mM PMSF, 5mg/ml 
leupeptin, 5mg/ml aproptinin protease inhibitors. The lysis buffer contained 50mM Tris-HCl 
(pH 7.5), 1mM EDTA, 1mM EGTA, 150mM NaCl, 1mM sodium-orthovanadate, 10mM sodium-
glycerophosphate, 50mM sodium fluoride, 0.27M sucrose, 10mM sodium pyrophosphate, 
1% (v/v) Triton X-100. Protein concentrations were measured by performing a Bicinchoninic 
Acid protein assay (BCA) (Fisher Scientific, Hampton, NH, USA) and 20 µg protein were used 
for Western blot. Blots were then incubated in primary antibody overnight rolling at 4 °C. 
Primary antibodies were diluted in 1% (w/v) milk diluted in Tris-Buffered Saline and Tween 
20 (TBST) as following; anti-HA (Cell Signaling technology, Leiden, The Netherlands), anti-
FLAG (Sigma-Aldrich, St. Louis, MO, USA), anti-V5 (Thermo Fisher, Rockford, IL, USA), anti-
β-actin (Sigma-Aldrich, St. Louis, MO, USA), all are raised in mice. After washing with TBST, 
blots were incubated for 1 hour rolling at room temperature (RT) in secondary antibody 
which was sheep anti-mouse antibody (Sigma-Aldrich, St. Louis, MO, USA). Then, proteins 
were visualized with Chemidoc (Bio-Rad Laboratories Inc, Hercules, CA, USA). Subsequent 
analysis was done using Image J [33].
Co-Immunoprecipitation
HEK293 or HeLa cells were seeded and transfected in petri dishes, 24 to 48 hours after 
transfection, cells were lysed with lysis buffer. BCA assay was performed to determine 
the protein concentration of the lysates. Input samples were taken to be able to check 
transfection efficiency by performing Western blot. For co-immunoprecipitation 
samples, 30 µl/sample protein A/G plus agarose beads (Santa Cruz Biotechnology, CA, 
USA) were washed with PBS. And 1.5 µl/sample in mouse raised antibody for human 
HA (Sigma-Aldrich, St. Louis, MO, USA) was added to the beads. For negative control, 
no antibody was added to the beads. Samples were then incubated for 2 hours rotated 
at 4 °C. Unbound antibodies were removed by washing with PBS. Then, lysates with the 
same amount of proteins (as calculated with the BCA test) were added to the beads and 
incubated overnight rotated at 4 °C. After incubation, lysates and beads were washed 
with lysis buffer. Then, Laemmli and Dithiothreitol (DTT) were added, and Western blot 
was performed. For FLAG-tagged protein immunoprecipitation, for each sample, 20 ug 
of Anti-FLAG M2 affinity agarose gel (Sigma-Aldrich, St. Louis, MO, US) were pre-blocked 
with 5% (w/v) BSA and 300 ug of total cell lysate (TCL) was pre-cleared with 20 ug of 
protein A/G agarose mix, for 2 hours at 4°C on a rotator. TCL supernatant was collected 
and incubated with pre-blocked FLAG beads for 2 hours at 4 °C on a rotator.
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ATP production
5,000 kidney cancer cells were plated per well in a 96-well plate and ATP production was 
measured after growing overnight. CellTiter-Glo 2 kit (Promega) was used in accordance 
with manufacturer’s instructions.
CRISPR-Cas9 experiments
Guide RNA (sgRNAs) targeting ARL15 were cloned into lentiCRISPRv2 plasmid (Addgene 
#52961) using Golden-Gate Assembly with the Esp3I endonuclease following the 
standard protocol [34]. For lentivirus production, HEK293T/17 cells were transfected 
using Lipofectamine 2000 (Invitrogen, Breda, The Netherlands) with 4:2:1 ratio of 
lentiCRISPRv2:PAX2: VSV-G. 24 hours later, the media was changed. 48 hours later, the 
media was collected and filtered through a 0.45 μm filter. To transduce the cells, media 
was substituted with HEK293T/17 supernatant containing virus with 8 μg/ml polybrene. 
48 hours later, the media was changed to fresh media containing puromycin and the 
selection was carried out for 7 days.
25Mg2+ uptake
ACHN, Caki-1, RCC4 and SK-RC-39 cells were seeded into 12-well plates. Two days after 
transfection, cells were washed once with basic uptake buffer without Mg2+ (125 mM NaCl, 
5 mM KCl, 0.5 mM CaCl
2








, 15 mM HEPES/NaOH, pH 7.5), 
followed by incubation for 0 or 15 minutes at 37°C with basic uptake buffer containing 1 
mM 25Mg2+ (Cortecnet, Voisins Le Bretonneux, France). After incubation, the basic uptake 
buffer containing 25Mg2+ was removed and cells were washed with ice cold PBS. Then cells 
were lysed with 1 ml nitric acid (Sigma Aldrich, St. Louis, MO, USA) which was then diluted 
in Milli-Q until a nitric acid concentration of 10%. Samples were analyzed with inductively 
coupled plasma mass spectrometry (ICP-MS).
Cell surface biotinylation
Petri dishes were coated with poly-L-lysine before seeding and transfection. Two days 





, pH 8.0 adjusted with NaOH, Milli-Q until total volume of 1,000 ml) followed by 
adding 0.5 mg/ml Sulfo-NHS-LC-LC-biotin (Thermo fisher scientific, Rockford, USA). After 
30 minutes incubation, cells were washed with 0.1% (w/v) PBS-CM BSA and PBS. Cells 
were then lysed with lysis buffer, and protein concentration was measured with a BCA 
test. Input samples were taken to be able to check transfection efficiency by performing 
Western blot. Then, lysates with the same amount of proteins (as calculated with the 
BCA test) were added with the neutravidin agarose beads (Thermo fisher scientific, 
Rockford, USA) and incubated overnight rotated at 4°C. After incubation, protein lysates 
were washed with lysis buffer. Then, Laemmli and DTT buffer were added to samples and 




Results are expressed as mean ± standard error of the mean (SEM). Biotinylation, Co-
Immunoprecipitation and ATP production results are statistically analyzed by performing 
one-way ANOVA followed by Tukey as post-test. 25Mg2+ uptake results are statistically 
analyzed by performing a two-way ANOVA followed by Tukey as post-test. Differences 
with P<0.05 were regarded as statistically significant.
Results
ARL15 is a new binding partner of CNNMs
To identify CNNM2 protein interactions, pull down of mouse CNNM2 carboxyl-terminal 
region was performed using DCT-enriched kidney lysates, followed by mass spectrometry 
(Figure 1A). Twenty-four interacting partners of CNNM2 were detected, including ARL15 
(Figure 1B). Since ARL15 has been shown to be involved in urinary Mg2+ excretion [15], we 
decided to further explore this particular interacting partner. To confirm the interaction 
between ARL15 and CNNMs, BioID of ARL15 was performed and we identified 221 proteins 
as potential interacting partners of ARL15 and CNNM2, CNNM3 and CNNM4 were among 
them (Figure 1F). Gene ontology (GO) biological process overrepresentation analysis 
indicated that Mg2+ ion homeostasis was one of the most highly enriched processes 
(Figure 1C). Immunoprecipitation demonstrated that CNNM3 and ARL15 interact 
endogenously (Figure 1D). To further confirm this association, co-immunoprecipitation 
assays were performed with overexpressed ARL15 and the four members of the CNNM 
family. ARL15 binding was observed to a similar extent for each CNNM protein (Figure 1E). 
Endogenous PRL-1 and PRL-2, which are well described interacting partners of CNNMs 
that regulate Mg2+ flux [10, 11], also co-precipitated with CNNMs and ARL15 (Figure 1E). 
The above data indicate that ARL15 is a novel interacting partner of the four members of 
the CNNM family of Mg2+ modulators. 
ARL15 interacts with CNNM2 cytoplasmic region
The topology for CNNMs consists of a signal peptide, three transmembrane domains 
(TM) and an intracellular C-carboxyl containing the CBS and a CNBH domain (Figure 2A) 
[8]. To determine which domain of CNNM2 is important for the interaction with ARL15, 
truncated CNNM2 proteins were co-immunoprecipitated with ARL15. The presence of 
the CBS domains is essential for the binding of ARL15 to CNNM2. The interaction of the 
proteins decreases by 36% when the CBS2 domain is removed (Figure 2B and 2C). No 
interaction with the transmembrane domain was observed. These results show that ARL15 
interacts with the cytoplasmic portion of CNNM2 and that the interaction is enhanced by 
the presence of the complete C-terminal region of the protein.
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Figure 1. Part 1
To determine whether the interaction between ARL15 and CNNMs was dependent on 
Mg2+ or not, ARL15 and CNNM were immunoprecipitated in the presence or absence of 
Mg2+ in the lysis buffer. Results showed that adding 1mM Mg2+ in the lysis buffer does not 
affect the association between ARL15 and CNNM2 compared to the condition of the lysis 
buffer without Mg2+ (Figure 2D). In line with this, the binding between ARL15 and CNNM3 
was similar in both conditions (Figure 2E).
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Figure 1. ARL15 interacts with CNNMs
A, Immunoblot of GST-mCNNM2 c-tail pGex and empty pGex was used as control. The C-tail of mCNNM2 is 
purified and bind to glutathione beads. The DCT enriched fraction from 8 parvalbumin GFP mice were added 
to the bead. B, List of binding proteins to mCNNM2 C-tail (emPAI value). C, Representative pathways related to 
metal ion transport and Golgi-trafficking identified using gene ontology biological process overrepresentation 
analysis with ARL15 interacting partners. D, Endogenous CNNM3 was immunoprecipitated from HEK293 
lysates and endogenous ARL15 co-immunoprecipitated with it. IgG antibody of the same subclass as CNNM3 
antibody was used as negative control. E, Anti-FLAG beads were used to immunoprecipitate overexpressed 
FLAG-tagged CNNM1-4 proteins. The blots show that ARL15 interacts with CNNM1-4, as well as endogenous 
PRL-1 and PRL-2. F, List of ARL15 interacting partners identified through BioID. emPAI, Exponentially modified 
protein abundance index; TCL, Total cell lysate; IP, Immunoprecipitation; GST, Glutathione-S-transferase; 
ARL5, ADP ribosylation factor like GTPase 15; CNNM, Cyclin M.
Docking models of the CNNM-ARL15 interaction
To assess the role of the various cytoplasmic CNNM2 cytosolic domains as targets of ARL15, 
docking computations were carried out. The coordinates of the flexible linker joining 
the Bateman and CNBH domains were modelled onto the available X-ray diffraction data 
of the CNNM2 cytosolic domains. Figure 3 displays the domain arrangement of CNNM2 
cytosolic domains (Figure 3A) as well as the electrostatic potential on their surface (Figure 
3B). Notably, the linkers joining the Bateman domain to the CNBH display a stretch of 
basic residues. Best score solutions displayed ARL15 interacting with both CNNM2 
monomers. ARL15 was partly inserted into the cleft between the Bateman domains and 
the CNBH domains (Figure 3C-D). In each of the two symmetric solutions, the total buried 
solvent accessible surface per partner was 2,175.7 Å2, 1,830.8 Å2 (932.6 Å2
,
 from CBS1, 262.3 
Å2 from the linker and 344.9 Å2 from the CNBH domain) with one of the two CNNM2 
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monomers and 344.9 Å2 (190.6 Å2
 
from CBS1* and 154.3 Å2 from CNBH*) for the interaction 
with the second CNNM2 monomer. Such values are typical of rather stable complexes, 
and in the upper limit of non-obligate interactions [35]. In addition, the complex displays 
complementarity of charges at the rim of the interface, as shown in Figure 3D.
As pointed out, the Bateman CBS1 domains contacted with ARL15, in particular that 
of the first monomer with a surface region defined between α−helix A, the β1-β2 hairpin 
loop and α-helix H1 in one of them, but also contacting the second monomer. Figure 3C 
shows the lowest energy solution found in different simulations. Other solutions with 
low energies corresponded to the hydrophobic surface of H0 helix pair, which interacts 
with the lipid bilayer, and spots of the CNBH domains in which the absence of coordi-
nates from the nearby unstructured regions disclosed an artifactual interaction site, oth-
erwise concealed. Notably, BD computations (Figure 3 E-G, Table 1) yielded results very 
similar to those displayed herein. Thus, the interaction model herein is compatible with 
a 1:1 CNNM2:ARL15 stoichiometry. Other sets of solutions targeted the same region, but 
displayed different orientations of ARL15 towards CNNM2 surface, and were not found in 
all simulations. The result in Figure 3, however, was hardly dependent on the modelled 
conformation of the linker—residues 525 to 546 (Figure 3D). Nevertheless, in most simu-
lations several positive residues of the linker mapped near the interface. As CNNM3 has 
been reported to bind ARL15 with an affinity higher than that for CNNM2, HEX docking 
simulations were also performed using a CNNM3 model (Figure 3 E-G). Notably, ARL15 
targeted the same site in CNNM3 as does in CNNM2, though the orientation differs by a 
slight rotation of ARL15. 
100
Chapter 5
Figure 2. ARL15 interacts with CNNM2 cytoplasmic region. 
A, Schematic overview of CNNM2 constructs including the predicted protein domains and truncations. B, 
HEK293 cells were co-transfected with truncated CNNM2-HA and ARL15-Flag. The upper two blots show 
the detection of the Flag-tagged proteins in anti-HA precipitated cell lysates. The lower two blots show 
input controls of HA-tagged and Flag-tagged proteins respectively. C, Quantification of ARL15/CNNM2 
binding between the different truncated CNNM2 proteins. Results are the mean ± SEM of 3 independent 
experiments. * indicate significant differences compared to CNNM2 + ARL15 transfected cells (P<0.05). D, Co-
immunoprecipitation of HEK293 cells transfected with ARL15-FLAG and HA-CNNM2 treated with or without 
1mM Mg2+ in lysis buffer. The upper two blots show the detection of the FLAG-tagged proteins in anti-HA 
precipitated cell lysates. The lower two blots show input controls of HA-tagged and Flag-tagged proteins 
respectively. E, Co-immunoprecipitation of HEK293 cells transfected with ARL15-FLAG and V5-CNNM3 
treated with or without 1mM Mg2+ in lysis buffer. The upper two blots show the detection of the FLAG-tagged 
proteins in anti-V5 precipitated cell lysates. The lower two blots show input controls of V5-tagged and 
FLAG-tagged proteins respectively. The figure shows a representative blot of 3 independent experiments. 
SP, Signal peptide; TM, Transmembrane; CBS, Cytosolic cystathionine β-synthase; CNBH, Cyclic nucleotide 
monophosphate-binding homology; ARL5, ADP ribosylation factor like GTPase 15; CNNM, Cyclin M; TCL, Total 
cell lysate; IP, Immunoprecipitation; IB, Immunoblotting;
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Figure 3. Model of the interaction between the CNNM2 cytosolic domains and ARL15. 
A, Richardson (ribbon) diagram of the cytosolic CNNM2 dimer domains. Each monomer is in a different 
color, and the model of flexible linker joining the Bateman domains to the CNBH ones are in light green. B, 
Electrostatic potentials at the surface of CNNM2 cytosolic domains. Electrostatic grids were generated with 
APBS 3.0 [36] at 150 mM ionic strength. C, Best solution of ARL15 (red ribbons) docking to CNNM2 computations. 
D, Dissection of the interface between ARL15 and CNNM2 (middle) illustrating both the surface and charge 
complementarity between the two partners. E, Overlay of two solutions (dark and light cyan) from different 
HEX docking computations with the representative structure of the most populated cluster (yellow) from 
Brownian dynamics computations. F, Overlay of the results from HEX docking computations between Arl15 
and CNNM2 and CNNM3. CNNM3 was aligned to CNNM2—which is shown. The ARL15 bound to CNNM3 is in 
red ribbons. G, Comparison of CNNM2 and CNNM3 electrostatic potentials at the surface. CBS, Cystathionine 
β-synthase; CNBH, Cyclic nucleotide monophosphate-binding homology; ARL5, ADP ribosylation factor like 
GTPase 15; CNNM, Cyclin M.
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Table 1: Brownian Dynamics data
No Size Repr ReprE ClAE CLAED ElE ElDesE HyDesE Spread  Stddev Max
1 61257 141 -25.858 -25.609 0.743 -7.640 3.766 -21.984 28.666 15.109 44.108
2 63258 277 -25.069 -26.597 1.261 -7.960 6.939 -24.048 19.155 7.041 32.403
3 13185 200 -25.504 -26.276 0.600 -4.104 2.758 -24.158 9.718 16.588 46.429
4 32649 363 -24.803 -26.204 1.889 -1.591 4.212 -27.424 17.866 11.585 29.227
5 9200 484 -24.473 -25.335 0.439 -3.661 3.750 -24.562 4.455 8.879 28.354
No, Cluster Number; Size, Number of representative entries for the cluster; Repr, Representative chosen; 
ReprE, Total interaction energy of the chosen Representative; ClAE, Average total energy of all cluster 
members weighted with number of representatives; CLAED, Weighted standard deviation of total energy 
of cluster entries in the complexes (f55) file; Ele, Electrostatic energy of the representative complex; 
ElDesE, Electrostatic desolvation energy of the representative complex; HyDesE, Hydrophobic desolvation 
energy of the representative complex; Spread, arithmetic average of rmsd’s of each cluster member from 
the representative, weighted by occupancy; Stddev, Stddev of the rmsd’s for a given cluster, weighted by 
occupancy; Max, Maximum rmsd within one cluster from the representative.
ARL15 and CNNM co-localize in the perinuclear region and in kidney DCTs
The subcellular localization for the ARL15-CNNM complex was determined by 
immunocytochemistry in HEK293 cells. Overexpression of the mCherry-tagged Golgi-
marker Beta-1,4-Galactosyltransferase 1 (B4GALT1) showed co-localization with ARL15 
and CNNM2 in HEK293 cells, suggesting that the function of ARL15 is exerted within the 
perinuclear region containing the endoplasmic reticulum (ER) and the Golgi-apparatus 
(Figure 4A). Similar results were obtained with ARL15 and CNNM3, confirming that the 
proteins predominantly co-localize in Golgi (Figure 4B). 
Since CNNM2 has been implicated in Mg2+ transport in the DCT segment of the kid-
ney [8], we investigated whether ARL15 co-localizes with CNNM2 in this segment of the 
nephron (Figure 4C). Immunostaining results showed that CNNM2 staining was concomi-
tant with ARL15 staining in mouse kidney sections. One of the ARL15 interacting partners 
identified using BioID was RPN1 (ribophorin I) (Figure 1F). RPN1 is part of the oligosac-
charyltransferase complex that is involved in N-glycosylation and is found in the ER [37]. 
To confirm the interaction, co-immunoprecipitation assays with overexpressed CNNM3, 
ARL15, and RPN1 were performed (Figure 4D). CNNM3 interacted with RPN1 and ARL15, 
corroborating the localization of the three proteins to the ER as well (Figure 4D).
CNNM3 N-glycosylation is modulated by ARL15 and Mg2+
CNNM2 has been previously shown to have an N-glycosylation site close to its amino (N)-
terminus [8]. Using NetNGlyc [38], N-glycosylation sites were predicted in CNNM1, CNNM2, 
CNNM3, and CNNM4. The N-glycosylation site is conserved on their extracellular domain 
(CNNM1 N97, CNNM2 N112, CNNM3 N73, and CNNM4 N85). To confirm that CNNM3 does 
indeed have an N-glycosylation site similar to CNNM2, the predicted N73 was mutated 
to A (N73A mutant). Compared to wild-type CNNM3, the N73A mutant migrated further 
down the gel, which is indicative for the loss of N-glycosylation (Figure 5A). Endo H and 
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PNGase F were used to characterize the type of glycans attached to CNNM3 (Figure 5B). 
When wild-type CNNM3 was treated with Endo H, which cleaves oligomannose glycans, 
the bottom band of the doublet shifted further. Cleavage with PNGase F shifted all bands 
of CNNM3 to a lower molecular mass, indicating that the top band represents the hybrid/
complex glycoform (Figure 5A). 
Since one of the enriched GO biological processes identified in ARL15 BioID was “Pro-
tein N-linked glycosylation via asparagine” (Figure 1C), we aimed to assess the effect of 
ARL15 on CNNM3 N-glycosylation. To this end, four different kidney cancer cell lines were 
used: Caki-1 and RCC4 as well as ACHN and SK-RC-39, belonging to renal clear cell carci-
noma and papillary renal cell carcinoma, respectively. ARL15 was stably overexpressed in 
these four cell lines and the pattern of endogenous CNNM3 bands was evaluated.
Figure 4. ARL15 and CNNMs co-localize in the Golgi system
A, Immunocytochemistry of HEK293 overexpressing ARL15 (a), CNNM2 (b), and mCherry-tagged Golgi-
apparatus marker, B4GALT1 (c). Nuclei are stained with DAPI (d). B, Immunocytochemistry of HEK293 
overexpressing ARL15 (a), CNNM3 (b), and mCherry-tagged Golgi-apparatus marker, B4GALT1 (c). Nuclei are 
stained with DAPI (d). C, Mouse kidneys were permeabilized and co-immunostained with (a) anti-ARL15 (in 
green) and (b) anti-CNNM2 (in red). (c) Merged picture of ARL15 in green and CNNM2 in red. (d) Merged 
picture stained for ARL15 in green, CNNM2 in red, and DAPI (nuclei) in blue. Bar in figure A and B represents 
5 μm, bar in figure C represents 50 μm. Representative image presented of three independent experiments 
with triplicates. G, Glomerulus, PT, Proximal tubule, DCT, Distal convoluted tubule. D, CNNM3 was 
immunoprecipitated from HeLa lysate with overexpression of ARL15-V5 and RPN1-V5. TCL, Total cell lysate; 
IP, Immunoprecipitation; ARL5, ADP ribosylation factor like GTPase 15; CNNM, Cyclin M; RPN1, Ribophorin I.
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In all four cell lines, overexpression of ARL15 resulted in the increase of hybrid/complex 
glycoform and a decrease in oligomannose glycoform of CNNM3 (Figure 5C). Using SK-
RC-39 cells, an interplay between ARL15 expression and Mg2+ concentration in the growth 
media was observed (Figure 5D). Lack of Mg2+ resulted in an increase of oligomannose 
CNNM3 glycoform. Additionally, CRISPR knockout of ARL15 led to a decrease of complex 
glycoform of CNNM3 as can be seen in the last two lanes (Figure 5D). 
Figure 5. CNNM3 N-glycosylation is modulated by ARL15 and Mg2+. 
A, Wild-type and N-glycosylation mutant CNNM3 were treated with PNGase F and Endo H glycosidases to 
assess the presence of different glycoforms of CNNM3 and to confirm N73 as the site of glycosylation. B, 
Schematic representation of different types of glycans. C, Overexpression of ARL15 increases complex CNNM3 
N-glycosylation in kidney cancer cells. D, SK-RC-39 cells were grown in the presence or absence of Mg2+ in the 
media and the status of CNNM3 glycoforms was assessed using Western blotting. CTRL, Control; sg, Single 
guide; Scr, Sccramble; ARL5, ADP ribosylation factor like GTPase 15; CNNM, Cyclin M; PNGase F, N-glycosidase 
F; Endo H, Endoglycosidase H.
ARL15 affect Mg2+ flux and ATP production
To study whether ARL15 regulates CNNM-dependent Mg2+ transport, its effect on Mg2+ 
transport capacity was determined using the stable 25Mg2+ isotope. Stably transduced 
kidney cancer cells with overexpression or CRISPR-mediated knockout of ARL15 were 
used. Overexpression of ARL15 decreased 25Mg2+ uptake, while ARL15 knockout increased 
25Mg2+ significantly, more than 3-fold in RCC4 and SKRC39 cells (Figure 6A). 
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Figure 6. ARL15 affects Mg2+ flux and ATP production. 
A, 25Mg2+ uptake measurements in ARL15 stably overexpressed and knockdown ACHN, Caki-1, RCC4, and SK-
RC-39 cells. These various types of renal carcinoma cell lines were incubated with 25Mg2+ for 15 minutes and 
results were normalized to 0 minute. Each data represents the mean of 3 independent experiments ± SEM. 
* indicates significant difference compared to control cells. B, ATP production in ARL15 stably overexpressed 
and knockdown SK-RC-39 and RCC4 cells. Results are the mean ± SEM of 3 independent experiments. C, 
Endogenous cell surface expression of CNNM3 was detected in SK-RC-39 cells by biotinylation. The upper 
immunoblots show CNNM3 cell membrane expression and the lower blot shows the total CNNM3 expression. 
D, The diagram shows the quantification of cell surface CNNM3 expression corrected for total CNNM3 protein 
expression. Results are the mean ± SEM of 3 independent experiments. sg, Single guide; Scr, Scramble; OE, 
Overexpression; ARL5, ADP ribosylation factor like GTPase 15; CNNM, Cyclin M.
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Since multiple enzymes involved in ATP production by using Mg2+ as a cofactor and ATP 
is bound to intracellular Mg2+ to form Mg-ATP [1], we decided to assess the impact of Mg2+ 
influx on ATP production. In RCC4 and SK-RC-39 cells, overexpressing ARL15 resulted in a 
significant decrease in ATP production (Figure 6B). 
Endogenous cell surface expression of CNNM3 was detected in SK-RC-39 cells with 
overexpression or CRISPR-mediated knockout of ARL15. The complex N-glycosylated 
CNNM3 glycoform runs at approximately 95kDa, oligomannose glycoform of CNNM3 runs 
at around 90kDa. Results demonstrated that plasma membrane expression of CNNM3 
was not altered in the presence or absence of ARL15 (Figure 6C and 6D). However, the 
oligomannose CNNM3 glycoform was observed at the plasma membrane in the ARL15 
knockout, compared to the ARL15 scramble group. 
Discussion
In this study, we identified ARL15 as a novel interacting partner of CNNMs. ARL15 binds to 
CNNMs in the ER and regulates their complex N-glycosylation in the Golgi system (Figure 
7). Our data suggest that the complex N-glycosylation of CNNMs reduces their activity at 
the plasma membrane, as reflected in a reduced 25Mg2+ uptake in renal carcinoma cells. 
As such, ARL15 may affect cellular Mg2+ homeostasis and energy metabolism.
ARL15 is a member of the superfamily of ARF-like (ARL) proteins, which have been 
functionally characterized as small GTPases. Although ARL15 has been relatively scarcely 
studied to date, many studies have demonstrated that other ARL and ARF proteins are 
involved in vesicle trafficking [39]. Our immunocytochemistry results in HEK293 cells 
demonstrated that ARL15 is predominantly localized in the Golgi system (Figure 4), which 
is in line with previous reports of ARL15 in 3T3-L1 pre-adipocytes [40]. Moreover, proxim-
ity labeling of ARL15 identified many Golgi-specific proteins (Figure 1F). 
However, the localization with RPN1, a protein of the oligosaccharyltransferase com-
plex, suggests that the interaction between ARL15 and CNNMs is already formed in the 
ER. Indeed, several ARF (-like) proteins, e.g. ARF1 and ARF3, have been shown to regulate 
ER-to-Golgi trafficking [41].
The main finding of our study is that ARL15 binds CNNMs and modulates their activ-
ity via N-glycosylation. Biosynthesis of glycoproteins commences in the ER, where a 
pre-assembled oligosaccharide is bound onto the nascent protein by oligosaccharyl-
transferases. After passing the ER, a series of reactions further assemble the glycan in 
the medial-Golgi and maturation takes place in the trans-Golgi. Three different types of 
N-glycans are commonly present on proteins; oligomannose, hybrid and complex N-gly-
cans. Our results demonstrate that ARL15 stimulates the formation of complex N-glycans 
on CNNMs. Although ARL15 does not possess the enzymatic capacity to change the gly-
cosylation per se, we have identified several proteins of the oligosaccharyltransferase 
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complex in our BioID experiments (e.g. DPM1, RPN1, LMAN1, STT3A and STT3B) (Figure 
1F). Moreover, protein N-glycosylation was among the enriched GO-terms in our analysis. 
We hypothesize that trans-Golgi trafficking via ARL15 is an essential step in the complex 
glycosylation of CNNMs. A similar mechanism has been postulated for ADP-ribosylation 
factor guanine nucleotide-exchange factor 1 (ARFGEF1), which regulates the N-glycosyl-
ation and trafficking of integrins [42].
Figure 7. Summary of the effect of ARL15•CNNM complex on Mg2+ flux. 
In the presence of ARL15, it interacts with CNNMs in the ER and Golgi, resulting in the complex N-glycosylation 
of CNNMs, which in turn decreases Mg2+ uptake. In the absence of ARL15, CNNMs are found in less complex 
glycoforms, which result in increased Mg2+ uptake. ER, Endoplasmic reticulum; ARL5, ADP ribosylation factor 
like GTPase 15; CNNM, Cyclin M.
The N-glycosylation of CNNMs is essential for their plasma membrane expression. CNNMs 
contain a single N-glycosylation site in the extracellular N-terminal region [8]. Mutation 
of the N73 residue to A in CNNM3 completely abrogated its membrane expression 
(Figure 5A). Similar results were previously obtained for N112 residue in CNNM2 [8]. In 
this study, we demonstrated that not only the presence of, but also the composition 
of the glycan is essential for the protein function. ARL15 overexpression resulted in a 
complex-glycosylation of CNNM3, which was accompanied by a significant reduction of 
25Mg2+ uptake. Vice versa, ARL15 downregulation resulted in a high-mannose glycan and 
increased 25Mg2+ uptake. Altogether, we propose a model in which the composition of 
the N-glycan affects CNNM activity.
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Multiple roles for N-glycosylation of plasma membrane proteins have been described, 
ranging from effects on membrane trafficking, membrane stability and protein 
degradation [43, 44]. In our experiments, neither ARL15 overexpression nor ARL15 
downregulation affected the plasma membrane expression of CNNM3 (Figure 6C), 
suggesting that membrane trafficking of CNNM3 is not affected by ARL15. Consequently, 
changes in N-glycosylation may directly affect the activity of CNNM3 at the plasma 
membrane. It has been extensively described that N-glycans interact with glycan-
binding proteins in the extracellular spaces, such as lectins. Lectin-glycan interactions 
are involved in many biological cellular processes such as apoptosis, differentiation as 
well as regulation of membrane transport [45]. Indeed, binding of lectins and other 
glycan-binding proteins has been shown to regulate TRPV5-mediated Ca2+ transport [46, 
47]. Whether the binding of lectins explains the changes in CNNM3 activity remains to 
be defined.
The interaction model that we developed is compatible with a 1:1 CNNM2:ARL15 sto-
ichiometry. ARL15 interacts with the Bateman CBS1 domains, in particular with a surface 
region defined between α−helix A, the β1-β2 hairpin loop and α-helix H1. Indeed, co-im-
munoprecipitation experiments confirmed that the CBS domains are essential for ARL15 
binding (Figure 2B). Overall, the interaction surface is small (355 Å, ca 700 Å of surface 
burial) and presents a core of hydrophobic and polar residues surrounded by charged 
ones. Interestingly, the positive-charged residues present in the CNNM2 docking site is 
complementarity to the negative-charged surface of ARL15 (Figure 3). Notably, no over-
lap is observed between the binding site of ARL15 and PRL, which mostly binds CBS2 by 
its long loop region comprising β5 and β6 [26]. 
The identification of ARL15 as a novel regulator of CNNM activity is of particular inter-
est in the DCT segment of the kidney. In the DCT, transient receptor potential cation 
channel subfamily M member 6 (TRPM6) facilitates apical Mg2+ transport [48]. Basolateral 
Mg2+ extrusion in the DCT is regulated by CNNM2. Consequently, mutations in CNNM2 
and TRPM6 have been shown to cause renal Mg2+ wasting in patients [14, 49, 50]. Interest-
ingly, the ARL15 locus was recently associated with urinary Mg2+ wasting in a GWAS [15]. 
In the same study, TRPM6 channel activity was shown to be significantly increased in the 
presence of ARL15 [15]. Our results demonstrate that ARL15 also binds CNNM2, suggest-
ing that both the apical and basolateral Mg2+ transport mechanisms are simultaneously 
regulated. These findings explain how ARL15 determined urinary Mg2+ excretion.
Interestingly, overexpression of ARL15 resulted in decreased ATP levels (Figure 6B). 
Intracellular Mg2+ and ATP are closely associated, as ATP must be bound to this cation 
to be biologically active [1]. Indeed, previous experiments have shown that PRL2 knock-
down decreased intracellular Mg2+ levels, reduced intracellular ATP levels and regulated 
cellular metabolism [4]. Given that ARL15 overexpression reduced CNNM-mediated Mg2+ 
uptake, the expression of ARL15 may indirectly regulate cellular metabolism. Indeed, 
ARL15 has been associated with a wide range of metabolic parameters and diseases 
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in GWAS, including adiponectin, high-density lipoprotein, diabetes mellitus and body 
shape [51-56]. As these studies did not analyze Mg2+ status as a modifying factor, it cannot 
be excluded that ARL15 has additional functions that explain these associations. Indeed, 
ARL15 has been demonstrated to modify the insulin-signaling pathway in myotubes [57].
Overall, our work establishes complex N-glycosylation of CNNMs as an essential pro-
cess to regulate their activity. This crucial post-translational modification promoted by 
ARL15 on CNNMs adds to recent mechanisms of CNNMs modulation such as their cir-
cadian rhythm expression and their regulation by Mg2+-sensitive translation [4, 58]. The 
increasing complexity of CNNMs regulation provides a dynamic system to ensure the 
correct levels of intracellular Mg2+ during metabolic changes and cell requirements. 
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Sodium (Na+), calcium (Ca2+) and magnesium (Mg2+) homeostasis plays a key role in a variety 
of physiological processes in the human body, such as cellular signal transduction, cell 
metabolism, bone development, enzymatic activity, neuronal conduction and excitability 
[1-3]. The final concentration and excretion of these electrolytes in the urine is determined 
by the kidneys through the reabsorption from the pro-urine into the bloodstream [2]. 
Paracellular and transcellular transport of electrolytes in the proximal tubule (PT), thick 
ascending limb of loop of Henle (TAL), distal convoluted tubule (DCT), connecting tubule 
(CNT), and collecting duct (CD) account for the reabsorption processes [4-6]. In particular, 
this is facilitated by i) cation-selective ion transporters, ii) endocrine and paracrine 
hormones, and iii) sensors that are sensitive to intra- or extracellular Na+, Ca2+, and Mg2+ 
fluctuations [7, 8]. Abnormal regulation of these processes is linked to a variety of diseases 
such as hypertension, diabetes, kidney stone formation and hypomagnesemia. The 
purpose of this thesis was to investigate the regulation of Na+ transporters in the kidney 
during treatment with sodium-glucose transport protein 2 (SGLT2) inhibitors, to develop 
Ca2+-binding peptides that may control the urinary Ca2+ concentration in hypercalciuria and 
kidney stone formation, and to study new players involved in renal Mg2+ handling.
Na+ handling in the proximal tubule in diabetes and 
hypertension
The role of potential Na+ compensatory mechanisms for SGLT2 inhibitors as 
cardiovascular protective therapies.
In the last decades, SGLT2 inhibitors have become novel and effective type of anti-
hyperglycemic drugs that increase glucosuria and ameliorate glycemic control. In addition to 
their glucose lowering effect, SGLT2 inhibitors can alleviate blood pressure (BP) by reducing 
systolic blood pressure (SBP) by 3-5 mmHg [9-11]. While it is likely in part due to associated 
natriuresis and polyuria, the molecular mechanism behind it is still not well documented. In 
Chapter 2, mice with high fat feeding were administrated the SGLT2 inhibitor dapagliflozin 
(DAPA) to investigate its effect on renal Na+ handling. These mice exhibited increased blood 
glucose levels that were alleviated upon 18-day DAPA treatment. Our results showed that 
the expression of the sodium-phosphate cotransporter (NaPi-2a) and sodium-hydrogen 
antiporter 3 (NHE3) is upregulated in the kidneys of DAPA-treated mice. 
The influence of SGLT2 inhibitors on the function and expression of NaPi-2a and NHE3 
is controversial. In 2018, Blau et al. found that the serum phosphorus level is increased in 
volunteers treated with the SGLT2 inhibitor canagliflozin [12]. This increased level of serum 
phosphorus was associated with an increased reabsorption of phosphate in the PT [13], 
which would be in line with the increased expression of NaPi-2a in our study. In contrast to 
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these findings, Thrailkill et al. demonstrated that canagliflozin treated diabetic mice exhibit 
no altered expression levels of NaPi-2a compared with vehicle treated diabetic mice [14]. The 
following reasons may explain the difference. First, Thrailkill et al. only used streptozotocin 
(STZ) to induce hyperglycemia [14], while we exposed the mice to a high fat diet prior to 
STZ administration to induce hyperglycemia. Second, canagliflozin was administrated for 10 
weeks to diabetic mice in their study [14], whereas we treated the mice with DAPA for 18 days. 
Interestingly, Pessoa et al. previously showed that SGLT2 and NHE3 are functionally 
interdependent [15]. Glucose promotes NHE3-regulated bicarbonate transport in the PT 
of Wistar rats, which could be inhibited by perfusion with the SGLT inhibitor phlorizin 
[15]. Immunostaining results showed that NHE3 was co-localized with SGLT2 instead of 
SGLT1 in the PT [15]. While they performed stationary in vivo microperfusion to rat prox-
imal tubules with phlorizin and sugars, and found that phlorizin inhibited NHE3 activity, 
gene or protein expression levels were not examined [15]. Nevertheless, NHE3 and SGLT2 
seem to be directly or indirectly coupled in the PT [15]. In addition, several studies have 
reported that alterations of renal NHE3 activity and expression are related to BP changes 
[16-18]. The BP is decreased in Nhe3 knockout mice compared to their wildtype litter-
mates [16]. Transgenic mice with NHE3 overexpression exhibited elevated BP, together 
with decreased urinary water and Na+ excretion [17]. Moreover, the activity and protein 
levels of NHE3 were found to be significantly increased in spontaneously hypertensive 
rats compared to Wistar-Kyoto (WKY) rats, which will probably lead to renal Na+ retention 
[18]. In line with our results, another study also demonstrated that luseogliflozin treat-
ment increases the protein expression levels of NHE3 in spontaneously hypertensive 
rats [19]. While there were no plasma or urine Na+ measurements in our study, it is most 
likely that increased expression of NHE3 and NaPi-2a functions as compensation for the 
decreased Na+ reabsorption by SGLT2, which may lead to Na+ retention. However, it is 
still uncertain to which magnitudes the NHE3 and NaPi-2a upregulation influences the 
urinary Na+ excretion and urine volume.
Notably, several studies reported that the BP reduction effect of SGLT2 inhibitors 
always occur in the early phase of the treatment [20, 21]. Indeed, SGLT2 inhibitor-induced 
natriuresis was observed shortly after the start of the SGLT2 inhibitor treatment in several 
clinical studies [22-25]. Similarly, canagliflozin has been shown to increase urine volume 
in type 2 diabetic patients in the beginning of the treatment [24, 26-29]. Though, the diu-
retic and natriuretic effects of SGLT2 inhibitors seem to be transient [19, 30]. In the begin-
ning of treatment, SGLT2 inhibitors result in natriuresis [31], which will lead to increased 
distal Na+ delivery to the macula densa [32, 33]. Then, the decreased hyperfiltration, affer-
ent vasoconstriction, and tubuloglomerular feedback will be triggered, through which 
the BP is decreased [34-36]. In our study, we found that NHE3 and NaPi-2a expression 
were upregulated. This will result in the decreased Na+ delivery to the macula densa, 
which may inhibit the BP reduction effect of DAPA. In addition, the loss of Na+ and water 




(Figure 1) [31]. This could explain why SGLT2 inhibitors reduced BP in the early phase of 
treatment. Therefore, clinical studies can combine SGLT2 inhibitors with RAAS blockade 
to better decrease BP in type 2 diabetes patients who suffer from hypertension [37, 38]. 
Weber et al. demonstrated that BP was significantly decreased in a combined DAPA and 
angiotensin-converting enzyme (ACE) inhibitor treated group compared to the placebo 
and ACE inhibitor treated group [37]. In another study, Kojima and colleagues addressed 
that combination treatment of luseogliflozin with lisinopril, which is an angiotensin-con-
verting enzyme inhibitor, significantly reduced BP compared to lisinopril alone [38]. The 
current thought of SGLT2 inhibition on renal Na+ handling is summarized in Table 1 and 2. 
Figure 1. Mechanism of the potential Na+ compensatory effect in the proximal tubule 
upon SGLT2 inhibition on the feedback of macula densa. 
SGLT2 inhibitor (Dapagliflozin) treatment may lead to reduced Na+ and glucose reabsorption in the PT (1), which 
activates the compensatory expression of NHE3 and NaPi-2a in the PT (2). Increased NHE3 and NaPi-2a may 
partially prevent the Na+ loss due to SGLT2 inhibition, which results in decreased distal Na+ delivery to the 
macula densa and inhibited tubuloglomerular feedback activity (3). Ultimately, this might lead to Na+ retention, 
activation of the renin–angiotensin–aldosterone system, and inhibition of the blood pressure reduction effect 
of dapagliflozin (4). SGLT2, sodium-glucose transport protein 2; G, glucose; NHE3, sodium–hydrogen antiporter 
3; NaPi-2a, sodium-coupled phosphate transporter type 2a; GLUT2, glucose transporter 2; NBC, sodium-
bicarbonate cotransporter; CA, carbonic anhydrase; RAAS, renin–angiotensin–aldosterone system.
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Interestingly, we did not observe changes in the expression of the sodium-potassium-
chloride cotransporter (NKCC2), sodium-chloride cotransporter (NCC) and epithelial 
sodium channel (ENaC) in the TAL, DCT, and CD, respectively. This seems surprising since 
inhibition of Na+ reabsorption in the PT is expected to turn on compensatory mechanisms 
and to activate Na+ transporters in the more distal parts of the nephron. For example, the 
expression of NCC is significantly increased in spontaneously hypertensive rats upon 13 
weeks of treatment with luseogliflozin [19]. The discrepancy between our studies may 
due to the fact that DAPA treatment was only 18 days. In response to water loss and 
reduced Na+ delivery at the distal tubule in the long term treatment, the expression 
of Na+ transporters may increase to compensate for Na+ loss, and renin release will be 
increased from the juxtaglomerular cells which can result in the activation of RAAS [39].
Taken together, Chapter 2 focused on the compensatory expression of Na+ trans-
porters in the local and downstream segments of the nephron in response to DAPA 
treatment. In order to better alleviate high BP in type 2 diabetic patients with long-term 
SGLT2 inhibitor treatment, it is interesting to isolate and analyze exosomes in urine sam-
ples to investigate the effect of the treatment with SGLT2 inhibitors on the expression of 
Na+ transporters (NKCC2, NCC, and ENaC (α, β, γ)) in the distal part of the nephron. Next, 
certain inhibitors can be used to block the individual Na+ transporters that are predomi-
nantly (up) regulated in type 2 diabetes patients. 
Hypercalciuria in kidney stone disease in Henle’s loop
Kidney stone prevention through a novel Ca2+-binding peptide
Kidney stones are mineral and acid salts that are formed in the urinary tract in the kidney 
[40]. The majority of stones consist of Ca2+ oxalate and Ca2+ phosphate [41]. Although 
medical therapy has largely improved kidney stone treatment, the recurrence rate after the 
first stone formation is still very high [42]. Therefore, we investigated our out-of-the-box 
idea to develop a potentially better remedy for treatment of kidney stones in Chapter 3. 
This idea is based on nature’s EF-hand motif, which is present in a large number of 
Ca2+-binding proteins and is involved in intracellular Ca2+-binding [43]. The structure of 
an EF-hand contains two alpha helices connected by a Ca2+-binding loop of 12 residues 
(Figure 2B). The Ca2+-binding affinities of various EF hands have been studied in detail, 
and several variations were made to residues of the Ca2+-binding loop that result in 
changes in Ca2+-binding affinities [44]. With further optimization, we aimed to generate 
an EF-hand containing peptide that i) exhibits Ca2+ binding capacity in the renal super-
saturation region (~5-10 mmol/L free Ca2+), namely the limb of Henle’s loop, but remains 
inert in the bloodstream (~1.2 mmol/L free Ca2+); ii) is not toxic to cells and has a good 
biosafety profile for ultimate in vivo treatment; and iii) exhibits minimal uptake/reabsorp-




Table 1. Current thought on the effect of SGLT2 inhibitors on renal Na+ handling in 
animals
Rodent studies
Animals Duration Diet Urine Na+ Urine V SGLTi Ref.
C57BL/6J mice 16W HFD N/A ↑ EMPA [45]
C57BL/6J mice 14 W HFD N/A ↑ CANA [46]
FLS-ob/ob mice 12W SD N/A ↓ IPRA [47]
ApoE-/- T2D 8 W WTD N/A ↓ CANA [48]
ApoE-/- T2D 12 W WTD N/A ↓ CANA [48]
T1D mice 3 W No N/A ↑ IPRA [49]
STZ-NAM T2D mice 1 D HFD N/A ↑ IPRA [50]
KK/Ay mice 4 W HFD N/A ↑ IPRA [51]
KK/Ay t mice 4W HFD N/A ↑ EMPA [52]
db/db mice 4 W No N/A ↑ TOFO [53]
db/db mice 1 D No ↑ ↑ EMPA [54]
db/db mice 10 W No N/A ↑ EMPA [55]
T1D rats 70 min No ↑ ↑ Phlorizin [56]
SD rats 1 D No N/A ↑ DAPA [57]
SD rats 2 h No ↑ ↑ LUSEO [58]
SHRcp rats 5 W No ↑ ↑ LUSEO [19]
ZDF rats 1 D No N/A ↑ DAPA [57]
ZDF rats 1 D No ↑ ↑ LUSEO [59]
OLETF rats 12 h 0.5% NaCl ↑ N/A EMPA [60]
OLETF rats 14 W No ↓ ↓ EMPA [61]
Albino rats 3 D chow diet N/A ↑ DAPA [62]
Wistar rats 6 W adenine N/A N LUSEO [63]
  WK rats 6 W adenine N/A N LUSEO [63]
GK T2DM rats 8 W CE-2 ↓ ↑ IPRA [64]
SGLT2, sodium-glucose cotransporter 2; SGLT2i, SGLT2 inhibitors; T1D, type 1 diabetes; T2D, type 2 diabetes; 
STZ, streptozotocin; NAM, nicotinamide; FLS-ob/ob mice, fatty liver shionogi-ob/ob mouse; KK/Ay, diabetic 
KK and lethal yellow (Ay) mice; SD rat, sprague dawley rat; WK, wistar kyoto; GK, goto-kakizaki; SHRcp, 
metabolic syndrome SHR/NDmcr-cp (+/+); ZDF, zucker diabetic fatty; OLETF, otsuka long-evans tokushima 
fatty; SD, standard diet; HFD, high fat diet; WTD, western-type diet; N, no change; No, no diet restriction; 
N/A, not available; IPRA, ipragliflozin; DAPA, dapagliflozin; TOFO, tofogliflozin; LUSEO, luseogliflozin; CANA, 




Table 2. Current thought on the effect of SGLT2 inhibitors on renal Na+ handling in 
patients
Clinical studies
Patients Duration Diet Urine Na+ Urine V SGLTi Ref.
T2D 12 W SD N ↑ DAPA [20]
T2D 12 W SD N/A ↑ DAPA [65]
T2D 12 W SRD ↑ ↑ CANA [24]
T2D 1 D Isocaloric N/A ↑ CANA [66]
T2D 2 W Isocaloric N/A N CANA [66]
T2D 1 W SD N/A ↑ LUSEO [67]
T2D 4 D No ↑ ↑ IPRA [68]
T2D 1 D SD N ↑ CANA [25]
T2D 18 D SD N N CANA [25]
T2D 1 D No ↑ ↑ CANA [22]
T2D 5 D No N ↑ CANA [22]
T2D 12 W SD N N DAPA [30]
T2D 4 D SRD ↑ ↑ IPRA [69]
T2D 1 D No N N DAPA [70]
T2D 12 W No N/A N DAPA [71]
T2D 1 M No N N TOFO [72]
T2D 6 M SD ↑ ↑ EMPA [73]
SGLT2, sodium-glucose cotransporter 2; SGLT2i, SGLT2 inhibitors; T2D, type 2 diabetes; SD, standard diet; 
SRD, sodium restricted diet; No, no diet restriction; N, no change; N/A, not available; IPRA, ipragliflozin; DAPA, 
dapagliflozin; TOFO, tofogliflozin; LUSEO, luseogliflozin; CANA, canagliflozin; EMPA, empagliflozin; Urine V, 
urine volume; Ref, reference; D, day; W, week; M, month.
As such, several small Ca2+-binding peptides (around 20-30 residues) were developed 
in our study. One peptide, Ac-DKNGDGYIDAAE-NH
2
, demonstrated a dose-dependent 
binding affinity to Ca2+ in the millimolar range. This peptide was developed based on 
the study of Reid et al. [74]. These authors developed an amino acid sequence (α-helix-
DKNGDGYISAAE-α-helix) which has a micromolar range Ca2+-binding affinity (Kd=58.8 
μmol/L) [74]. By using the Ca2+- binding loop (DKNGDGYISAAE) of their amino acid 
sequence as a template, we changed the amino acid at position 9 from S to D. Hereby, 
our data is in line with earlier studies showing that acidic residues paired on the x axes in 
the chelating positions of the loop (in bold in our peptide sequence: DKNGDGYIDAAE, 
Figure 2B), together with charged D on the z position are important for determining Ca2+-
binding affinity [74, 75]. In comparison with the study of Reid et al. [74], the Ca2+-binding 
affinity of our peptide is decreased. This could be explained by the fact that the peptide 
in our study is shorter than the Ca2+-binding peptide developed by Reid et al [74]. A 
similar observation has been documented on peptides from EF-hand proteins, showing 




Although, the peptide-based treatment has become a promising therapeutic method 
[77], the potential peptide toxicity remains a bottleneck in the development of peptide-
based remedies [78]. Therefore, we tested the toxicity of the designed peptide and 
demonstrated that cell viability was not affected by this peptide (Ac-DKNGDGYIDAAE-
NH
2
) in human kidney-2 (HK-2) proximal tubular cells. By calculating and comparing the 
composition of the amino acid sequence in toxic and non-toxic peptides, Gupta et al. 
demonstrated that the average amino acid composition in toxic peptides contains C in 
the highest amount, followed by N and P [79]. The average amino acid composition of I, 
K, L, and R in the toxic peptides are very low [79]. The residues C and P are not present in 
the peptide we selected. Although residue N is present, it is close to the amino-terminus 
of the peptide. Gupta et al. found that N is frequently present in the carboxyl-terminus 
of toxic peptides [79]. Interestingly, by counting the cumulative difference between the 
average amino acid composition of preferred residues in the toxic and non-toxic peptides, 
A, I, V, and F were shown to be ample in non-toxic peptides [79]. Likewise, A and I are 
present in the peptide we selected. Together, these suggest that the peptide likely has a 
good safety profile in terms of toxicity. But success of a peptide in a therapeutic setting 
depends on many other factors including stabilization, aggregation behavior, circulation 
time, renal clearance, immunogenicity, which need to be experimentally determined. 
Due to the small size, the peptide is expected to be freely filtered. However, it should 
overcome uptake by proximal tubular cells in order to reach the site of action, the limb 
of Henle’s loop. In our study, we found that the selected peptide exhibited mild cellular 
uptake in HK-2 cells. In the PT, low molecular weight proteins or peptides can be taken 
up through multiligand receptors [80-82] or apical endocytic pathway [83]. Vegt and col-
leagues injected radiolabelled peptides in megalin-deficient mice and addressed that a 
significantly lower amount of peptide was taken up in the kidneys of megalin-deficient 
mice compared to wildtype mice [84]. This suggests that megalin plays an important role 
in the renal peptide reabsorption [84]. HK-2 cells are commonly used since the cellular 
parameters are rather similar to the physiology of renal proximal tubular cells [85]. There-
fore, the peptide uptake in the HK-2 cells provides insight that the peptide we designed 
may also be taken up by the PT in mice or humans. Though, it has to be considered that 
the observed dose-dependent uptake of the Ca2+-binding peptide might also be caused 
by force-feeding cells with high amounts of the peptide. It was significantly less in com-
parison to a control cell-penetrating peptide that has been reported be taken up through 
endocytosis [86] or direct translocation [87, 88]. Importantly, Vegt et al. demonstrated 
presence of radiolabelled peptides in the urine of wildtype mice, yet at lower amounts 
than the megalin-deficient mice. And radioactivity did not differ significantly in the 
bloodstream and most other organs, except for the kidney between these mice [84]. This 
study provides evidence that peptides can reach the limb of Henle’s loop. Hence, future 
in vivo studies should assess renal clearance in addition to the tissue distribution, immu-
nogenicity, and efficacy of this peptide in animals. 
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For such future studies, it is crucial to establish a mouse model with kidney stone disease. 
Chapter 3 described a first approach by treating healthy male C57BL/6J mice with 1% 
(v/v) ethylene glycol (EG) via drinking water for 28 days. While EG is known to induce 
Ca2+ deposits in animals [89], these were not present in the mice from our study. This 
could be due to the fact that hypercalciuria was not induced in high Ca2+ diet treated 
mice, the urinary pH was similar between the normal Ca2+ and high Ca2+ diet treated 
groups, or that C57BL/6J mice had the capacity to prevent stone formation in the kidney 
[90]. Notably, Ca2+ deposits were present in Swiss albino mice administrated with 0.75% 
(v/v) EG in the drinking water for 28 days [91]. A difference in genetic background may 
explain the discrepancy. Additionally, Okada and co-workers successfully induced Ca2+ 
oxalate crystal deposits in C57BL/6J mice by injecting glyoxylate intra-abdominally [90]. 
Generating transgenic mouse is another tool to induce kidney stones in vivo. In 2004, 
Wesson and colleagues showed that EG in the drinking water of Tamm-Horsfall protein 
(THP) knockout mice results in Ca2+ deposits in the kidneys, and not in the kidneys of 
wildtype mice [92]. Finally, rats could also be considered for our future study as kidney 
stone formation in rats was shown to share similarities with kidney stone formation seen 
in humans, such as the oxalate metabolism process [93]. Moreover, EG was also widely 
and successfully used in several rat studies [89, 93, 94]. Upon identifying the optimal 
kidney stone animal model, injection of the peptide will be performed to investigate its 
biodistribution, safety, and efficacy by repeated administration in a kidney stone animal 
model (Figure 2A and C). 
Together, our study provided a first step towards developing a Ca2+-binding peptide 
with supersaturation-specific Ca2+ buffering ability and set up a systematic methodology 




Figure 2. Kidney stone prevention through a novel Ca2+-binding peptide.
A, the kidney consists of ~1 million nephrons as schematically depicted below, with the different segments color-
coded. B, schematic representation of the Ca2+-binding EF-hand structure, with the tested peptide sequence 
underneath. C, proposed assessment for functional consequences of the Ca2+-binding peptide (orange) in the 
loop of Henle of an animal model that is prone to stone formation. PT, proximal tubule; TAL, thick ascending 
limb of loop of Henle; DCT, distal convoluted tubule; CNT, connecting tubule; CD, collecting duct.
Fine tuning of Mg2+ reabsorption in the distal 
convoluted tubule
Identification of a novel gene, ARL15
Mg2+ is one of the most important cations for energy metabolism and multiple enzymatic 
reactions involved in DNA and protein synthesis [95]. It is filtered by the glomerulus and 
is mainly reabsorbed in the TAL and DCT of the kidney [96]. A genome-wide association 
study (GWAS) identified a novel gene, ADP ribosylation factor like GTPase 15 (ARL15), to 
be associated with urinary Mg2+ excretion in seven European cohorts [97]. Other GWAS 
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demonstrated that variation at the ARL15 locus is also associated with fasting insulin 
levels, plasma adiponectin levels, and triglyceride concentrations [98-101]. The role of 
ARL15 in the regulation of adiponectin and adiponectin receptor I and insulin signaling 
was confirmed by in vitro studies [102, 103]. Interestingly, we found that Arl15 mRNA and 
protein levels are most abundant in mouse white adipose tissue, which is the main site 
of adiponectin secretion [104, 105]. Furthermore, Rocha et al. demonstrated that Arl15 
knockdown in differentiated adipocytes results in decreased mRNA levels of Adiponectin, 
and impaired adipogenesis in pre-adipocytes [106]. In contrast, our study in Chapter 4 
did not show changes in mRNA expression of Adiponectin or other metabolism- or Mg2+-
related genes in Arl15 heterozygous (Arl15+/−) mice. Alterations in serum electrolytes levels 
and 24 hours urinary electrolytes excretion were not found in Arl15+/- mice compared to 
Arl15 wildtype (Arl15+/+) mice. Certain compensatory mechanisms may be activated to 
counteract for the heterozygous knockout of ARL15, since Arl15 knockout mice are lethal 
after birth. Although compensatory mechanisms could not be detected by RT-qPCR in 
our study, we cannot exclude changes in protein expression or activity. A similar study 
on the ADP-ribosylation factor (ARF)-related protein 1 (ARFRP1), which shares 30.8% 
similarity to ARL15, showed that heterozygous Arfrp1 (Arfrp+/-) mice developed normally 
whereas homozygous Arfrp1 knockout (Arfrp1-/-) mice exhibited embryonic lethality [107]. 
Interestingly, mice with specific deletion of Arfrp1 in adipocytes showed a lipodystrophic 
phenotype and enhanced lipolysis in adipocytes [108]. In light of these studies, additional 
experiments should focus on investigating protein levels of ARL15-related proteins to 
better understand the potential compensatory mechanisms. Moreover, adipocyte-
specific and kidney-specific Arl15 knockout mice can be generated and challenged with 
various diets to explore the role of ARL15 in metabolism and renal electrolyte handling. 
Exploring the novel function of ARL15 by BioID
In Chapter 4, we studied this novel gene and investigated its potential role in the kidney. 
I-TASSER tertiary structure prediction confirmed that ARL15 belongs to the small GTPase 
superfamily. Other members of this superfamily, like Rab and Arf, are known to be 
involved in vesicle trafficking from the endoplasmic reticulum (ER) to the Golgi [109]. 
ARL15 shares 33.5% similarity with ARF6, which is localized in the plasma membrane 
[110] and intracellular compartment [111]. Immunostaining results from our study and 
Rocha et al. proved that ARL15 is localized in the Golgi complex, the plasma membrane 
and intracellular compartment of 3T3-L1 cells [106]. Other studies demonstrated that 
ARF6 is involved in endocytic vesicular transport [112] and increased the cell surface 
expression of transferrin [113]. In accordance with this, Corre et al. showed that ARL15 
increases the activity of the Mg2+ channel transient receptor potential melastatin 6 
(TRPM6), probably by influencing its trafficking [97]. In Chapter 5, Biotin identification 
(BioID) results revealed that ARL15 interacts with TRPM7, a close homologue of TRPM6. In 




TRP family member, TRPV2, by protein-protein interaction prediction [114]. Additionally, 
ARL15 interacts with amino acid transporters, Ca2+ transporters, potassium (K+) trans-
porters, and other metal ion transporters including zinc (Zn2+) transporters (Chapter 5). 
Together, these findings broadened the basic knowledge on the function of ARL15, and 
strengthened the idea that ARL15 may act as small GTPase to interact and modify various 
types of transporters [97].
Gene ontology (GO) overrepresentation analysis of ARL15 BioID results suggest that 
ARL15 is involved in N-linked protein glycosylation. This pathway coincides with those 
observed in earlier studies evaluating the effects of small GTPase on glycosylation [115]. 
Protein glycosylation is a crucial and ubiquitous post-translational modification that can 
influence protein structure, stability, expression, and function [116-118]. Notably, BioID 
results revealed dolichol-phosphate mannosyltransferase subunit 1 (DPM1), dolichyl-di-
phospho-oligosaccharide (RPN1), lectin mannose binding 1 (LMAN1), and STT3 oligosac-
charyltransferase complex catalytic subunits A and B (STT3A and STT3B) as the glycosyla-
tion-related proteins that have the highest relative binding abundance with ARL15. DPM1 
transfers mannose from GDP-mannose (GDP-Man) to dolichol mannose (Dol-Man) in the 
synthesis of dolichol-phosphate mannose (Dol-P-Man) [119]. RPN1, which is exclusively 
found in the ER, is the component of N-oligosaccharyl transferase complex [120, 121]. 
This complex attaches high mannose oligosaccharides to N residues found in the nascent 
polypeptide chain consensus motif, this process is the first step of N-linked glycosylation 
[120, 121]. The LMAN1 functions as a glycoprotein transport cargo receptor that identifies 
sugar residues of glycoproteins and plays a crucial role in the transport or recycling of 
these proteins [122-124]. STT3A and STT3B are important for transferring the oligosac-
charide in the process of glycosylation [125]. STT3A conveys glycan chains onto N resi-
dues of target proteins in the ER [126, 127]. STT3B is used to attach oligosaccharides onto 
N residues of target proteins [126, 127]. The binding between ARL15 and DPM1, RPN1, 
LMAN1, STT3A, and STT3B further support a role for ARL15 in the modification of protein 
glycosylation from ER to Golgi. 
The functional interaction of ARL15 with CNNM proteins
Importantly, our Western blot results demonstrated that ARL15 affects the N-linked 
glycosylation of cyclin M 3 (CNNM3) (Chapter 5). The N-glycosylation of its homologue, 
CNNM2, is shown to be crucial in regulating CNNM2 plasma membrane expression [128]. 
Structurally, CNNM2 and CNNM3 have nearly 69% amino acid similarity [129], and the 
N-glycosylation site is conserved on their extracellular domain (CNNM2 N112 and CNNM3 
N73) [128]. Interestingly, our mass spectrometry results identified ARL15 as the binding 
partner of CNNM2 in the DCT of the mouse kidney. Moreover, co-immunoprecipitation 
results demonstrated that ARL15 predominantly binds to the CBS2 motif of CNNM2.
Although the exact molecular function of CNNM proteins is still under debate [130, 
131], it has been elucidated mutations in CNNM2 lead to hypomagnesemia and CNNM 
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protein members are shown to be involved in Mg2+ transport [132, 133]. CNNM2 is local-
ized to the basolateral side of the DCT, where is suggested to play a role in Mg2+ extrusion 
[128]. Here, TRPM6 (and TRPM7) channels are responsible for facilitating apical Mg2+ trans-
port [134]. Interestingly, our BioID results present that ARL15 interacts with TRPM7. In a 
previous study by our group, 2-amino-ethoxydiphenyl borate, a non-selective TRPM6/7 
inhibitor, was shown to abolish CNNM2-mediated 25Mg2+ uptake in HEK293 cells [132]. 
Together, this suggests a connection between apical and basolateral Mg2+ transport 
mechanisms that may be simultaneously regulated by ARL15.
Our functional studies revealed that stable knockdown of ARL15 in various types of 
renal cell carcinoma cell lines resulted in increased 25Mg2+ uptake and stable overexpres-
sion of ARL15 led to decreased 25Mg2+ uptake (Chapter 5). Notably, in our cell surface 
expression experiments, neither ARL15 overexpression nor ARL15 knockdown affected 
the plasma membrane expression of CNNM3, which suggests that membrane trafficking 
of CNNM3 is not affected by ARL15. However, ARL15 knockdown resulted in disturbed gly-
cosylation of CNNM3, suggesting that glycosylation of CNNM3 is important for its func-
tion. As a result of disturbed glycosylation CNNM3 may not be able to monitor or sense 
the intracellular Mg2+ concentration, which could lead to increased Mg2+ influx in ARL15 
knockdown cells. 
Recent studies showed that phosphatase of the regenerating liver (PRLs), which is 
a sub-family of the protein tyrosine phosphatases (PTP), interact with the extended 
loop of cystathionine-beta-synthase (CBS) 2 domain of CNNM3 [133, 135]. The binding 
between PRL2 and CNNM3 was increased under Mg2+-deficient conditions, which led to 
an increase in the intracellular Mg2+ concentration [133]. Interestingly, Western bot results 
also showed that the expression of PRL2 is decreased in renal carcinoma cells overex-
pressing ARL15 (data not shown). The decreased expression of PRL2 could explain why 
ARL15 overexpression leads to decreased Mg2+ uptake in renal cell carcinoma cell lines 
(Figure 3).
Interestingly, ARL15 overexpression also decreased ATP production (Chapter 5). Mg2+ 
is used as a cofactor for multiple enzymes involved in ATP production, and ATP is bound 
to intracellular Mg2+ to form Mg-ATP as a biologically active molecule [96]. Hardy et al. 
demonstrated that intracellular ATP production is decreased upon cellular Mg2+ deple-
tion, and that PRL expression is increased in response to low Mg2+ conditions [136]. In the 
same study, they addressed that this Mg2+-dependent upregulation of PRL2 was acti-





Figure 3. Proposed mechanisms for the ARL15/CNNMs complex regulating Mg2+ transport. 
In the DCT segment of the kidney, TRPM6/7 channels facilitate apical Mg2+ transport. Basolateral Mg2+ 
extrusion is regulated by CNNMs. When TRPM6/7 Mg2+ channels are closed, intracellular Mg2+ is low which will 
increase the expression levels of PRL2 (1) and concomitantly its binding to the CBS2 domain of CNNM (2). This 
will result in an increase of intracellular Mg2+ (3). Increased intracellular Mg2+ may increase ARL15 expression 
and/or activity (4), which will facilitate the glycosylation process of CNNM from endoplasmic reticulum (ER) to 
Golgi (5) to cell membrane (6). Increased intracellular ARL15 may act as negative feedback that decreases PRL2 
expression, leading to less binding between CNNM and PRL2 (7), and a subsequent decrease in intracellular 
Mg2+ levels by Mg2+ extrusion via a yet unidentified transporter (8). ARL15, ADP ribosylation factor like GTPase 
15; TRPM6/7, Transient receptor potential cation channel subfamily M member 6/7; CNNM, Cyclin M. PRL2, 
phosphatase of the regenerating liver 2.
Reduced Mg2+ levels stimulated mTORC2 activity, a downstream target of AMPK, which 
in turn was responsible for increasing PRL2 protein levels, without affecting mRNA status 
[136]. Inhibiting mTORC1 had no effect on the Mg2+-dependent increase in PRL2 protein 
expression, while combined mTORC2 and mTORC1 inhibition decreased the expression 
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of PRL2 [136]. Given that ARL15 overexpression affected CNNM-mediated Mg2+ uptake 
and ATP production, the expression of ARL15 may indirectly regulate cellular metabolism.
Together, our study established ARL15 as a novel negative regulator of Mg2+ homeo-
stasis by modulating the N-glycosylation of CNNMs. 
Scientific impact and future perspectives
In Chapter 2, we found that DAPA treatment activates compensatory changes in the PT 
in diabetic mice by upregulating the expression of NaPi-2a and NHE3. This compensatory 
effect in the PT may lead to an imbalance in renal Na+ handling in type 2 diabetes patients 
who suffer from hypertension. Future studies could focus on isolating and investigating 
urinary exosomes from type 2 diabetes patients to study the effect of SGLT2 inhibitors on 
BP by analyzing the expression of distal nephron Na+ transporters such as NKCC2, NCC, 
and ENaC (α, β, γ). Then, the upregulated Na+ transporter can be blocked by its inhibitor 
to improve BP control in type 2 diabetes patients.
In Chapter 3, we developed a Ca2+-binding peptide with potential properties for fur-
ther testing in kidney stone mouse model. A first study was started to induce kidney 
stone formation in C57BL/6J mice by administrating 1% (v/v) EG in their drinking water 
combined with a high or normal Ca2+ diet. While kidney stones were not observed in 
these mice, Chapter 3 provided a solid theoretical basis and methodology reference on 
the knowledge related to kidney stone formation and the development of a novel treat-
ment to prevent kidney stone disease.
In Chapter 4, we identified the novel Mg2+-related ARL15 gene and tested its function 
by the characterization of heterozygous knockout mice. Arl15+/- mice displayed a normal 
phenotype, and showed no alterations in serum Mg2+ concentrations and 24 hours urinary 
Mg2+ excretion. In addition, the mRNA expression level of renal Mg2+-, metabolism-, and 
membrane trafficking-related genes was not changed. These results suggest that ARL15 
may not be involved in the regulation of renal electrolyte transport in the kidney. Future 
studies can focus on generating Arl15 kidney-specific knockout mice and challenge these 
mice with Mg2+-deficient diets to further reveal the function of ARL15 in the kidney.
In Chapter 5, we revealed the importance of ARL15 in maintaining Mg2+ homeostasis 
by interacting with CNNMs at their carboxy-terminal conserved CBS domains. ARL15 was 
shown to regulate complex N-glycosylation of CNNMs. Knockdown of ARL15 resulted in 
a significant increase of 25Mg2+ uptake and ATP production in multiple kidney cancer cell 
lines. Our work provided new insights on how the interaction between ARL15 and CNNMs 
regulates N-glycosylation, Mg2+ transport, and ATP production. Future studies should reveal 
the interconnection between these processes, and demonstrate whether the ARL15-CNNM 
complex may provide new paths towards treating Mg2+-related diseases.
In conclusion, elucidating the mechanisms involved in the maintenance of Na+, Ca2+ 
and Mg2+ homeostasis in both health and disease improves our understanding of their 
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Sodium (Na+), magnesium (Mg2+) and calcium (Ca2+) homeostasis is critical for a variety 
of physiological processes in the human body. The kidney plays a crucial role in the 
regulation of this electrolyte balance. The concentration of serum Na+, Mg2+, and 
Ca2+ is determined by the kidneys through the reabsorption of these electrolytes by 
transporters, ion channels and sensors in the proximal tubule (PT), thick ascending limb 
of loop of Henle (TAL), distal convoluted tubule (DCT) and connecting duct (CD) of the 
kidney. A disturbed electrolyte balance is associated with a variety of diseases such as 
hypertension, diabetes, renal carcinoma, and kidney stones. The aim of this thesis was I) 
to investigate the expression of Na+ transporters in the kidney upon inhibiting the Na+-
glucose transporter 2 (SGLT2) in the PT; II) to identify Ca2+-binding peptides to reduce the 
urinary Ca2+ concentration and potentially prevent kidney stone formation; III) to study 
the novel urinary Mg2+-related gene ARL15 (ADP ribosylation factor like GTPase 15) in the 
kidney; and IV) to investigate how ARL15 regulates Mg2+ transport by interacting with the 
cyclin and CBS domain divalent metal cation transport mediators (CNNMs) in the kidney. 
Potential compensatory mechanisms of Na+ transporters upon inhibition 
of SGLT2 in the proximal tubule
SGLT2 inhibitors have progressively attracted attention due to their function in increasing 
glucose excretion, ameliorating glycemic control and alleviating blood pressure. The 
latter is possibly due to the fact that SGLT2 inhibitors lead to natriuresis. However, the 
molecular mechanism is still unknown. In Chapter 2, diabetic mice were administrated 
with the SGLT2 inhibitor dapagliflozin (DAPA) and the expression of renal Na+ transporters/
ion channels was studied. The diabetic mice exhibited increased blood glucose levels 
upon 18-day DAPA treatment, and mRNA levels of sodium-hydrogen antiporter 3 (Nhe3), 
and sodium-phosphate cotransporter (Napi-2a), were upregulated in kidneys of DAPA-
treated mice. However, changes in expression of distal Na+ transporters such as sodium-
potassium-chloride cotransporter (NKCC2) and sodium-chloride cotransporter (NCC) in 
the TAL and DCT, respectively, were not detected. The results of this study proved that 
DAPA treatment results in compensatory changes in the PT of the kidney in diabetic mice.
Development of Ca2+-binding peptides to prevent kidney stone formation 
in Henle’s loop 
Kidney stone disease (nephrolithiasis) is becoming a major medical concern in the 
world. Although medical therapies have largely improved nephrolithiasis treatment, the 
recurrence rate is still very high. Therefore, an improved and effective remedy to avoid 
kidney stone recurrence is needed. In Chapter 3, several Ca2+-binding peptides were 
developed, based on the established Ca2+-binding EF-hand domain. The Ca2+-binding 




dose-dependent response to CaCl
2
 concentrations in the millimolar range for peptide 
4 (Ac-DKNGDGYIDAAE-NH
3
). This peptide did not result in cellular toxicity and exhibited 
minimal cellular uptake by proximal tubular human kidney 2 (HK-2) cells. A Ca2+-binding 
affinity in the high millimolar range (2-10 mM) could allow for Ca2+-binding in the pro-
urine without affecting serum Ca2+ levels (1-2 mM). Future studies need to further 
optimize the Ca2+-binding kinetics of the identified peptide. In order to investigate the 
biological function of this peptide in healthy mice and in a mouse model with kidney 
stones, C57BL/6J mice were administrated with 1% (v/v) ethylene glycol (EG) via drinking 
water and subsequently treated with either a normal Ca2+ diet (0.92% (w/w)) or a high Ca2+ 
diet (2% (w/w)) for 28 days. Yet, Ca2+ crystal deposition in the kidney was not detected 
in any of the conditions. Chapter 3 demonstrated that Ca2+-binding peptides can be 
used to bind Ca2+ in the physiologically relevant range. Optimized Ca2+-binding peptides 
should be investigated in other mice models than C57BL/6J which better reflect kidney 
stone disease.
Fine tuning Mg2+ reabsorption in the distal convoluted tubule
Previous genome wide association studies (GWAS) identified the ARL15 locus to be 
associated with urinary Mg2+ excretion in 9.099 individuals in seven European cohorts. 
ARL15 is localized in the TAL and DCT of the kidney where it could be involved in renal Mg2+ 
reabsorption through regulating the channel activity of the Mg2+ channel TRPM6. In order 
to further understand the function of ARL15, we characterized ARL15 and investigated 
its role in the kidney by using Arl15 heterozygous (Arl15+/−) mice in Chapter 4. Results 
demonstrated that ARL15 belongs to the small GTPase superfamily and it is predicted to 
bind Mg2+. The tissue expression pattern of Arl15 showed that it is ubiquitously expressed 
and predominantly found in lung, inguinal fat, epididymal fat, spleen, testes and kidney. 
Homozygous Arl15 knockout mice died after birth. By challenging Arl15+/− mice with a 
high fat diet, we did not detect significant differences in the serum Mg2+ concentration 
and 24-hrs urinary Mg2+ excretion between Arl15+/+ and Arl15+/− mice. In addition, there 
were significant changes detected in the mRNA expression levels of Mg2+-related genes, 
metabolism-related genes, and membrane trafficking-related genes in the kidneys of 
either Arl15+/+ or Arl15+/− mice on the high fat or low fat diets. In summary, our results 
suggest that Arl15+/− mice have a normal phenotype, and exhibit no changes in renal Mg2+ 
handling.
ARL15 as a new binding partner of CNNM
By proximity-dependent biotin identification (BioID) and co-immunoprecipitation, we 
demonstrated that ARL15 binds to proteins of the CNNM family. Interestingly, CNNMs 
have been reported to regulate Mg2+ transport at the basolateral membrane of the 
DCT. Subsequently, we investigated how ARl15 regulates CNNM activity in Chapter 5. 
Immunostaining indicated that CNNM2 and ARL15 co-localize along the basolateral 
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membrane of the DCT of mouse kidney. Co-immunoprecipitation demonstrated that 
ARL15 predominantly binds to the CBS2 domain of CNNMs. Our BioID results indicated 
that ARL15 is involved in N-linked glycosylation. Transient overexpression of ARL15 in 
human embryonic kidney 293 (HEK293) cells resulted in an increased N-glycosylation of 
CNNM3 proteins. The functional consequences of ARL15-dependent glycosylation were 
examined by 25Mg2+ uptake experiments. We showed a significant decrease of 25Mg2+ 
uptake upon overexpression of ARL15 and a significant increase of 25Mg2+ uptake upon 
knockdown of ARL15 in multiple kidney cancer cell lines. Moreover, knockdown of ARL15 
in renal cell carcinomas resulted in disturbed glycosylation of CNNM3. Altogether, our 
results established ARL15 as novel regulator of Mg2+ transport in the DCT. 
This thesis provided new insights regarding compensatory mechanisms of Na+ trans-
porters in the PT upon inhibiting SGLT2, made the first step towards testing a novel 
approach in the treatment and prevention of kidney stones, and further revealed a novel 
regulatory mechanism of Mg2+ transport within the DCT. Together, this will help to under-





De natrium- (Na+), magnesium- (Mg2+), en calcium (Ca2+) -balans is cruciaal voor vele 
fysiologische processen in het menselijk lichaam. De hoeveelheid Na+, Mg2+, en Ca2+ in 
het bloed wordt deels bepaald door de nieren. Heropname van deze mineralen vindt 
plaats in verschillende delen van de nier, waaronder de proximale tubulus, het dikke 
opstijgende been van de lis van Henle, het distaal convoluut en de verbindingsbuis. Een 
verstoorde mineraalbalans is geassocieerd met onder meer hoge bloeddruk, diabetes, 
nierkanker en nierstenen. Het doel van dit proefschrift was om: I) te onderzoeken wat het 
effect is van remming van de Na+-glucose transporter 2 (SGLT2) op de aanwezigheid van 
eiwitten betrokken bij de Na+ heropname in de nier; II) Ca2+-bindende eiwitfragmenten 
te ontwikkelen die zeer specifiek de Ca2+ concentratie in de urine kunnen verlagen om 
niersteenvorming te voorkomen; III) het nieuwe Mg2+-gerelateerde gen ARL15 (ADP 
ribosylation factor like GTPase 15) in de nier te bestuderen; en IV) te achterhalen hoe 
ARL15 de Mg2+ heropname in de nier reguleert door middel van de interactie met cyclin 
en CBS domein divalent metal cation transport mediators (CNNMs).
Compensatoire mechanismen van Na+ heropname door remming van 
SGLT2 in de proximale tubulus
De afgelopen decennia is er meer aandacht gekomen voor SGLT2 remmers door hun 
rol in het verbeteren van de bloedsuikerspiegel en het verlagen van de bloeddruk. 
SGLT2 remmers verlagen de bloeddruk door een verhoogde uitscheiding van Na+ in 
de urine, ook wel natriurese genoemd. In hoofdstuk 2 kregen muizen met diabetes 
de SGLT2 remmer dapagliflozin (DAPA) toegediend en werd de aanwezigheid van 
genen en eiwitten relevant voor Na+ heropname in de nier bestudeerd. De muizen met 
diabetes vertoonden een verhoogde glucosewaarde in het bloed die sterk verlaagd was 
na een 18-daagse behandeling met DAPA. Om de effecten van SGLT2 remmers op Na+ 
heropname in de nier te bestuderen, zijn de eiwitten die Na+ opnemen in de verschillende 
delen van de nier in kaart gebracht. De aanwezigheid van de genen natrium-waterstof 
uitwisselaar 3 (Nhe3) en natrium-fosfaat cotransporter (Napi-2a) in de proximale tubulus 
was verhoogd in DAPA-behandelde muizen. Er werden geen verschillen waargenomen 
in de aanwezigheid van de genen Nkcc2 en Ncc (belangrijk voor het transport van Na+ in 
de lis van Henle en het distaal convoluut) tussen DAPA-behandelde en onbehandelde 
muizen met diabetes. De resultaten van deze studie bewijzen dat DAPA-behandeling 
zorgt voor verhoging van compensatoire eiwitten die betrokken zijn bij Na+ heropname 




Ontwikkeling van Ca2+-bindende peptiden om niersteenformatie te 
voorkomen in de lis van Henle
Nierstenen (nefrolithiase) zijn een wereldwijd toenemend medisch probleem. Patienten 
die nierstenen hebben gehad, hebben een grote kans op terugkeer ondanks de 
verbeterde behandeling. Een effectievere methode om nierstenen te voorkomen is 
dan ook noodzakelijk. In hoofdstuk 3 zijn Ca2+-bindende eiwitfragmenten ontwikkeld. 
Hiervoor is gebruikt gemaakt van de structuur van een natuurlijk Ca2+-bindend eiwit, 
het zogenaamde EF-hand domein. De binding van Ca2+ aan deze eiwitfragmenten is 
onderzocht door gebruik te maken van circulair dichroïsme spectroscopie. Deze metingen 
lieten een dosisafhankelijk effect zien van de calciumconcentratie op eiwitfragment 
4 (Ac-DKNGDGYIDAAE-NH
3
). Daarnaast werd aangetoond dat dit eiwitfragment niet 
resulteerde in cellulaire toxiciteit, en het vertoonde slechts minimale cellulaire opname 
in proximale tubulus humane nier 2 (HK-2) cellen. Ca2+-binding aan dit eiwitfragment bij 
concentraties in de hoge millimolaire eenheid (2-10 mM) zou Ca2+ weg kunnen vangen in de 
voorurine zonder de Ca2+ waarde in het bloed te beïnvloeden (1-2 mM). Verder onderzoek 
is nodig om de binding van Ca2+ aan het beoogde eiwitfragment te optimaliseren. 
Om de biologische rol van dit eiwitfragment te onderzoeken, zijn diermodellen met 
nierstenen nodig. Hiertoe werden muizen behandeld met 1% (v/v) ethyleenglycol (EG) 
in het drinkwater en eveneens een Ca2+-rijk dieet gevoerd gedurende 28 dagen. Echter, 
kristalafzetting in de nier werd niet waargenomen. Concluderend, hoofdstuk 3 laat zien 
dat Ca2+-bindende eiwitfragmenten gebruikt kunnen worden om Ca2+ te binden binnen 
fysiologische concentraties. Geoptimaliseerde Ca2+-bindende eiwitfragmenten dienen 
getest te worden in alternatieve muismodellen waarin nierstenen beter vormen dan in 
de hier gepresenteerde studie.
Het nauwkeurig instellen van de Mg2+ heropname in het distaal convoluut
Eerdere genoom-brede associatiestudies (GWAS) hebben een associatie geïdentificeerd 
tussen ARL15 en de urinaire Mg2+ uitscheiding in zeven Europese cohorten van totaal 
9.099 individuen. ARL15 is aanwezig in de lis van Henle en het distaal convoluut van de 
nier, waar het mogelijkerwijs betrokken is bij de heropname van Mg2+. ARL15 behoort 
tot de superfamilie kleine GTPases en bindt mogelijk Mg2+. Om de functie van ARL15 
in de nier beter te begrijpen werden in hoofdstuk 4 muizen gebruikt die over een 
heterozygote uitschakeling van het Arl15 gen beschikken (Arl15+/-). Muizen zonder het 
Arl15 gen sterven na geboorte. Arl15 wordt aangemaakt in meerdere weefsels, en met 
name in de longen, buikvet, milt, testis en nieren. Arl15+/- muizen die blootgesteld werden 
aan een vetrijk dieet vertoonden geen significante veranderingen in de hoeveelheid 
Mg2+ in het bloedplasma of in de uitscheiding van Mg2+ in de urine gedurende 24-uur, 
ten opzichte van gezonde muizen. Daarnaast werden er geen significante verschillen 
waargenomen in aanwezigheid van genen betrokken bij de Mg2+-balans, bij metabolisme 
of bij membraantransport tussen de nieren van Arl15+/- en gezonde muizen op een 
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vetrijk of vetarm dieet. Samenvattend, onze resultaten tonen aan dat Arl15+/- muizen 
beschikken over vergelijkbare erfelijke eigenschappen als gezonde muizen, en dat zij 
geen abnormaliteiten vertonen wat betreft de Mg2+ heropname in de nier.
ARL15 als nieuwe interactiepartner van CNNM
Door gebruik te maken van biochemische bindingstudies, waaronder de zogeheten 
(nabijheid-afhankelijke) biotine identificatie (BioID) en co-immunoprecipitatie, hebben 
wij aan kunnen tonen dat ARL15 aan eiwitten uit de CNNM-familie bindt. CNNMs 
staan erom bekend het Mg2+ transport te regelen aan het basolaterale membraan van 
niercellen. In hoofdstuk 5 is onderzocht hoe ARL15 de activiteit van deze CNNM eiwitten 
reguleert. Met behulp van immunohistochemische kleuringen van nieren van de muis 
werd aangetoond dat CNNM2 en ARL15 samen aanwezig zijn in distaal convoluutcellen. 
Uit co-immunoprecipitatie experimenten bleek dat ARL15 voornamelijk bindt met het 
CBS2 domein van CNNM. Onze BioID resultaten suggereren dat ARL15 betrokken is bij 
N-gebonden glycosylering. Een verhoogde aanwezigheid van ARL15 resulteerde in 
een verhoogde glycosylering van CNNM3 eiwitten in humane embryonale niercellen 
(HEK293). De functionele consequenties van ARL15-afhankelijke glycosylering werden 
onderzocht middels experimenten met een stabiel 25Mg isotoop. Er was een significante 
vermindering van Mg2+ opname bij verhoogde aanwezigheid van ARL15 in meerdere 
nierkankercellijnen, en een hogere Mg2+ opname wanneer ARL15 was uitgeschakeld. 
Bovendien was er een verstoorde glycosylering van CNNM3 bij uitschakeling van 
ARL15. Tezamen suggereren onze resultaten dat ARL15 het Mg2+ transport in het distaal 
convoluut reguleert door de activiteit van CNNM eiwitten te bepalen.
Concluderend hebben de studies beschreven in dit proefschrift geleid tot nieuwe 
inzichten in de mechanismen achter Na+ heropname in de proximale tubulus bij het 
gebruik van SGLT2 remmers. Daarnaast is een eerste stap gezet in het opzetten van een 
vernieuwende benadering voor de preventie van nierstenen. Tot slot is er een nieuw reg-




















Adipor1 Adiponectin receptor 1
Adipor2 Adiponectin receptor 2
Adrb3 Beta-3 adrenergic receptor
Afr1 ADP ribosylation factor 1
Afr6 ADP ribosylation factor 6
ADP Adenosine diphosphate
AMP Adenosine monophosphate
ANOVA Analysis of variance
AQP1 Aquaporin-1
AQP2 Aquaporin-2
ARL15 ADP ribosylation factor-like GTPase 15
Arfgef-1 ADP ribosylation factor guanine nucleotide exchange factor 1
Arfgef-2 ADP ribosylation factor guanine nucleotide exchange factor 2
ATP Adenosine triphosphate
Atp1a1 ATPase sodium potassium transporting subunit alpha 1






BioGRID Biological general repository for interaction datasets
BP Blood pressure
BSA Bovine serum albumin
C
CA  Carbonic anhydrase
CANA  Canagliflozin
Ca2+  Calcium
cAMP Cyclic adenosine monophosphate






CD Circular dichroism (Chapter 3)
cDNA Complementary DNA
Cl- Chloride
CNBH Cyclic nucleotide binding homology
CNNM1 Cyclin and CBS domain divalent metal cation transport mediator 1
CNNM2 Cyclin and CBS domain divalent metal cation transport mediator 2
CNNM3 Cyclin and CBS domain divalent metal cation transport mediator 3
CNNM4 Cyclin and CBS domain divalent metal cation transport mediator 4
CNT Connecting tubule
CRISPR Clustered regularly interspaced short palindromic repeat
Cldn16 Claudin16
Cldn19 Claudin19
COM Calcium oxalate monohydrate
Cpt1 Carnitine palmitoyltransferase 1
Cpt Carnitine palmitoyltransferase 2
C-terminal carboxyl terminal
D
D  Aspartic acid 
DAPA Dapagliflozin
DARS Decoys as a reference state
DCT Distal convoluted tubule
DMEM Dulbecco’s modified eagle’s medium




Dol-P-Man Dolichol phosphate mannose
DTT Dithiothreitol
DUF21 Domain of unknown function-21
E
E  Glutamic acid
EDTA Ethylene diamine tetra acetic acid
EGF Epidermal growth factor
GFP  Green fluorescent protein
EGTA Ethylene glycol tetra acetic acid
EG   Ethylene glycol
Ele Electrostatic energy of the representative complex





EmPAI Exponentially modified protein abundance index
ENaCα Epithelial sodium channel α
ENaCβ Epithelial sodium channel β
ENaCγ Epithelial sodium channel γ




FACS Fluorescence activated cell sorting
Fabp1 Fatty acid-binding protein 1
FDA Food and drug administration
FITC Fluorescein isothiocyanate
FLS   Fatty liver shionogi
FXYD2  FXYD domain containing ion transport regulator 2
G
G  Glucose (Chapter 1)
G Glycine (Chapter 3)




GFR Gomerular filtration rate
GAPDH Glyceraldehyde 3 phosphate dehydrogenase
GLUT1 Glucose transporter 1




GWAS Genome wide association studies
H



















HSH Hypomagnesemia with secondary hypocalcemia








KEGG Kyoto encyclopedia of genes and genomes
KDa Kilo Dalton
KK/Ay   Diabetic KK and lethal yellow
L
L  Leucine
ICP-MS Inductively coupled plasma mass spectrometry
LD Light-dark
LF      Low fat diet










NBC  Sodium bicarbonate cotransporter
NC Normal calcium diet
NADPH Nicotinamide adenine dinucleotide phosphate
NCC Sodium chloride cotransporter




NHE3 Sodium hydrogen exchanger 3
NKCC1 Sodium potassium chloride cotransporter 1
NKCC2 Sodium potassium chloride cotransporter 2
NaPi-2a    Sodium phosphate cotransporter
O
OLETF Otsuka long-evans tokushima fatty





PCR Polymerase chain reaction
P
i 
          Inorganic phosphate
Pepck Phosphoenolpyruvate carboxy kinase
PT Proximal tubule
PVALB    Parvalbumin
PEPCK      Phospho-enolpyruvate carboxykinase
Plin1       Perilipin 1
PNGase F N-glycosidse F
PMCA Plasma membrane calcium-ATPase
PNGase F Peptide N-glycosidase F
PTP       Protein tyrosine phosphatases
PRL1       Phosphate of the regenerating liver1
PRL2       Phosphate of the regenerating liver2
R
R  Arginine
RAAS      Renin-angiotensin-aldosterone system
Repr Representative chosen
ReprE Total interaction energy of the chosen representative
RMSD Root-mean-square deviation
RNA Ribonucleic acid
ROS Reactive oxygen species
RPN1 Dolichyl-diphospho-oligosaccharide
RT Reverse transcriptase





SBP Systolic blood pressure
SD Sprague dawley
SEM Standard error of the mean
SGLT1 Sodium glucose cotransporter 1
SGLT2 Sodium glucose cotransporter 2
sgRNA Single guide RNA
Scnn1a  Sodium channel epithelial 1 subunit alpha
Scnn1b  Sodium channel epithelial 1 subunit beta
Scnn1g  Sodium channel epithelial 1 subunit gamma
Slc2a2  Solute carrier family 2 member 2
Slc5a1  Solute carrier family 5 member 1
Slc5a2 Solute carrier family 5 member 2
Slc12a1  Solute carrier family 12 member 1 
Slc12a3 Solute carrier family 12 member 3
Slc18a1  Solute carrier family 8 member 1
Slc26a6 Solute carrier family 26 member 6
Slc34a1  Solute carrier family 34 member 1
Slc41a1 Solute carrier family 41 member 1
Slc41a3 Solute carrier family 41 member 3
STT3A STT3 oligosaccharyltransferase complex catalytic subunits A
STT3B STT3 oligosaccharyltransferase complex catalytic subunits B
STZ     Streptozotocin
T
TCL Total cell lysis
T1DM       Type 1 diabetes mellitus
T2DM       Type 2 diabetes mellitus
TAL Thick ascending limb of Henle’s loop
TOFO  Tofogliflozin
TRPM6  Transient receptor potential cation channel subfamily M member 6
TRPM7  Transient receptor potential cation channel subfamily M member 7
TRPV5  Transient receptor potential cation channel subfamily V member 5
U







WK  Wistar kyoto
WT Wildtype




ZDF  Zucker diabetic fatty
Zn2+ Zinc
Protein and gene names used within this thesis are abbreviated and formatted 
according to the guidelines depicted in the genetic nomenclature guide published by 
Trends in Genetics. An example is depicted below in Table 1, i.e. the gene ARL15 with its 
corresponding protein ADP ribosylation factor-like GTPase 15 (ARL15) as example.
Table 1: Gene and protein abbreviations & nomenclature
Species Gene Protein
Human (Homo sapiens)1 ARL15 ARL15
Mouse (Mus musculus)2 Arl15 ARL15
Zebrafish (Danio rero)3 arl15 ARL15
1. McAlpine P: Genetic nomenclature guide. Human. Trends Genet. 39–42, 1995
2. Davisson MT: Genetic nomenclature guide. Mouse. Trends Genet. 35–38, 1995
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Chao Ma was born in Jilin, China, on the 17th of 
October 1988. After graduating from high school, he 
obtained his bachelor with a major in Resource and 
Environmental Sciences at Jilin Agriculture University in 
Jilin, China. In 2012, he decided to pursue his interest in 
life science and joined Professor Shuping Zhang’s lab at 
Tsinghua University in Beijing, China. During his master 
study, he focused on examining the tissue distribution 
of Renalase in ApoE-/- mice fed a high-fat diet and the 
effect of valsartan on the expression of Renalase. He 
found that Renalase is a potential-related gene of lipid 
metabolism and atherosclerosis, and it may be the possible molecular target of valsartan 
to help stabilize atherosclerotic plaque. His master research consisted of studying the 
function of a novel Mitochondria-localized Glutamine Acid Rich Protein (MGARP) in the 
development of the retina, with emphasis on photoreceptor cells, by using in utero 
electroporation in Mgapr-/- embryonic mice. In 2016, Chao joined the department of 
Physiology at the Radboud university medical center (Radboudumc) as a PhD candidate. 
Under the supervision of Prof. dr. Joost Hoenderop, Dr. Jeroen de Baaij and Dr. Jenny 
van der Wijst, his research focused on investigating the effect of dapagliflozin treatment 
on the expression of renal sodium transporters/channels on high-fat diet diabetic mice. 
This part of work provides insights on the treatment of both hypertension and diabetes 
in Type 2 diabetes patients. In another study, he developed several small peptides with 
optimized Ca2+-binding affinity to act as Ca2+ buffers in Henle’s loop, without affecting 
serum Ca2+ levels. This may provide the first evidence for an effective approach to further 
study treatment and prevention of kidney stones. His PhD research work also consists 
of studying the functional implication of ARL15 for CNNMs-mediated Mg2+ transport. 
Chao presented his work by oral and poster presentations at scientific conferences. In 
2019, he received the travel grant to visit the American Society of Nephrology meeting 
in Washington, D.C., USA. Additionally, Chao successfully completed the PhD training 
program of the RIMLS graduate school and supervised four master students and five 






The data generated during my PhD project at the Radboudumc were documented 
according to the Findable, Accessible, Interoperable and Reusable (FAIR) guiding 
principles.1 All the primary and processed data obtained during my PhD work are 
stored on the local digital servers which belong to the department of Physiology and 
Radboudumc. In addition, all data were accessible on Labguru, an electronic lab book, 
which is managed and supported by the Information and Communication Technology 
(ICT) unit of Radboudumc and daily backed-up on local Radboudumc servers. The animal 
studies described in Chapter 2, Chapters 3 and 4 were approved by the University of 
Ulster Animal Ethics Review Committee, the Animal Ethics Board and the Central Animal 
Laboratory of the Radboudumc and the MRC Harwell Institute Ethical Review Committee 
and the MRC Harwell Animal Welfare, all in agreement with the Experiments on Animals 
Act (Wet op de dierproeven, Wod). To make sure the data is accessible to the associated 
staff, all data (including raw data, descriptive files, figures, and file names) is stored and 
archived in accordance with the protocols of the department of Physiology.
1.  Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data 
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people who helped me along the way. In this chapter, I would therefore like to express my 
gratitude to my supervisors, colleagues, collaborators, friends, and family who motivated, 
helped, and supported me and thus, in their own way, contributed to this thesis.
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touched that you even helped me to find my mistakes in my references, there are around 
500 references in total in my thesis. Thanks for the ideas and inputs you provided to my PhD 
study, and your strong leadership in the work, and your advice to my life. I am very happy to 
work and talk with you both at work and after work. I never have the feeling that you are my 
professor or boss, however, I always regard you as a very good friend who always support 
me, cheer up me, and steer me to the correct direction both scientifically and personally. 
Therefore, I am not surprised that you won the University Teaching Prize, and you also made 
a great contribution to the physiology study and published a lot of great papers in top 
journals. You are a perfect example of showing that you can be excellent in everything you 
put effort into. Jeroen, it’s really nice that I start to work together with you in my second 
year. You are such an amazing and smart guy with unbelievable leadership. Communicating 
with you is such a cozy thing that I enjoyed a lot. Thank you for guiding me for the ARL15 and 
CNNM study. We finally made it into a story. You give me so many good ideas and inspired 
me so much. I still remember in the CNNM meeting, when I was giving a presentation, you 
and Joost gave me so many eye contacts and inspired me a lot. I have the feeling that you 
and Joost are even more nervous than me. At that point, I feel so happy and lucky to have 
two supervisors like you two people. I do enjoy the nice talks with you at the lunch time, 
work discussion, drinking beers in Nijmegen, having Chinese food, and we had very a nice 
time in Washington D.C in the ASN meeting. Jenny, you started to supervise me in my third 
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year, you are so nice, patience, and sweet. You are always there to help us and listen to us. 
I do enjoy the nice talks with you in the coffee break time, lunch time, experiments time, 
work discussion, and the amazing dinner at your home. You also give me a lot of good ideas 
on my projects. Now, I also learned a lot of chemistry knowledge through our kidney stone 
project. We met almost weekly in the last few months to talk about my thesis. Thank you so 
much for helping me to correct the structure of the thesis, mistakes, and providing great 
ideas on how to make the figures better. Now, I am much more confident in writing than 
before. René, thank you for your great vision, leadership, and your extraordinary ability to 
our RIMLS institute and our department. We appreciate the efforts taken by you. We love 
our human oriented institute and department so much. Especially as foreigners, I never feel 
lonely. I really enjoy the talks with you in the work meetings and the dinner in the ASN 
meeting. 
Dr. Jo Zhou, thank you for mentoring me for four years. In these four years, you gave 
me a lot of useful suggestions and advices to help me to master my PhD work and my 
future career choice. I do enjoy the nice talks with you. Thank you very much. 
The collaborations with other research groups have been of great benefit for my work 
in my PhD study. I am grateful to all of the people who were directly or indirectly involved 
in and contributed to my projects. Prof. Dr. Michel Tremblay, thank you for your inputs, 
ideas, and scientific discussions on the ARL15 and CNNM project! It has been wonderful to 
work together with your team. Your enthusiasm in science inspired me a lot. Also Eugene, 
it’s really nice to collaborate with you for our ARL15 and CNNM story. You are a hard worker 
and an extremely motivated guy. We finally made our ARL15 and CNNM project into a very 
nice story and good luck with your PhD in Montreal. Serge, you made a  lot of unbeliev-
able contributions to CNNM and PRL study, I am really happy to see that you addressed 
a detailed mechanism study of ATP, PRL, and AMPK/mTORC2 pathway at various levels, 
which will definitely boost the study of magnesium, PRL, and CNNM. I am looking forward 
to seeing more and more papers from you. Dr. Alfonso Martínez de la Cruz, thanks for all 
of the works you did for the structure biology part of the ARL15 and CNNM paper. I do enjoy 
the nice scientific discussion, nice talks with you in our zoom meeting and CNNM meeting. 
Structure biologists are our best friends, your knowledge and findings on the structure 
of CNNM, ARL15, and PRL will always be highly appreciated. Dr. Roger Cox and Dr. Ying 
Bai, thanks for providing us with Arl15+/- mice samples, these samples boost our study and 
navigated us to the correct direction. We will definitely combine all of our data and make it 
into a nice story. Prof. Dr. Roland Brock and Sander Van Asbeck, thanks for your technical 
supports and suggestions for my kidney stone project. 
Luke, it’s really nice to meet you in the Netherlands. In the past few years, we went to 
so many places and had so many nice memories. The nice beer, food, and traveling in 
Rotterdam, Arnhem, Haarlem, Nijmegen, and Doetinchem. In my first year, you helped 
me so much in my SGLT2 project, helping me to involve in European lifestyle, and my 




of course now my paranimf, and we still keep in touch although you left our department. 
Thanks for your support in these years, especially your help in polishing my cover letter 
and CV for my postdoc position. Thank you for your nice present which will definitely 
help me to know more about Los Angeles very fast. By the way, I still remember our plan 
to travel in the USA and to go to visit Marco in Mexico next year, hope to see you soon. I 
wish you all the best for your life in the Netherlands with Emma. And I am sure that we 
will keep in touch and keep seeing each other. Mi amigos, Paco, Juan, Sara, Maria, you 
guys have very strong postdoc power. Paco, you are a very funny guy, I still remember we 
can’t understand each other’s English in the beginning, and we always need Eric V or 
Caro to be our translator, but this did not affect our friendship. I do enjoy the nice time 
with you playing football, funny talks, watching the World cup, yearly beer night, and 
your supports in my PhD study. I am very happy that you are enjoying your nice life with 
your wife and your son Daan A. But, by the way, it seems that we still can’t understand 
each other’s English, even until now. Juan, I always have the feeling that you are on your 
way to travelling or on your way back from travelling. We had a nice time in the Düssel-
dorf Christmas market and enjoyed the nice beer and wine, Germany Schweinhaxen, and 
Japanese noodles in Düsseldorf. You are my true friend, and of course now my paranimf. 
I do enjoy the nice talks with you at dinner time after work, and thanks for your traveling 
suggestions on my tour around Europe. We should always keep in touch, and I am sure I 
will meet you again in California and China. I hope you will enjoy your life in either Europe 
or Argentina in the future. Sara, I do enjoy the nice talks with you at lunch time, drinking 
beers at Olivier in Utrecht with the gang and your boyfriend. You are a very outgoing lady 
who can always cheer people up. I always have the feeling that you can always give me a 
lot of useful suggestions and helps whenever I need help. Thanks for your useful and 
good suggestions for my postdoc searching. I am quite happy that you are enjoying a 
nice time in Switzerland. Like you said science is small, I am sure we will meet each other 
one day. Maria, my neighbor in my last few months in our department. We also had a lot 
of nice talks at lunch time. Thank you for your supports and kind suggestions for my PhD 
work and postdoc searching. I wish you all the best for the future; you’ve been and always 
will be a great friend to me. Sami and Eric V, the Cilia Team. Sami, we had so many talks 
outside and inside the lab, you are a very good company after work in the lab. Both of us 
are foreigners in the lab, so we always support each other and help each other. I do enjoy 
the travelling with you, playing football with you. Thanks for the nice suggestions you 
gave me in the Netherlands. In my last few days in the Netherlands, we met in Maastricht 
and made a lot of nice pictures, all of these are very nice memories of my life. I am very 
happy with you on your success in your postdoc career by winning many grants and pub-
lishing many papers. In the second year of my PhD, we made the plan to travel to Paris, 
but later, we didn’t manage to do it. In two months, you will come to the USA; we should 
travel in the USA as we planned in Amsterdam. I hope all is going well for you, and we can 
always have a chat whenever we want to talk to each other. Eric V, my dear friend, we had 
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a lot of nice memories together. Talking together during coffee breaks, drinking beers at 
Olivier in Utrecht, Arnhem, and my place, attending your marriage party and gender 
reveal party, and the yearly drink in Arnhem. We also had a very nice time in Washington 
in the ASN meeting. Thank you for guiding me around Washington, and we made many 
nice pictures together. All of these consist of my good memories in the Netherlands. I am 
very happy that you are enjoying your new job, your life with Mirte and Lotte V. I wish 
you and your family all the best for the future and I am sure that we will keep in touch and 
keep seeing each other. You are always welcome wherever I am living. Hacene, it’s also 
very nice to meet you in the Netherlands. We both work in the metabolism team. It has 
been wonderful to work together with you during these past few years although we 
didn’t work together directly. You were a great company inside the lab after work and 
outside the lab on the weekends. We explored Nijmegen so much and made a lot of nice 
pictures. Thanks for your support in these years. I am very happy that you are enjoying 
your time with your family and your work in Algeria. You’ve been and always will be a 
great friend to me. I wish you all the best for your PhD and your future and I am always 
happy to hear from you and talk to you. Valentina, a hard worker, and extremely moti-
vated PhD. You were a great company in the lab in the evening and weekend. Although 
we haven’t worked directly together on a project, yet I cherish good memories with you 
such as the nice talks during the breaks, dinner time, drinking beers at Olivier in Utrecht, 
and Arnhem. I wish you all the best for your PhD and scientific career. Marco, My Spanish 
learning was initiated by you. I still remember the first word you taught me was Adios, mi 
amigo. Together with you, and Luke, we went to many bars and restaurants in Nijmegen. 
Hopefully, Luke and I can manage to go to visit you in Mexico. I wish you all the best for 
your work and life. Steef, we work in the same team, you are a very smart guy with critical 
thinking. I enjoyed the nice talks with you and thanks for your suggestions on my pro-
jects. It has been great to work together with you in the past few years. I had a great time 
sharing my data and having scientific discussions with you. Omar, you are the first people 
who went to pick me up in Nijmegen, and introduced the people in the lab to me. Your 
enthusiasm and sense of humor did motivate me a lot at the beginning of my PhD study. 
It has been nice to work together with you in the sodium team. Lisanne, you are a very 
warmhearted girl. I do enjoy the nice talks with you in the coffee breaks, and I hope that 
you can find a good job, and always be happy. Gijs, you are a very funny guy. I found that 
you always have a lot of topics to talk with different people. It was nice to work with you 
to learn more about CNNM protein, and we are making a lot of progress on it. Thank you 
for your immunocytochemistry results for our ARL15 and CNNM story, and also thanks for 
giving a lot of good suggestions on improving the manuscript. It was really a lot of fun to 
have the CNNM meeting with you, drink beers after the meeting, and the nice talks with 
the collaborators who are working very hard on elucidating the function of CNNM. 
Lynette, ARL15 is a great protein, I am very happy to work together with you to investi-




cussion with you. I am very looking forward to seeing your great story on ARL15 kid-
ney-specific knockout mice. Lotte, we may not have worked directly together on a 
project, yet we both study novel genes related to hypomagnesium. I am very looking 
forward to your pinkbar protein stories. I do like the nice talks with you on the weekend, 
coffee break time, lunch time, and the glow festival in Eindhoven. You still need to tell 
more about your stories and experience in China. With many colleagues, I have had the 
privilege to develop amazing friendships. Just like those people mentioned above, this is 
also true for Michael, Sjoerd, Mark, and Eric B. Together with you guys, Luke, Paco, and 
Eric V, we have the yearly beer drink event in Arnhem before Christmas, lots of nice talks, 
food & drinks together, we had a lot of fun times and I hope they continue! 
Femke, thank you so very much for helping me in the molecular works. I do enjoy our 
nice talks in the coffee break, sharing my data with you, the great inputs from you, and 
the nice scientific talks in the lab meeting. You’ve been and always will be a great friend 
to me. Caro, you also helped me a lot on animal studies and the staining. It has been 
great to work together with you and be your neighbors in my first two years. I do enjoy 
the nice talks with you at lunch time, coffee break times, and physiology events. You act 
like a running sun who always bright other people’s life. Irene, thank you for making 
our department so organized, and the items we ordered delivered in good condition. I 
also appreciate the greetings from you through Facebook at the beginning of this year. 
Rosanne, thanks for helping me to arrange everything at the beginning of my PhD work. 
You made my life much easier. Rachel, Véronique, Judith, and Janneke, thanks for 
arranging the meetings, events, and paperwork for our department. Your contributions 
are highly appreciated. Jojanneke, thanks for organizing the teaching, I feel very happy 
and honored to be involved in the teaching. Nicolai, I enjoy the nice talks with you in the 
meetings and thank you for your tips and suggestions on my career choice. 
Sidra, Milou, Shirin, and Sanedy, you guys are unbelievably good, smart, and hard-
working master students. I am so honored to supervise you. Thanks for the contributions 
you made to the ARL15 and CNNM story, and the kidney stone story. 
Furthermore, I would like to express my appreciation to all the rest who bring/brought 
our department to the ‘next level’, Andreas, Elja, Charlotte, Claudia, Mohammad, 
Daan, Ellen, Frans, Kim, Laura, Niky, Barnabas, Margo, Marjolein, Anique, Lara, 
Wouter , Peter, Selma, and Theun, and all the people from Integrative Physiology and 
anyone that I might have forgotten! 
Tommy, my language partner in Tsinghua University, you are the first foreigner I met 
in Beijing, and I always believed that I wouldn’t come to the Netherlands if I didn’t meet 
in China. Our friendship starts in China, and we had a lot of nice talks in Tsinghua Univer-
sity and in Beijing. I wish you all the best for your future and your life in the Netherlands 
and hope we keep on seeing and messaging each other. You’ve been and always will be 
a great friend to me, our time together in China and the Netherlands were unbelievably 
great! Thank you for recommending me the Dutch universities, then, I have the oppor-
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tunities to come to the Netherlands where I met a lot of amazing people and had an 
incredibly great memory. I will always cherish my memories in the Netherlands in my life.
Brazilian Omar, it was super nice to meet you on the 7th floor of RIMLS. We had a lot 
of nice talks after work and had a lot of good time in Nijmegen and Maastricht. You are a 
very hardworking and motivated PhD; I wish you all the best for your life in the Nether-
lands and your research career.
Hans, my landlord, I am the only guy who stayed at your place for more than one year, 
and it’s 4 years in total in the end. We had a lot of nice memories in Nijmegen and Ger-
many. Thanks for your help, suggestions, nice dinners, and supports in these four years. I 
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